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Abstract 
 
Medulloblastoma is a malignant embryonal tumour of the cerebellum which most 
commonly affects children. A subset of tumours is thought to arise from cerebellar granule 
cell precursors (GCPs) that fail to undergo normal neuronal development, following the 
hyper-activation of the Sonic hedgehog (Shh) signalling pathway.  
  To identify candidate genes that might be important for medulloblastoma 
pathogenesis, I investigated patterns of gene expression and alternative splicing in 14 
paediatric medulloblastoma and five normal cerebellar samples using Affymetrix Human 
Exon arrays. Statistical analysis of the gene expression data identified a group of 
medulloblastomas with a molecular signature of Shh pathway activation. These tumours 
showed higher expression levels of genes involved in spindle formation, cytokines, and cell 
cycle regulation. Further studies using an in vitro mouse GCP cell culture model, in which 
Shh is necessary for the maintenance of the progenitor state, showed that a selection of 
candidate genes was also over-expressed when GCPs were cultured in the presence of Shh, 
as compared to control cells, as well as in human medulloblastoma cell lines. Ongoing and 
future in vitro experiments will investigate the potential role of candidate genes in 
sustaining the growth of precursor and tumour cells. 
  Exon-level analysis of gene expression showed that abnormal expression of 
different transcript variants is likely to occur in medulloblastoma. I selected several 
examples of differential exon usage and validated these using an independent set of normal 
and tumour specimens. Tumour-associated splicing alterations were highly consistent, 
enabling clear separation of normal and cancer samples and in some cases of different 
medulloblastoma molecular subgroups. Interestingly, Shh-treated GCPs recapitulated the   6
splicing patterns observed in the tumour samples for six out of the eight genes analysed, 
suggesting that the preferential expression of specific transcript forms is regulated during 
normal cerebellar development. The possible relationship between inappropriate splicing 
and medulloblastoma pathogenesis will be the subject of future investigation.   
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Chapter 1 
Introduction 
 
 
 
1.1. Medulloblastoma 
  Medulloblastoma is a highly malignant embryonal tumour of the cerebellum. It 
represents the most common brain cancer in children, with an incidence of 0.48 for girls 
and 0.75 for boys in every 100,000 paediatric patients/year [1]. Medulloblastoma 
mainly occurs within the first decade of life, with a peak in incidence between 4 and 7 
years of age. However cases in the young adult and adult populations have also been 
described [2]. Despite advances in the clinical management of this disease, 
approximately one third of patients remain incurable and the majority of survivors 
suffer from severe long-term side effects caused by therapeutic treatments [3]. The 
outcome of medulloblastoma is significantly related to the age of the patient and the 
extent of disease at diagnosis [4, 5]. Children younger than 3 years of age have a poorer 
prognosis than older children partly because their treatment regime does not include 
radiotherapy. This is because cranial irradiation to the developing brain can cause 
severe neurological sequelae [3]. Also, evidence of metastatic spread within the central 
nervous system (CNS) at diagnosis, which occurs in one third of patients, is indicative 
of unfavourable prognosis [4, 6].  
  Novel therapies and prognostic markers are necessary to reduce mortality rate of 
medulloblastoma and to improve the quality of life of survivors in the long-term. A 
better understanding of the molecular pathogenesis of medulloblastoma is essential for 
the development of new therapeutic approaches which are likely to derive from the 
investigation of key cellular pathways implicated in tumour initiation and growth. A  
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concerted effort is currently being undertaken to improve medulloblastoma 
classification based on the integration of both clinical and molecular parameters, which 
will allow a better prediction of disease outcome and lead to the development of disease 
risk stratification schemes [7-9].  
 
1.2. Medulloblastoma pathology 
  According to the 2007 World Health Organisation (WHO) classification of CNS 
tumours, medulloblastomas are classified as one of five histological variants: classic, 
desmoplastic/nodular, medulloblastoma with extensive nodularity (MBEN), large cell 
medulloblastoma and anaplastic medulloblastoma [2]. However, in most clinico-
pathological and molecular studies, desmoplastic/nodular medulloblastomas and MBEN 
are combined into a single category of desmoplastic tumours, as they share many 
fundamental histological features. Similarly, the large cell/anaplastic histological 
category includes both anaplastic and large cell medulloblastomas, both of which are 
characterised by cytological features of anaplasia [7].  
 
1.2.1. Classic medulloblastoma 
  The classic histological subtype is the most frequent, accounting for up to 75% 
of cases [3-5]. Classic medulloblastomas grow as sheets of generally small round cells 
with a high nuclear:cytoplasmic ratio and an ability to invade adjacent brain tissue and 
meninges. Less than half of these cases form neuroblastic (Homer-Wright) rosettes, 
which consist of circular columns of tumour cell nuclei arranged around a central core 
of cytoplasmic processes (Table 1.1) [10].  
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Table 1.1. Summary of medulloblastoma histology. 
 
The table shows frequency and 5-year overall survival (OS) for the three major medulloblastoma 
histological categories. The data in this table has been derived from McManamy et al. [11] and, unless 
otherwise stated, refers to the entire paediatric population. Histological images reproduced from Gulino et 
al.[12] are shown for comparison.  
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1.2.2. Desmoplastic medulloblastoma 
  Desmoplastic medulloblastomas account for approximately 15% of the tumours, 
but represent up to 60% of the tumours occurring in children of less than three years of 
age and adults [11]. Desmoplastic medulloblastomas are associated with a better overall 
prognosis, which is particularly relevant for disease risk stratification within the infant 
population [9, 13]. They display a characteristic biphasic architecture consisting of 
nodular areas of more differentiated cells surrounded by reticulin-rich internodular 
regions, featuring densely packed, highly proliferating cells, and pericellular deposition 
of collagen (Table 1.1).  
 
1.2.3. Large cell/anaplastic medulloblastoma 
 Large-cell/anaplastic  medulloblastomas have been reported to account for 
approximately 5-15% of medulloblastomas [11, 14], although features of moderate or 
severe anaplasia have been identified in up to 24% of cases [15]. These tumours are 
characterised by marked nuclear pleomorphism, cellular wrapping, extensive apoptosis 
and intense mitotic activity (Table 1.1). The patients often present with metastatic 
disease and this type of medulloblastoma is generally associated with a poor prognosis 
[14, 15].  
 
1.3. Medulloblastoma cytogenetics  
  Medulloblastomas are not characterised by any single defining chromosomal 
abnormality, but rather show a range of cytogenetic alterations (Figure 1.1) [16]. The 
presence of an isochromosome 17q (i17q), which combines the loss of 17p and 
duplication of 17q, has been widely acknowledged as the most frequent chromosomal 
abnormality in medulloblastomas, affecting approximately 40% of cases [16-18]. The  
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individual loss of the short arm of chromosome 17 has also been frequently reported 
[16-18]. These abnormalities are found in all of the medulloblastoma histological 
variants and have been significantly associated with a poor outcome for patients [8, 18]. 
However, little is known about the individual genes mapping to these chromosomal 
regions whose loss/amplification might favour medulloblastoma development.  
  Another frequently observed chromosomal abnormality in medulloblastoma is 
the loss of an entire copy of chromosome 6. Interestingly, this aberration is exclusively 
found in medulloblastomas with abnormal activation of the Wingless (Wnt) signalling 
pathway (assessed by identifying mutation in the CTNNB1 gene encoding β-catenin, β-
catenin nucleo-positivity, or gene expression profiling), and is a strong biomarker of 
good prognosis [8, 19, 20]. Other regions of extensive chromosomal gain and loss 
include loss of chromosomes 8, 9q, 10q, 11 and 16q; and gain of chromosomes 1q, and 
7; all of which are observed in up to 40% of cases [16, 21]. Still, it is unclear whether 
the disruption of individual genes in these regions might be relevant to medulloblastoma 
pathogenesis.  
  Double minutes, fragments of extra-chromosomal DNA generated by gene 
amplification, have also been commonly observed in cytogenetic studies of 
medulloblastoma primary tumours and cell lines [22, 23]. MYCN (at 2p24) and MYC (at 
8q24) are the most frequently amplified loci in medulloblastomas. Their amplification 
has been found in up to 10% of tumours, and is strongly associated with the large 
cell/anaplastic phenotype and unfavourable patient outcome [8, 18, 24].  
  Recently, Pizer and colleagues proposed a scheme of disease risk stratification 
based on a combination of histological and molecular tumour features, with the aim of 
improving medulloblastoma survival rates while reducing the long-term side effects of  
 
21
 
 
 
 
 
Figure 1.1. Schematic overview of common chromosomal gains and losses in medulloblastoma.  
The red and green bars shown on the right and left of each chromosome indicate common chromosomal 
gains and losses, respectively. Amplifications of the MYCN and MYC genes are represented as narrow 
pink bars matching their genomic location on chromosomes 2 and 8. Asterisks designate chromosomal 
abnormalities which have been associated with a favourable (single asterisk) or poor (double asterisk) 
outcome for patients. Adapted from Ellison [7] and Northcott et al. [25]. 
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treatment [9]. A large-cell/anaplastic histology as well as evidence of metastatic disease, 
suboptimal surgical resection and amplification of the MYC or MYCN oncogenes are all 
considered independent high risk biomarkers. Absence of any of these high risk disease 
features is associated with a standard risk. Finally, the presence of positive biomarkers, 
among which is the activation of the Wnt pathway, is predictive of a better outcome [9]. 
On this basis, two European clinical trials are currently being implemented, which will 
test whether alternative treatment options could be used for different disease risk groups 
to improve the outcome for patients with medulloblastoma.  
  Although histological and cytological studies of medulloblastomas have 
provided important biomarkers for the clinical management of the disease, there is a 
general consensus that our ability to predict the clinical behaviour of medulloblastoma 
and to counteract its growth and relapse depends on a better understanding of the 
molecular mechanisms that drive oncogenesis in the cerebellum. Therefore, the 
pathways and molecules which regulate normal and abnormal cerebellar development 
are being intensively studied since they represent potential targets of novel therapeutic 
approaches [26-28].  
 
1.4. The structure of the mature cerebellum 
  In mammals, the cerebellum is largely responsible for the coordination of motor 
activities in the brain [29]. It is located in the posterior fossa of the skull and it consists 
of a central vermis, flanked by two lateral hemispheres (Figure 1.2A). Both the vermis 
and the hemispheres are folded into lobules, and each lobule is subdivided into folia by 
a series of parallel fissures (Figure 1.2B). The cerebellum is also divided into a cortex 
and a mass of centrally located neurons known as the deep cerebellar nuclei. The 
functions of the cerebellum depend on the activities of at least five neuronal types [30],  
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located in specific layers within the cerebellum. The most abundant are the granule 
neurons, which regulate the activity of the underlying Purkinje cells. Purkinje neurons 
are the only output neurons of the cerebellar cortex and they form an orderly single cell 
layer (Purkinje cell layer, PL) in the mature cerebellar cortex, interspersed between the 
internal granule cell layer (IGL) and the molecular layer (ML) (Figure 1.2C). Granule 
neurons project their ascending axons from the IGL into the ML, where they form 
synapses with Purkinje cells and ML interneurons, i.e. stellate and basket cells. The IGL 
also contains Golgi neurons and astrocytes, while the Bergman glia are predominantly 
located in the PL [30, 31].  
 
1.5. Overview of cerebellar development 
  The development of the cerebellum occurs over a long period of time, from the 
early embryonic period until the first two post-natal weeks in mice [32]. The cerebellum 
arises from the most anterior rhombomere of the hindbrain. The isthmic organiser, a 
signalling centre located at the boundary separating the midbrain and hindbrain, has 
been shown to play an essential role in the establishment of the cerebellar territory 
during early embryonic development and the specification of the different cerebellar 
cell types [33]. Cells in the cerebellum arise at different times of development from two 
distinct germinal zones: the ventricular zone, which gives rise to multipotent precursors 
of both cerebellar neurons and glial cells, and the more dorsally located rhombic lip, 
from which granule neurons originate [34]. The first cells to be formed in the 
developing cerebellum migrate radially from the ventricular zone to evolve into the 
deep cerebellar nuclei and Purkinje neurons of the cerebellar cortex. Subsequently, 
stellate, basket and Golgi interneurons are generated from the same germinal matrix 
[34]. Conversely, granule cell precursors (GCPs) originate from the rhombic lip. They  
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Figure 1.2. Structure of the adult mouse cerebellum.  
 
A) Dorsal view of the adult mouse cerebellum. The cerebellar vermis (CV) and the cerebellar 
hemispheres (CH) are indicated. Adapted from Chizhikov and Millen [35]. 
 
B) Para-sagittal section of the cerebellar vermis. Black arrows indicate the three distinct layers of the 
mature cerebellar cortex: the molecular layer (ML), the Purkinje cell layer (PL), and the internal granule 
cell layer (IGL). A red arrow indicates deep cerebellar nuclei (DCN). One of the folia is labelled by a 
bracket. Adapted from Chizhikov and Millen [35]. 
 
C) Hematoxylin and Eosin staining of a section of mouse cerebellum. The three layers of the mature 
cerebellar cortex are indicated: ML, molecular layer; PL, Purkinje cell layer; IGL, internal granule layer. 
Stellate neurons are detectable in the ML (arrowhead), while Purkinje neurons and granule cells are 
located in the PL and IGL, respectively.  Adapted from Oliver et al. [36]. 
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then migrate across the outer surface of the cerebellum to form the external germinal 
layer (EGL). During post-natal development, precursor cells in the EGL undergo 
extensive proliferation generating a large pool of GCPs. As new GCPs are generated, 
older precursors exit the cell cycle, differentiate into mature neurons and migrate 
inward, past the Purkinje cell layer, to their final destination, the IGL (Figure 1.3A). At 
about three weeks of age, the mouse cerebellum is completely developed. The EGL 
disappears and the IGL is populated with mature granule neurons. The same process 
occurs in the human cerebellum and continues during the first eleven post-natal months 
[34].  
  Recently, a new stem cell population was identified in the white matter of the 
adult mouse cerebellum [37]. These cells express the neural stem cell marker prominin-
1 (CD133), are able to form self-renewing neurospheres in vitro and can differentiate 
into astrocytes, oligodendrocytes and neurons in vivo. Thus, the mouse cerebellum 
contains at least three different neural precursor cell populations from which 
medulloblastoma and its variants might develop. 
 
1.6. Control of GCP proliferation in the post-natal cerebellum 
1.6.1. The Sonic hedgehog signalling pathway 
  Cerebellar granule neurons are the most abundant cell type in the brain and 
constitute the main cell population in the cerebellum. The observation that mutations in 
genes that encode components of the Sonic hedgehog (Shh) signalling pathway could 
result in the formation of cerebellar tumours in mice and humans suggested that this 
pathway might have a major role in the regulation of granule cell precursor proliferation 
and differentiation [38-40]. Indeed, several studies have demonstrated that the Shh 
mitogen is an essential regulator of GCP post-natal expansion. Addition of recombinant  
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Figure 1.3. Shh signalling in the post-natal cerebellum. 
 
A) Schematic representation of the mouse cerebellum during the post-natal expansion of GCPs. 
Mitotically active GCPs are found in the outer EGL, and Shh secreted from Purkinje neurons sustains 
their proliferation. As new GCPs are generated, older GCPs exit the cell cycle, differentiate into neurons 
and migrate inward, through the Purkinje cell layer, to reach the internal granule layer (IGL). EGL, 
external germinal layer; ML, molecular layer; PL, Purkinje cell layer; DCN, deep cerebellar nuclei. 
Adapted from Ruiz i Altaba [41]. 
 
B) Shh signalling pathway. Binding of Shh to the trans-membrane receptor Ptch inhibits the repression of 
Smo by Ptch. Smo can in turn activate an intracellular signalling pathway that increases the nuclear 
activity of the Gli family of transcription factors, which regulate the expression of target genes.  
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Shh protein to mouse GCPs in culture induces a significant increase in their 
proliferation rate, as measured by thymidine and bromodeoxyuridine (BrdU) 
incorporation assays. Conversely, blocking the Shh signalling pathway in vivo with an 
anti-Shh antibody causes a decrease in GCP proliferation resulting in a significantly 
thinner EGL and defects in cerebellar foliation [42, 43]. During normal cerebellar 
development, Shh is produced and secreted by Purkinje neurons. GCPs express all of 
the downstream elements of the Shh pathway, which allows them to respond to it [43]. 
Binding of Shh to the receptor Patched (Ptch) on the surface of GCPs results in Ptch 
inhibition and consequently in the release of the Ptch-partner receptor Smoothened 
(Smo). Smo in turn activates downstream effectors of the pathway, leading to the 
nuclear translocation of the Gli transcription factors and eventually the transcriptional 
activation of target genes, which induce a pro-proliferative response (Figure 1.3B) [43]. 
Although three Gli proteins have been described that can mediate the cellular response 
to Shh signalling in vertebrates, it has been shown that Gli2 is the major effector of the 
Shh mitogenic signal during cerebellar development. Indeed, depletion of Gli2 but not 
Gli1 results in a thinner EGL and reduced cerebellar foliation [42].  
 
1.6.2. Shh effectors  
  While the role of Shh in promoting GCP proliferation has been widely 
established, the mechanisms underlying this mitogenic effect remain to be elucidated. 
To identify target genes activated by Shh, several groups over the last few years have 
used whole-genome approaches to investigate changes in gene expression induced by 
Shh in mouse GCPs both in vitro and in vivo [44-46]. Consistent with the mitogenic 
effects of Shh, many of the genes whose expression increases after Shh stimulation are  
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involved in the regulation of cell cycle progression, DNA replication and the negative 
regulation of differentiation [45, 47]. 
 
1.6.2.1. Mycn 
 The  Mycn gene, which encodes a basic helix-loop-helix (bHLH) transcription 
factor, has been identified as one of the early transcriptional targets of the Shh pathway 
(Figure 1.4). Overexpression of Mycn alone is sufficient to induce GCP proliferation in 
vitro, even in the absence of Shh [45, 48], whereas the conditional disruption of Mycn in 
the developing mouse brain results in impaired GCP proliferation in the EGL [49]. 
Interestingly, in the Ptch
+/- mouse model of medulloblastoma, loss of the Ptch gene has 
been associated with an increased stability of the Mycn protein, suggesting that Shh can 
increase the level of Mycn activity through both transcriptional and post-transcriptional 
mechanisms [50]. The MYCN gene is overexpressed in the majority of human 
medulloblastomas [51] and its amplification, together with the amplification of the MYC 
oncogene, is seen in almost 10% of cases [25]. Overexpression of Mycn in the 
developing cerebellum induces the formation of classic and nodular desmoplastic 
medulloblastomas in genetically engineered mice [51]. Furthermore, dexamethasone 
treatment of genetically modified mice with Shh-induced medulloblastomas leads to the 
proteasomal degradation of the Mycn protein via the activation of glycogen synthase 
kinase 3ß (Gsk-3ß). This eventually results in the inhibition of tumour growth and 
increased survival of tumour-prone transgenic mice [52]. This suggests that Mycn is 
required for the Shh-induced proliferation of GCPs in the normal developing cerebellum 
as well as for the initiation and maintenance of medulloblastoma. In Shh-treated 
cultured GCPs, the increased expression of Mycn is followed by an increase in the level  
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Figure 1.4. Control of GCP proliferation in the post-natal cerebellum. 
In the post-natal cerebellum, Shh plays an essential role in triggering GCP proliferation by inducing 
downstream effectors that favour GCP progression through the cell cycle. Among these, Mycn and Mad3 
regulate each other and induce the expression of type D Cyclins and E2F transcription factors. Bmi1 
represses the expression of negative regulators of the cell cycle, including p16, p19 and p21, and this 
favours GCP proliferation. Yap1 has been shown to form a complex with Irs1 and translocate to the 
nucleus where it binds its transcriptional partner Tead1 to induce the expression of target genes. A 
possible positive feedback loop has been suggested, in which Gli2 expression is induced by the Yap1-
Tead1 complex. The expression of Bmp2 and Bmp4 in the maturing GCPs as well as the accumulation of 
Notch downstream effectors (e.g. Hes5) counteract Atoh1 positive enhancement of Shh signalling and 
eventually favor GCP differentiation.  
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of expression of Cyclin D1 and of the E2F1 and E2F2 transcription factors, all of which 
are positive regulators of the cell cycle [45].  
 
1.6.2.2. Mad3 
  Mad3, which encodes a bHLH transcription factor transiently expressed in 
proliferating GCPs during post-natal cerebellar development, is also up-regulated as a 
result of Mycn expression [53]. Mad3 is essential for sustained Shh-dependent GCP 
proliferation and when expressed by itself Mad3 can trigger GCP proliferation and 
Mycn gene expression in vitro [53]. Like Mycn,  Mad3 is overexpressed in 
medulloblastomas derived from Ptch
+/- mice compared to normal cerebellum. It has 
been suggested that the Mycn and Mad3 proteins positively regulate each other’s 
transcription but induce the expression of different sets of genes that are required for the 
post-natal expansion of GCPs (Figure 1.4) [53]. 
 
1.6.2.3. Bmi1 
  The polycomb group gene Bmi1 is another target of the Shh signalling pathway 
that contributes to the proliferation of GCPs both in vitro and in vivo [54]. The Bmi1 
protein is expressed in the EGL during the post-natal development of the cerebellum 
and deletion of the Bmi1 gene impairs GCP survival and expansion in vivo, resulting in 
the depletion of the IGL. It has been suggested that Bmi1 regulates Shh-dependent GCP 
proliferation by repressing the transcription of genes that inhibit cell proliferation 
(Figure 1.4) [55].  
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1.6.2.4. The IGF pathway and Irs1   
  An additional molecule identified as an effector of the Shh mitogenic signal in 
GCPs is insulin receptor substrate 1 (Irs1) (Figure 1.4) [56]. The Irs1 protein was shown 
to be essential for insulin-like growth factor (IGF)-induced proliferation of different cell 
types [57] although its role in GCP proliferation has only recently been investigated. 
Components of the IGF signalling pathway are expressed both in the developing and the 
mature cerebellum, and activation of the pathway is required for the proliferation of 
GCPs and medulloblastoma cells in vitro [58]. Interestingly, the IGF pathway has been 
shown to enhance Shh signalling in cultured mouse GCPs by inhibiting Gsk-3ß, which 
blocks GCP cell cycle progression by targeting the Mycn protein for degradation via the 
proteasome [58]. Irs1 is a downstream effector of the IGF signalling pathway and is 
expressed in the EGL of the developing mouse cerebellum. Shh treatment of GCPs 
favours Irs1 protein stability via the inhibition of mTOR-mediated Irs1 protein turnover. 
Moreover, overexpression of Irs1 can promote GCP proliferation in vitro in the absence 
of Shh [56].  
 
1.6.2.5. Yap1 
  The oncogenic transcriptional coactivator yes-associated protein 1 (Yap1) has 
recently been found to have a role in Shh-induced GCP proliferation [59]. Yap1 was 
initially identified as being overexpressed and occasionally amplified in human 
medulloblastomas characterised by hyper-activation of the Shh signalling pathway [59]. 
Immunofluorescence staining of mouse cerebellar sections at different developmental 
stages showed that Yap1 is strongly expressed in the EGL at the peak of GCP 
expansion (post-natal day 7), but is also detected in the mature cerebellum suggesting 
that it may play multiple roles at different stages of cerebellar development. In in vitro  
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GCP cultures, an increase in the levels of Yap1 mRNA and its protein is observed in the 
presence of Shh [59]. Furthermore, Shh is able to induce the translocation of the Yap1 
protein from the cytoplasm to the nucleus, possibly by favouring its interaction with the 
Irs1 protein, as the two molecules are found in the same protein complex in Shh-treated 
GCPs as well as in a mouse model of Shh-induced medulloblastoma [59]. As is the case 
for Irs1, the ectopic expression of Yap1in cultured GCPs strongly increases cell cycle 
progression even in the absence of Shh, while its depletion causes a dramatic decrease 
in Shh-induced GCP proliferation. Yap1 interacts with and activates different 
transcription factors, which in turn induce the expression of cell cycle related genes. 
Immunoprecipitation analysis showed that Yap1 binds to its transcriptional partner 
Tead1 in Shh-treated GCPs and in silico analysis suggests that the Gli2 gene is one of 
the putative targets of the Yap1/Tead1 complex (Figure 1.4) [59]. 
 
1.6.3. Atoh1 
  The control of GCP proliferation results from the balanced interaction of 
different signalling pathways. While Shh plays a major role in promoting the clonal 
expansion of GCPs in the developing cerebellum, additional signals are essential for the 
regulation of GCP differentiation. The Atoh1 gene, which encodes a bHLH transcription 
factor expressed in neuronal precursors in the rhombic lip and subsequently in the EGL, 
is the earliest marker of the GCP lineage and is essential to maintain GCPs in a 
proliferative state [60]. GCPs derived from the rhombic lip of Atoh1 null mice are 
normal in their specification and viability, but are unable to differentiate into mature 
granule neurons. Components of the Notch signalling pathway are significantly down-
regulated in Atoh1 null GCPs compared to control cells, suggesting that Atoh1 controls 
GCP differentiation, at least in part, by regulating Notch signalling [60]. Moreover,  
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Atoh1 modulates a negative feedback loop which results in its own repression following 
the activation of the Notch downstream effector Hes5, which inhibits Atoh1 
transcription. Therefore, accumulation of the Atoh1 protein eventually reduces its own 
expression consequently blocking Notch signalling, which allows GCPs to differentiate 
[60]. More recently, Atoh1 has been shown to directly sustain Shh signalling through 
the direct transcriptional regulation of Gli2, which in turn controls the activity of the 
Shh pathway (Figure 1.4) [61]. Consistent with this, Atoh1  deletion prevents the 
formation of Shh-driven medulloblastomas in mice which bear an oncogenic 
constitutively active allele of the Smo gene [61].  
 
1.6.4. Bone morphogenetic proteins   
  The bone morphogenetic protein (Bmp) family is also implicated in the 
regulation of GCP cell cycle exit, migration and differentiation during early cerebellar 
development. Bmps are secreted members of the transforming growth factor β super-
family which, upon interaction with their receptors, activate an intracellular signalling 
cascade leading to the nuclear translocation of Smad effector proteins and the 
transcriptional activation of a variety of target genes [62]. During the embryonic 
development of the cerebellum, Bmp6 and Bmp7 are expressed by dorsal midline cells, 
which are adjacent to the rhombic lip primordium and are implicated in the proliferation 
and migration of GCPs [63]. Addition of Bmp6 or Bmp7 to rhombic lip cerebellar 
progenitors in culture induces the expression of GCP markers, including Atoh1 [63], 
and constant Bmp7 expression antagonises GCP differentiation by inducing the 
expression of Atoh1 and sustaining cell cycle progression [64, 65]. In contrast, Bmp2 
and Bmp4 are expressed in GCPs in the EGL and in mature granule neurons in the IGL. 
Both Bmp2 and Bmp4, but not Bmp7, are able to induce cell cycle arrest and  
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differentiation of cultured GCPs [65, 66]. More interestingly, Bmp2 and Bmp4 have 
been shown to antagonise Shh-dependent proliferation of GCPs and medulloblastoma 
cells in vitro and in vivo by triggering the post-transcriptional down-regulation of the 
Atoh1 protein (Figure 1.4) [65].   
 
1.6.5. Fibroblast growth factor 
  Fibroblast growth factors (FGFs) and their receptors play diverse roles during 
mammalian development. In the CNS, they are involved in the regulation of 
neurogenesis, axon growth, differentiation, as well as neuronal survival in the 
developing and adult brain [67]. Genes encoding several FGF ligands and receptors are 
expressed in the mouse cerebellum during both late embryogenesis and early post-natal 
development [68]. Interestingly, basic FGF (bFGF or FGF2) has been suggested to act 
as a negative regulator of Shh-induced GCP proliferation, both in vitro and in vivo [43, 
69]. Addition of bFGF to cultured GCPs causes a 90% reduction in thymidine 
incorporation [43] and prevents the induction of Shh target genes (Gli1, Mycn, cyclin 
D1) [69]. Also, bFGF suppresses the Shh-dependent activation of a Gli1-responsive 
promoter in fibroblasts, which suggests that FGF can block Shh signalling upstream of 
Gli1-mediated transcription. GCPs treated with bFGF in vitro undergo morphological 
changes indicative of cell differentiation and express lower levels of proliferation 
markers, such as Ki67 [69]. Furthermore, intracisternal injection of bFGF into the 
developing mouse cerebellum accelerates the differentiation of GCPs resulting in a 
significantly thinner EGL by post-natal day 7 (P7) and an increase in NeuN-positive 
post-mitotic neurons in the inner EGL and in the molecular layer. [69]. Of note, 
immunohistochemical analysis of the expression of Fgfs during mouse cerebellar 
morphogenesis revealed that the Fgf2 protein is detectable from P0 in a few GCPs  
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located in the inner EGL as well as in some migrating GCPs in the molecular layer. By 
P7, Fgf2 is expressed by some of the granule neurons in the IGL [68]. This is 
compatible with a role for Fgf2 in modulating GCP cell cycle exit and differentiation in 
vivo. However, Fgf2 knockout mice do not display any cerebellar phenotype suggesting 
a possible redundant role for several Fgfs in the control of GCP proliferation and 
differentiation [70]. 
 
1.6.6. REN 
 The  REN gene has been recently identified as a putative tumour suppressor 
which is frequently lost in human medulloblastoma [71]. Indeed, REN maps to 
chromosome 17p13.2, the most commonly deleted chromosomal region in 
medulloblastoma, and its level of expression significantly decreases in both diploid and 
hemizygous tumours compared to the normal cerebellum [71]. Interestingly, in the 
developing mouse cerebellum, the highest levels of REN mRNA and protein expression 
are detected in the inner EGL and in the IGL. Consistently, REN expression increases as 
GCPs undergo differentiation in vitro; whereas REN overexpression causes a block in 
GCP proliferation, even in the presence of Shh, and an up-regulation in the level of 
expression of the p27 protein [72]. In addition, REN overexpression significantly 
suppresses Gli-dependent gene transcription and causes a decrease in the level of Gli1 
mRNA, possibly by interfering with the nuclear translocation of Gli1 in response to Shh 
signalling [72].  
 
1.7. The origin of Shh-driven medulloblastoma 
  Medulloblastomas often originate on the surface of the cerebellum, where GCPs 
are proliferating during embryonic and early post-natal development and they express  
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several of the genes which sustain GCP proliferation [28]. Therefore, it has been 
hypothesised that medulloblastomas originate from GCPs following the abnormal 
activation of signalling pathways which control GCP progression through the cell cycle 
[26-28].  
  The Shh signalling pathway is one of the best characterised regulatory pathways 
implicated in medulloblastoma initiation and maintenance. Initial evidence for a role of 
the Shh pathway in medulloblastoma came from the observation that patients affected 
by Gorlin’s syndrome had inherited an inactivating mutation in the PTCH gene [73, 74]. 
Gorlin’s syndrome (also known as nevoid basal-cell carcinoma syndrome) is a 
hereditary condition characterized by a range of developmental abnormalities and an 
increased predisposition to nevoid basal cell carcinoma and medulloblastoma [75]. 
Subsequent studies found that mutations affecting the PTCH gene are also present in up 
to 10% of sporadic medulloblastomas, predominantly in those with a desmoplastic 
histology [39, 40]. In addition, alterations in other components of the Shh pathway 
occur in approximately a further 15 % of cases [76-78]. Moreover, approximately 15% 
of mice carrying a single allele of the Ptch gene develop tumours of the cerebellum 
which resemble human medulloblastomas [38]. Even when they do not develop 
malignancies, the majority of Ptch
+/- mutant mice display an abnormal accumulation of 
pre-neoplastic, GCP-like cells at the cerebellar surface by 4 to 6 weeks of age [79, 80]. 
When Ptch
+/- mice were crossed with mice expressing the GFP protein under the control 
of the Atoh1 promoter, both tumours and pre-neoplastic cells which developed in the 
cerebellum of transgenic mice expressed the GFP protein, strongly supporting the 
hypothesis that they were derived from the granule cell lineage [36].  
  Similar approaches have been used to generate alternative medulloblastoma 
mouse models, as well as to demonstrate the implication of other tumour-related genes  
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in the development of medulloblastoma from mouse GCPs. Hatton et al. generated a 
transgenic mouse in which a constitutively active mutant form of the Smo gene (SmoA1) 
was regulated by the NeuroD2 promoter, which is primarily expressed in GCPs [81]. 
More than 90% of Smo
A1/A1 homozygous mice had an abnormal expansion of cells in the 
EGL by two weeks of age, and developed medulloblastomas as early as one month after 
birth [81].  
  Using the Cre-LoxP system, Marino et al. developed genetically engineered 
mice in which the Rb and p53 genes were specifically deleted in the GFAP-expressing 
cell populations, including GCPs [82]. All of the mice examined developed Atoh1-
positive tumours on the surface of the cerebellum which closely resembled human large 
cell/anaplastic medulloblastomas [82]. In a follow up study, the authors demonstrated 
that the combined loss of the Rb and p53 tumour suppressor genes predisposed target 
cells to the accumulation of additional genomic mutations [83]. These included the 
amplification and consequent overexpression of the Mycn,  Gli2 and Ptch2 genes, 
suggesting Rb/p53-mediated oncogenesis may occur via the abnormal activation of the 
Shh signalling pathway [83].  
 Interestingly,  p53 has been shown to enhance Shh-induced tumorigenesis in 
other mouse models of medulloblastoma. The loss of the p53 gene significantly 
accelerated medulloblastoma formation in Ptch
+/- mice [84], while the overexpression 
of either Mycn or Cyclin D1 in primary GCPs isolated from p53 and Ink4c double 
knockout mice induced medulloblastoma formation when the cells were injected into 
the brains of immuno-compromised animals [85].  
  Recent experiments have shown that Shh is required for the control of stem cell 
growth and maintenance in the adult brain [86], and that primary medulloblastomas 
express markers of neural stem cells and can differentiate into both neuronal and glial  
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cell types [87-89]. This suggested that additional cerebellar cell types other than GCPs 
may also be transformed as a result of the aberrant activation of the Shh pathway and 
give rise to medulloblastoma. To investigate this hypothesis, Yang et al. developed a 
conditional allele of the Ptch gene which allowed its specific inactivation in either 
Atoh1-expressing GCPs or GFAP-expressing multipotent stem cells located in the 
ventricular zone of the embryonal mouse cerebellum [90]. The authors observed that in 
both cases the transgenic animals developed medulloblastomas with 100% penetrance. 
However, tumours initiating from multipotent stem cells grew more rapidly, suggesting 
that the cells from which medulloblastomas develop do have an impact on the clinical 
course of the disease. Interestingly, although neural stem cells of the ventricular zone 
have the potential to differentiate along both the neuronal and the glial lineages, they 
only gave rise to medulloblastomas [90], suggesting that a neuronal specification is 
essential for Shh to induce its oncogenic effects in the cerebellum. In agreement with 
these observations, Schüller et al. demonstrated that following the activation of the Shh 
signalling pathway, both multipotent and unipotent cells within the GCP lineage were 
able to generate medulloblastomas, but not other brain cancers, and that the tumour 
growth rate varied according to the cell type which was targeted [91]. Importantly, these 
studies demonstrated that GCPs are not the only cell type from which medulloblastoma 
can originate, and that the Shh signalling pathway can exert its oncogenic potential at 
different stages of cerebellar development, but it requires its target cells to commit 
along the GCP lineage.  
 
1.8. Shh-independent medulloblastomas  
  Although increasing evidence supports a role for Shh in medulloblastoma 
formation, a majority of human medulloblastomas do not show alterations in the Shh  
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pathway and are likely to be Shh-independent [20, 92]. Approximately 25% of the 
tumours are characterised by alterations in the Wnt signalling pathway [20, 92], but 
very little is known about their possible cell of origin. Wnt signalling is essential for the 
proliferation of neural stem and precursor cells during brain development [93]. The 
activity of the Wnt pathway is directly related to the amount of free cytosolic β-catenin, 
a downstream component of the pathway which interacts with other transcription factors 
to regulate gene expression. In normal cells, the cytosolic level of the β-catenin protein 
is kept low by the interaction of β-catenin with a multiprotein complex which favours 
its phosphorylation and degradation via the proteasome. When Wnt ligands bind to their 
receptors on the cell surface, the β-catenin multiprotein complex is inactivated allowing 
β-catenin to translocate to the nucleus where it can activate gene transcription. Loss of 
Wnt-1, a member of the Wnt gene family, can block mouse cerebellar development by 
inhibiting the specification of the midbrain-hindbrain junction from which the 
cerebellum originates [94]. Furthermore, conditional β-catenin knockout mice in which 
the Wnt pathway is inhibited at mid-gestation also display defects of the midbrain–
hindbrain region as well as cerebellar vermis hypoplasia [95]. It has been suggested that 
early multipotent precursor cells which depend on Wnt signals in the cerebellum, rather 
than unipotent GCPs, might be the cells of origin of medulloblastomas that have 
alterations in the Wnt pathway [96, 97]. As yet, no mouse models of medulloblastoma 
in which the Wnt pathway is altered have been developed. However the overexpression 
of a constitutively active form of the β-catenin protein in GCPs in vivo or ex vivo does 
not alter cerebellar development, nor does it induce malignant transformation 
(unpublished observations by M. Thompson and colleagues, and Y. Pei and R. 
Wechsler-Reya, reported in [97]). This suggests that GCPs may not be susceptible to 
mutations affecting the Wnt pathway.   
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  Earlier this year, Sutter et al. reported the development of medulloblastoma in 
immuno-compromised mice injected with CD133-positive neural stem cells obtained 
from the post-natal mouse cerebellum and genetically engineered in vitro to inactivate 
both the p53 and the Rb tumour suppressor genes [89]. The same group had previously 
shown that the combined loss of p53 and Rb in cerebellar GCPs gave rise to 
medulloblastoma with 100% penetrance [82]. A comparison of gene expression 
between medulloblastomas originating from the two different cell types showed 
significant differences, with GCP-derived tumours expressing high levels of markers of 
the GCP lineage (e.g. Atoh1, Gli1, Mycn, Ptch2), and stem cell-derived tumours 
strongly expressing genes typically associated with a neural stem cell phenotype (e.g. 
Sox2, Nestin) [89]. This was the first study in which non-GCP cerebellar cells have been 
genetically engineered to give rise to medulloblastoma independently of Shh signalling. 
It suggests that the disruption of the same key regulatory pathways can trigger 
medulloblastoma formation from different cell types and at different stages of cerebellar 
development. This type of approach is likely to provide significant insights into the 
putative cell of origin of Shh-independent medulloblastomas. 
 
1.9. Gene expression profiling of medulloblastoma 
  To identify novel genes involved in medulloblastoma, several investigators have 
performed gene expression analysis of human primary tumours and normal brain or 
cerebellum [98-103]. One of the earliest studies of this kind was carried out by Michiels 
and colleagues in 1999 [98], who used the serial analysis of gene expression (SAGE) 
technique to compare expression profiles between a human medulloblastoma and a 
sample of normal fetal brain. SAGE exploits DNA sequencing to measure the frequency 
with which specific short nucleotide sequence tags corresponding to unique gene  
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transcripts are represented within a cDNA library generated from the tissue of interest 
[104]. The major advantage of this technique is that it does not require prior knowledge 
of the genome under investigation and is therefore completely unbiased. The authors 
identified 138 sequence tags with significantly different counts in the two samples 
examined. Among these, sequences corresponding to the ZIC1 and OTX2 genes were 
expressed at a higher level in the tumour sample compared to normal brain. ZIC1 and 
OTX2 gene expression was verified by Northern blot analysis and found to be increased 
in a set of six independent medulloblastoma samples compared to fetal brain [98]. As 
the two genes are normally expressed in the germinal zones of the developing 
cerebellum, this study provided initial evidence supporting the hypothesis that 
medulloblastoma may originate from cerebellar precursor cells. Table 1.2 contains a 
summary of the major findings of this and the following studies.  
  Approaching the problem from a different perspective, MacDonald et al. used 
DNA microarrays to identify differences in gene expression between metastatic and 
non-metastatic medulloblastomas [99]. Approximately one-third of medulloblastoma 
patients present with metastatic disease at the time of diagnosis and up to two-thirds 
will display dissemination of neoplastic cells to the brain and spine by the time of 
relapse [6]. Moreover, the evidence of metastatic disease at diagnosis is among the most 
powerful independent indicators of poor medulloblastoma prognosis [9]. Thus, the 
investigation of changes in gene expression that are associated with metastatic 
medulloblastoma could provide useful prognostic markers as well as putative targets for 
new therapeutic strategies directed against tumour dissemination. MacDonald and 
colleagues identified an 85-gene signature which allowed an accurate classification of 
medulloblastomas into either the metastatic or the non-metastatic subgroup [99]. The 
gene coding for the platelet-derived growth factor receptor (PDGFR) was one of the  
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Table 1.2. Gene expression profiling of medulloblastoma.  
 
Study  Technology  Experimental outline  Major findings 
Michiels et al.  
1999 
[98] 
SAGE  MB versus fetal CB  Markers of cerebellar precursors (e.g. 
ZIC1 and OTX2) are highly expressed in 
MB  
MacDonald et al. 
2001 
[99] 
Affymetrix 
microarray 
Metastatic MBs versus non‐
metastatic MBs 
An 85‐gene signature distinguishes 
metastatic from non‐metastatic MBs. 
PDGFR as a biomarker of tumour 
aggressiveness. 
Pomeroy et al. 
2002 
[100] 
Affymetrix 
microarray 
Comparison of different CNS 
tumour types 
Despite sharing histological features, 
MBs and PNETs can be distinguished 
based on gene expression profiles.  
   Classic MBs versus 
desmoplastic MBs 
Desmoplastic MBs express a specific 
gene signature indicative of Shh 
signalling pathway activation.  
      Poor outcome MBs versus 
good outcome MBs 
Genes associated with cerebellar 
differentiation (e.g. TRKC) are predictive 
of good outcome. Genes implicated in 
cell proliferation and metabolism (e.g. 
MYBL2) are predictive of poor outcome. 
Boon et al.  
2003 
[101] 
SAGE  MBs versus normal brain  Identification of tumour‐associated 
genes (e.g. PRAME, CD24, PRL, TOP2A, 
and MYCN). 
Park et al.  
2003 
[102] 
cDNA 
microarray 
MBs versus normal 
cerebellum 
MBs overexpress genes implicated in cell 
proliferation and migration (e.g. Cyclin 
D2, Ezrin) and share expression profiles 
with cells in the EGL.  
Neben et al.  
2004 
[103] 
Two colour 
cDNA 
microarray 
Poor outcome MBs versus 
good outcome MBs 
Identification of 54 genes whose 
increased level of expression is 
predictive of unfavourable outcome (e.g. 
AURKA). 
Kho et al. 
2004 
[105] 
Affymetrix 
microarray 
Integrated analysis of human 
MBs (from Pomeroy et al. 
[100]) and mouse cerebellum 
at post‐natal days 1 to 60. 
Gene expression similarities between:  
Human MBs and mouse P1‐P10 CB.  
Human CB and mouse P30‐P60 CB.  
Human metastatic MBs and mouse P5 
CB.  
 
The table summarises the experimental outline of the major studies of gene expression in human 
medulloblastomas and their main findings. MB, medulloblastoma; CB, normal cerebellum; CNS, central 
nervous system. 
 
 
 
genes which most strongly correlated with a metastatic phenotype. In vitro studies 
demonstrated an essential role for PDGFR in promoting MAPK-dependent cell 
migration of Daoy medulloblastoma cells [99], suggesting that it might represent an 
important biomarker of tumour aggressiveness.  
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  In 2002, Pomeroy et al. used an Affymetrix GeneChip array representing over 
6,000 human genes to analyse a large cohort of CNS malignancies, including primitive 
neuro-ectodermal tumours (PNETs), atypical teratoid/rhabdoid tumours and 
medulloblastomas [100]. Their aim was to provide molecular evidence that the different 
tumour types constituted distinct entities, despite similarities in their histology [100]. 
Indeed they found that each one of the different tumour types expressed a defining set 
of genes which were indicative of their putative cells of origin. In particular, 
medulloblastomas, as opposed to PNETs, expressed genes characteristic of cerebellar 
granule neurons (e.g.  ZIC1 and NSCL1). This suggests that despite having been 
classified under the same broad category of embryonal brain tumours for a long time, 
medulloblastomas and PNETs represent distinct molecular and biological tumour types, 
in which different transcriptional programmes are activated [100].  
  In the same study, the authors addressed the possibility that the diverse 
histologies within the medulloblastoma tumour type were associated with different 
molecular profiles. They compared gene expression profiles of classic and desmoplastic 
medulloblastomas and identified a specific gene signature for the desmoplastic 
histology. This signature included genes belonging to the Shh signalling pathway (e.g. 
GLI1, PTCH, MYCN, IGF2), providing early evidence linking abnormal activation of 
the Shh pathway to sporadic desmoplastic medulloblastomas [100].  
  Regardless of their possible role in the aetiology of medulloblastoma, 
differentially expressed genes may be useful biomarkers of disease course and 
responsiveness to therapy. Pomeroy et al. analysed gene expression in a series of 60 
primary medulloblastomas from patients who underwent similar post-surgical treatment 
to identify candidate genes whose level of expression correlated with patient outcome. 
Among the best predictors of favourable outcome were genes related to cerebellar  
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differentiation (e.g. TRKC and NSCL1), whereas genes implicated in cell proliferation 
and metabolism (e.g.  MYBL2,  E2F5,  CENPF) were expressed at higher levels in 
tumours associated with a poor prognosis [100]. Although the molecular mechanisms 
by which the genes identified might affect prognosis are not clear, the identification of a 
gene expression signature which can predict patient outcome undoubtedly represents an 
extremely valuable tool in clinical practice.  
  More studies investigating medulloblastoma gene expression profiles followed 
the work by Pomeroy and colleagues. In 2003, Boon et al. reported how they used 
SAGE to profile a series of 20 primary medulloblastomas and samples from multiple 
regions of the human adult and paediatric brain [101]. They identified 30 transcripts 
expressed at high levels in the tumour samples but with little or no expression in the 
normal brain. These included the cancer-testis antigen PRAME, CD24, PRL, TOP2A, 
and MYCN [101]. In same year, Park et al. applied cDNA microarray technology to 
compare the expression of 1,200 genes between six samples of paediatric 
medulloblastoma and total normal cerebellum [102]. Among the genes expressed at 
higher level in the tumour samples were genes implicated in cell proliferation and 
migration, e.g. Cyclin D2, Ezrin. Interestingly, they identified a larger number of genes 
whose expression decreased in medulloblastomas compared to normal cerebellum, and 
which included Tenascin-C, GABBR1, encoding the GABA-B receptor subunit 1, and 
TRKB. They also performed immunocytochemical analysis for some of the candidate 
genes using sections of normal human fetal cerebellum and found that 
medulloblastomas shared similar expression profiles with precursor cells in the EGL 
[102].  
  Another study on medulloblastoma gene expression was carried out by Neben et 
al. to identify genes whose expression level could be indicative of patient survival  
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[103]. A cohort of newly diagnosed medulloblastomas was analysed by two-colour 
cDNA microarrays using a sample of universal human RNA derived from ten human 
cancer cell lines as a reference. The array included approximately 2,600 genes with 
relevance to mitosis, cell cycle control, oncogenesis or apoptosis. Analysis of individual 
gene hazard ratios identified 54 genes whose increased level of expression was 
predictive of unfavourable outcome [103]. The expression of nine of these genes was 
verified on a larger series of 180 medulloblastomas using tumour tissue microarrays. 
Positive staining for aurora kinase A (AURKA/STK15), which is implicated in the 
regulation of chromosome segregation during mitosis, was identified as an independent 
prognostic factor for overall survival. Moreover, amplification of the AURKA gene was 
detected in 32.5% of the medulloblastoma samples by fluorescent in situ hybridisation 
and was associated with poor survival [103].  
  An interesting approach to the molecular characterisation of human 
medulloblastoma was developed by Kho et al., who applied principal component 
analysis to summarise and compare gene expression profiles associated with human 
medulloblastomas and different post-natal stages of normal mouse cerebellum [105]. 
Using this statistical tool, they observed that human medulloblastoma samples shared 
similar patterns of gene expression with mouse cerebellum at post-natal days 1-10 (P1-
P10), whereas normal human cerebellar samples were more similar to mouse P30-P60 
cerebella. They also found a strong association between metastatic medulloblastomas 
and mouse P5 cerebella, and between less aggressive tumour samples and mouse 
cerebella of more than five post-natal days, suggesting that tumour clinical behaviour 
can be predicted by the expression profile of development-related genes [105]. This 
study represents one of the first genome-wide analyses providing a developmental 
perspective on tumorigenesis, and strongly emphasises the importance of studying the  
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molecular programmes regulating normal cerebellar development for a better 
understanding of medulloblastoma pathogenesis.  
These early analyses of medulloblastoma gene expression demonstrated the use 
of large scale approaches for the unbiased identification of genes affecting tumour 
clinical behaviour. They also provided strong evidence of the profound connections 
between normal cerebellar development and medulloblastoma oncogenesis, indicating 
that the same genes are implicated in both processes, so that the combined study of the 
two systems can be used to investigate human medulloblastoma aetiology.  
 
1.10. Molecular classification of human medulloblastoma based on gene expression 
profiles 
Over the last few years, continuous improvements in microarray technology 
have boosted the scale of gene expression analysis up to the whole-genome-level [106]. 
Several groups have exploited the high resolution capacity of novel microarray 
platforms to perform genome-wide analysis of human medulloblastoma gene expression 
and detailed the existence of discrete tumour molecular subgroups, making a large 
contribution to our understanding of medulloblastoma molecular heterogeneity [20, 92].  
The first of a series of seminal papers in the field was published by Thompson et 
al. in 2006 [20]. The authors profiled a cohort of 46 paediatric medulloblastomas of the 
classic, desmoplastic and large cell/anaplastic histological subtypes. They applied 
unsupervised cluster analysis to subgroup the tumour samples according to the 
expression patterns of the most variable genes, with the assumption that differences in 
gene expression would be caused by distinct sets of genetic alterations that caused the 
tumour to form in the first place. Five distinct subgroups were identified, each of which 
expressed a unique gene signature indicative of the presence of key molecular  
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alterations, as verified by gene sequence analysis and FISH [20]. The authors found 
subgroup-specific alterations affecting the Shh signalling pathway (mutations of PTCH 
and SUFU) in tumours that showed overexpression of genes belonging to the same 
pathway (SHH tumours). Similarly, a second molecular subgroup displayed a gene 
expression profile and a pattern of genetic alterations suggestive of Wnt signalling 
pathway activation (WNT tumours). Importantly, these two sets of combined genetic 
and transcriptional alterations appeared to be mutually exclusive, clearly suggesting that 
tumours belonging to the two molecular subgroups originated from alternative 
oncogenic processes. In contrast, the other three molecular subgroups did not clearly 
associate with any specific regulatory pathway [20].  
Two years later, Kool et al. used an even more comprehensive approach to 
investigate the associations between gene expression profiles and genetic abnormalities 
of medulloblastomas characterised by distinct clinico-pathological features. A total of 
62 human medulloblastomas were profiled using Affymetrix microarrays, and 52 of 
them were also analysed by comparative genomic hybridisation (CGH) to search for 
copy number alterations [92]. The authors initially performed an unsupervised 
clustering of the samples included in the microarray experiment and found that they 
recapitulated the five molecular clusters previously identified by Thompson et al. [20]. 
Indeed, the tumours in the SHH subgroup showed increased levels of transcripts 
encoded by genes involved in Shh signalling, such as PTCH, BOC, GLI1 and GLI2. 
These tumours also had a significantly higher frequency of 9q loss [92]. Conversely, 
WNT tumours overexpressed several of the Wnt pathway genes, including AXIN2, 
LEF1, WNT11 and WNT16. They all also carried mis-sense mutations of the CTNNB1 
gene resulting in single amino acid changes in the β-catenin protein, and all of the cases  
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examined showed monosomy of chromosome 6, in agreement with data from 
Thompson et al. [20] and Clifford et al. [19].  
The authors also provided a more detailed description of the molecular features 
characterising the remaining three medulloblastoma subgroups (subgroups C, D and E). 
Tumours in these three clusters were closely related and showed increased levels of 
expression of genes implicated in neuronal (subgroups C and D) and retinal 
differentiation (subgroups D and E). In contrast with SHH and WNT tumours, clusters 
C, D and E often showed gain of chromosome 18. Gain of chromosome 17q, frequently 
in the form of i17q, was strongly associated with tumours in clusters C and D [92].  
Interestingly, the five medulloblastoma molecular subgroups also differed in 
terms of clinical and histological features. Evidence of metastatic disease at diagnosis 
was significantly more frequent in tumours of the C, D and E clusters. SHH tumours 
occurred more frequently in patients younger than three or older than 25 years of age, 
whereas the age of the patients with the other tumour subgroups generally ranged 
between 3 and 20 years. Moreover, all of the WNT tumours were of classic histology, 
whereas most of the SHH tumours were desmoplastic medulloblastomas [92].  
More recently, Northcott et al. applied a similar whole-genome approach to 
study the molecular heterogeneity of human medulloblastoma [107]. The investigators 
profiled a total of 90 primary medulloblastomas. Unsupervised hierarchical clustering of 
the most differentially expressed genes across the entire data set generated four discrete 
subgroups. As had been described by Thompson et al. [20] and Kool et al. [92], the 
investigators clearly identified the SHH and WNT subgroups, whereas they only 
observed two additional clusters, which they called C and D. In agreement with 
previous observations, SHH tumours showed the frequent loss of chromosome 9q,  
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whereas most of the WNT tumours carried a single copy of chromosome 6. 
Isochromosome 17q was only found in clusters C and D [107].  
These studies significantly advanced our knowledge of the molecular 
background characterising human medulloblastomas. Whether the four/five tumour 
molecular subgroups identified originate from the same cell lineage via the 
accumulation of different genetic alterations, or whether they arise from distinct cell 
types remains to be elucidated. Nevertheless, the importance of a detailed molecular 
classification of medulloblastomas is indisputable. Potential stratification schemes for 
medulloblastoma patients that take into account molecular parameters as well as clinical 
and histological features have been recently proposed and are likely to be implemented 
for clinical practice in the near future [7]. Table 1.3 summarises the major genetic, 
transcriptional and clinical features defining the different medulloblastoma molecular 
subgroups.   
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Table 1.3. Genetic, transcriptional and clinical associations of medulloblastoma 
molecular subgroups.  
 
   Medulloblastoma molecular subgroups    
  WNT  SHH  Non‐WNT/SHH 
Proportion of 
medulloblastomas 
15%  25%  65% 
Age at diagnosis  Median age ~ 10 years     
(range 6‐20) 
Median age ~ 3 years       
(range 1.5‐35.3) 
Median age ~ 8 years       
(range 2‐25.6) 
      Uncommon between 5 and 
15 years of age 
  
Histological variant  Mainly classic MBs  Mainly desmoplastic MBs  Mainly classic MBs 
   No desmoplastic MBs  50% of LC/A MBs  50% of LC/A MBs 
Metastatic disease 
at diagnosis 
Rare  Rare  Frequent 
Chromosomal 
abnormalities 
Monosomy of chromosome 6  Loss of chromosome 9q  Loss of chromosome 17p 
    Rare MYCN amplification  Isochromosome 17q 
         Rare MYC/MYCN amplification 
Gene mutations  Frequent β‐catenin mutations  PTCH mutations in some MBs    
      Rare SUFU mutations    
Gene expression 
patterns 
Wnt signalling pathway  Shh Signalling pathway  Neuronal differentiation 
      Markers of GCPs  Retinal differentiation 
Prognosis  Very good   Good if desmoplastic MB  Poor if metastatic 
      Poor if LC/A MB  Poor if LC/A MB 
 
MB, medulloblastoma; LC/A, Large cell/anaplastic. Adapted from Ellison [7], with data derived from 
Thompson et al. [20], Kool et al. [92], Northcott et al. [107]. 
 
 
1.11. Alternative mRNA splicing 
  Changes in gene expression are necessary for cells to differentiate and respond 
to extracellular and environmental signals, as well as for cell death, proliferation and 
malignant transformation. In prokaryotic organisms, the combined activation and 
repression of different sets of genes is the main mechanism which defines the identity of 
a cell. However, the discovery of introns in the eukaryotic genome and of the process of 
splicing, which removes them from immature mRNAs, introduced another level of  
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complexity in the way gene expression is modulated to generate a large variety of 
protein products [108].  
Intron sequences must be precisely excised to form mature mRNAs, or frame 
shift alterations would be introduced, which could result in inappropriate protein 
translation [109]. Introns are much longer than exons, reaching up to tens of thousands 
of nucleotides in length, and they contain several regulatory elements, including splice 
donor and acceptor consensus signals, the branching sequence preceding the acceptor 
site, splicing enhancers and silencers [109-111]. The combination of all of these cis-
acting elements, together with their counterparts located within the exon sequences and 
RNA secondary structures, defines which sequences will be included in the mature 
mRNA product [109, 112].  
The spliceosome is a complex of specialised RNA and protein subunits, 
containing at least five types of small nuclear ribonucleoproteins (snRNPs) and a large 
number of auxiliary proteins. It is responsible for intron excision and exon joining 
during each one of the splice events that are necessary to generate a mature mRNA 
molecule [109, 113]. Depending on the availability and relative abundance of the trans-
acting regulatory proteins, there is variability in the selection of certain splice sites, so 
that the same precursor molecule can be processed in different ways giving rise to 
alternative mature mRNA forms [112].  
At the most basic level, it is possible to distinguish between two modes of 
splicing: constitutive splicing refers to the usage of certain exons which are always 
included in the final mRNA products; whereas, alternative splicing occurs when two or 
more splice sites compete so that the corresponding exons can be either retained in or 
removed from the mature mRNA. In addition, alternative splicing is subclassified into 
several modes (Figure 1.5). The extent of any individual exon inclusion or exclusion  
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Figure 1.5. Alternative modes of splicing.  
Constitutive exons are always included in the mature mRNA (a) and therefore do not affect the quality of 
the final mRNA product. A consistent increase in the variety of mRNA molecules is obtained through the 
alternative usage of exons, introns, promoters and polyadenylation sites (b-h). Cassette exons are 
individual exons which can be independently included or excluded from the mature mRNA (b). 
Alternative 5' and 3' splice sites allow the inclusion/exclusion of only part of an exon (c, d). Mutually 
exclusive splicing involves the selection of only one from an array of two or more exon variants (e). 
Finally, intron retention (f), alternative promoters (i.e. alternative 5' ends of the transcript) (g) and 
alternative polyadenylation sites (i.e. alternative 3' ends of the transcript) (h) all contribute to mRNA 
diversity. Reproduced from Ward and Cooper [114].  
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depends on the strength of the cis-regulatory sequences as well as on the presence of 
specific trans-acting splicing proteins which in turn are modulated by a variety of 
cellular stimuli [112]. 
 
1.11.1 Alternative splicing in cancer biology 
The presence of any individual exon in a mature mRNA can significantly 
influence the final protein product, in terms of translation efficiency, protein stability, 
subcellular localisation, protein-protein interaction and protein activity [108]. It is easy 
to imagine how a change in exon inclusion rates could result in the disruption of protein 
functions and eventually lead to a pathological cell response. Indeed, it has been 
estimated that up to 50% of human disease-causing mutations affect the splicing process 
[115]. Inappropriate splicing can be generated either from mutations in the cis-acting 
elements within individual genes, or changes in the trans-acting factors that are required 
for normal splicing or splicing regulation [114, 115]. 
Defects in mRNA splicing are commonly found in a variety of human cancers 
[116-118]. Mutations that alter cis-acting splicing sequences can affect the pattern of 
mRNA isoforms that are expressed and, as a consequence, protein function. Activation 
of signalling pathways that regulate the expression and activity of trans-acting splicing 
factors can result in a change in the proportion of normal mRNA splice variants. Both 
cases can lead to a significant change in the global pattern of protein expression within a 
cell and cause the deregulation of critical cellular processes, including cell proliferation 
and differentiation, all of which contribute to cancer initiation and growth (Table 1.4 
and Figure 1.6) [119]. Several studies have documented the expression of tumour-
specific splice forms in a variety of systems, and suggested that they may represent 
useful biomarkers for tumour classification and prognosis as well as novel targets for  
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cancer therapy (reviewed in [117, 120, 121]). Moreover, there is evidence for numerous 
genes that participate in the regulation of mRNA processing to be causally implicated in 
cancer (Table 1.4) [117].  
As our knowledge of the mechanisms regulating alternative mRNA splicing in 
higher eukaryotes improves, it becomes increasingly clear that an exon-level approach 
to the study of human cancer is likely to reveal a completely novel range of candidate 
events critically implicated in tumorigenesis.  
 
 
Table 1.4. Examples of disruptions in mRNA splicing mechanisms that are associated 
with malignant disease. 
 
Gene (function)   Mechanism of 
splicing disruption  
Molecular 
consequences  
Biological implications   Reference  
CD44 
(multifunctional 
receptor)  
Splice form 
imbalance  
High levels of 
CD44v6 induced 
by RAS signalling  
CD44v6 sustains late RAS 
signalling and mitogenic 
progression.  
Cheng et al. 
2006  
[122] 
KLF6       
(tumour 
supressor)  
Splice form 
imbalance  
High levels of 
KLF6‐sv1  
KLF6‐sv1 antagonises the 
tumour suppressor function 
of KLF6 and promotes 
tumour growth and 
dissemination in both 
ovarian and prostate cancer 
models. Biomarker of poor 
prognosis in prostate, lung, 
and ovarian cancer.  
DiFeo et al. 
2009  
[123] 
KLK8 
(peptidase) 
Splice form 
imbalance  
High levels of 
KLK8‐T4  
Biomarker of poor prognosis 
in lung cancer.  
Planque et al. 
2010  
[124] 
KIT     
(oncogene) 
Mutation in cis‐
acting sequence  
Deletion of 
intron 10 3’ 
splice site  
Aberrant splicing resulting in 
constitutive protein 
activation.  
Chen et al. 
2005  
[125] 
BRCA1    
(tumour 
suppressor)  
Mutation in cis‐
acting sequence  
Nonsense 
mutation exon 
18 skipping  
Predisposes to breast and 
ovarian cancer.  
Mazoyer et al. 
1998  
[126] 
SFRS1     
(splicing factor)  
Overexpression of 
trans‐acting 
splicing factor  
Inappropriate 
splicing of BIN1, 
MNK2 and S6K1 
target genes  
BIN1 loses its tumour 
suppressor properties, MNK2 
and S6K1 acquire 
transforming functions.  
Karni et al. 
2007  
[127] 
 
The table illustrates some examples of alterations affecting the splicing process and which have been 
described in association with human cancer.   
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Figure 1.6. Causes and consequences of splicing pattern alterations.  
Defects in mRNA splicing can result from mutations affecting the cis-regulatory elements or the 
deregulation of trans-acting splicing factors. Both can lead to the alteration of critical cellular processes 
and initiate or sustain tumour growth. Adapted from Srebrow and Kornblihtt [118].  
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1.11.2. Relevance of alternative splicing in medulloblastoma  
  During the last couple of years, a few studies have investigated specific 
alternative splicing events occurring in medulloblastoma [128-131]. These studies 
suggested that differential expression of specific splice isoforms might alter 
medulloblastoma biology and provide new clues for the investigation of the signalling 
pathways involved in tumorigenesis.  
 
1.11.2.1. The ErbB-4 gene   
 Ferretti  et al. analysed the expression pattern of ErbB-4 splice variants in human 
medulloblastomas [128]. ErbB-4 is a member of the ErbB family of receptors which are 
implicated in both development and tumorigenesis [132]. In particular, ErbB-4 is highly 
expressed during the development of the cerebellum and its levels decrease into 
adulthood [133]. Two major cytoplasmic splice variants of the ErbB-4 gene have been 
described, CYT-1 and CYT-2, which differ in their C-terminal domain. CYT-1 includes 
a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2 [134]. By 
analysing medulloblastoma tissues derived from Ptch
+/- mice, mouse GCP cultures and 
human medulloblastoma cell lines, the investigators observed a negative correlation 
between the levels of expression of the ErbB-4 and Gli1  genes, suggesting that 
activation of the Shh signalling pathway negatively regulates ErbB-4 expression [128]. 
Interestingly, in primary human medulloblastomas, low levels of Gli1 are associated 
with increased levels of the ErbB-4 CYT-1 form [128]. In vitro studies using 
medulloblastoma cell lines showed that activation of the ErbB-4 receptor with its ligand 
neuregulin resulted in enhanced resistance to starvation and to etoposide-dependent 
apoptosis only when the CYT-1 isoform was expressed. In contrast, expression of CYT-
2 inhibited cell proliferation [128]. Moreover, the authors measured CYT-1:CYT-2  
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ratios in a series of human medulloblastomas and found that higher values were 
characteristic of large cell/anaplastic tumours and were associated with a poorer 
prognosis for patients [128].  
 
1.11.2.2. Survivin 
  Survivin is a member of the inhibitor of apoptosis protein family, and it is 
overexpressed in most human cancers [135]. In addition to the full length survivin 
protein, three alternatively spliced forms have been described, which differ in their 
subcellular localisation and unique functions [136]. In particular, full length survivin 
and survivin-deltaEx3 have been shown to possess anti-apoptotic properties in human 
tumours, whereas survivin-2B counteracts this anti-apoptotic activity [136]. Expression 
analysis of survivin splice variants in human medulloblastoma showed that all of the 
described forms were expressed at higher levels relative to normal adult brain and 
cerebellum [130, 137]. More importantly, high levels of survivin protein, and especially 
of the deltaEx3 variant, were indicative of a poor prognosis for patients [130, 137].  
 
1.11.2.3. The Ptch gene 
  Using a specifically designed oligonucleotide microarray containing exon 
junction probes for the PTCH gene, Nagao and colleagues identified exon 12b as a 
novel alternative exon located between exons 12 and 13, and expressed in the heart and 
brain, particularly in the cerebellum, of both humans and mice [138]. Exon 12b contains 
a stop codon which results in a truncated PTCH protein [138]. In a subsequent study, 
the authors used a Gli-luciferase reporter construct to investigate the biological activity 
of the PTCH12b truncated protein. They found that, in contrast to the wild type PTCH 
protein, PTCH12b was unable to repress luciferase activity. However, when the two  
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proteins were co-expressed, PTCH12b reversed PTCH-mediated luciferase suppression, 
suggesting that it has a dominant negative effect on wild type PTCH [129]. 
Interestingly, two cases of Gorlin’s syndrome were described, in which inclusion of 
exon 12b in the PTCH transcript followed the activation of cryptic splice donor sites 
which resulted from the partial disruption of the authentic splice donor site due to point 
mutations [138]. This suggests that mutations in the PTCH gene which favour the 
imbalanced expression of the PTCH12b  isoform could initiate tumorigenesis [138]. 
Moreover,  PTCH12b was found to be expressed in medulloblastoma cell lines and 
primary tumours [129]. 
 
1.11.2.4. The Mtss1 gene 
  Metastasis suppressor 1, Mtss1, encodes an actin-binding protein which has been 
shown to regulate actin filament assembly [139]. In the epidermis, Mtss1  has been 
identified as a Shh-responsive gene which participates in the regulation of Gli-
dependent transcription [140]. Glassmann et al. described a splicing shift occurring 
during the maturation of GCPs in the developing mouse cerebellum, in which Mtss1 
exon 12 is replaced by the CNS-specific exon 12a [131]. Of note, the authors found 
that, besides being expressed in immature GCPs, exon 12 is also preferentially 
expressed in primary human medulloblastomas, indicating that expression of the 
alternative exon 12a may be associated with cellular differentiation [131]. Bioinformatic 
analysis of the Mtss1 gene suggested a possible role for exon 12a in favouring the 
interaction of the Mtss1 protein with tyrosine kinases implicated in the regulation of 
cerebellar cell migration and histogenesis [131].  
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1.12. Aim of this study 
  The aim of this project is to investigate global patterns of differential gene 
expression and alternative splicing in medulloblastoma samples isolated form a cohort 
of paediatric patients treated at Great Ormond Street Hospital and normal cerebellar 
samples. I will initially analyse the gene expression profiles of primary tumour tissues 
to classify them into one of the molecular subgroups described in the literature. I will 
then compare gene expression patterns between medulloblastoma subgroups and normal 
cerebellum with the aim of identifying biologically interesting candidate genes whose 
level of expression correlates with a malignant phenotype. Putative tumour-related 
genes will be further investigated using in vitro cultures of mouse cerebellar granule cell 
precursors as well as human medulloblastoma cell lines to assess their possible role in 
regulating cerebellar cell proliferation and malignant transformation.  
  I will also perform a statistical analysis of differential exon expression for the 
identification of splice variants which associate with medulloblastoma. Technical 
validation of a selection of candidate events will be carried out to confirm the reliability 
of the methodology. I will then look for possible similarities between splicing patterns 
characteristic of human medulloblastomas and normal cerebellar development, to 
investigate whether alterations in splicing programmes regulated in the cerebellum may 
be relevant to the pathogenesis of medulloblastoma.  
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Chapter 2 
Materials and methods 
 
 
 
2.1. Human specimen collection and classification 
2.1.1. Samples for exon array analysis 
The array study included 14 snap-frozen paediatric medulloblastoma samples (a 
mix of female and male samples between 1 and 14 years of age) obtained from the 
Histopathology Department of Great Ormond Street Hospital (GOSH), with the 
approval of the local research ethics committee (LREC ref. no. 06/Q0508/57). In 
addition, a sample of normal cerebellar tissue was obtained from a juvenile patient who 
had undergone brain surgery at GOSH for the removal of a pilocytic astrocytoma of the 
posterior fossa. Additional normal cerebellar total RNA samples to be used as controls 
for the study were purchased from commercial sources and included one adult 
cerebellar RNA (Applied Biosystems/Ambion), one pool of 24 individual adult 
cerebellar RNAs (Clontech Laboratories), and two fetal cerebellar RNAs (BioChain 
Institute). A detailed description of all samples included in this study is reported in 
Table 3.1, on page 97.  
 
2.1.2. Samples for validation of differential splicing  
Twenty human primary medulloblastoma RNA samples were kindly provided 
by Professor Steve Clifford from the Northern Institute for Cancer Research, Newcastle 
upon Tyne, UK. All samples had been profiled using Affymetrix 3' arrays and classified 
into medulloblastoma molecular subgroups as reported in Kool et al. [92].  
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  Six frozen specimens of normal adult cerebellum were obtained from the UCL 
Institute of Neurology Queen Square Brain Bank (QSBB), following ethical committee 
approval. A further four normal cerebellar total RNA samples were obtained from 
commercial sources and included two adult and one fetal cerebellar RNAs (all 
purchased from BioChain Institute), and one pool of 10 individual adult cerebellar 
RNAs (Clontech Laboratories). Sample clinical information can be found in Table 5.2, 
on page 186. 
 
2.1.3. Tumour histopathology 
A histopathological review of the selected medulloblastoma cases for the array 
study was undertaken by a clinical neuropathologist (Dr. Thomas Jacques). 
Haematoxylin and eosin (H&E) slides from the original diagnosis were re-evaluated and 
tumour features of anaplasia, nodularity and desmoplasia (collagen deposition) were 
graded for each tumour sample according to published criteria [15, 141]. Anaplasia was 
graded as none, slight, moderate or severe according to increasing levels of nuclear 
enlargement and pleomorphism, extensive mitosis, extensive apoptosis and cell 
wrapping. The extent of anaplasia was considered diffuse when anaplasia was present in 
all fields examined; otherwise, it was designated focal. Nodularity was graded 
according to the percentage of tumour area that consisted of nodules: extensive (96-
100% of the area contained nodules), widespread (51-95%), moderate (11-50%), slight 
(1-10%), or none (no nodules). Desmoplasia was scored as being present or absent. 
According to this histological grading, each tumour was classified into one of the major 
medulloblastoma variants: classic (no or slight anaplasia, no or slight nodularity), 
desmoplastic (presence of desmoplasia and nodularity) or anaplastic (moderate or 
severe anaplasia).   
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Prior to RNA extraction, a 10 µm tissue section was cut from each frozen 
tumour sample using a cryostat and H&E staining was performed by Sian Gibson in the 
histopathology laboratory of GOSH. Stained sections were then examined to confirm 
that the frozen specimen was representative of the tumour. 
 
2.2. Exon array study 
2.2.1. RNA processing and array hybridisation 
  Total RNA was extracted from frozen tissue specimens as described in section 
2.4.1.1. Two g of each RNA sample was processed by Nipurna Jina and Sean Barry at 
the ICH Gene Microarray Centre at UCL using the Affymetrix GeneChip Whole 
Transcript Sense Target Labelling Assay [142]. The majority of ribosomal RNA was 
depleted from each RNA sample to increase sensitivity, then an in vitro transcription-
based linear amplification was carried out and finally, single stranded DNA targets were 
generated in the sense orientation. A schematic representation of the major steps of the 
procedure is shown in Figure 2.1. Fragmented and labelled DNA was applied to the 
Affymetrix GeneChip Human Exon 1.0 ST arrays. Hybridisation was performed for 16 
hours at 45 
oC with constant rotation. The following day chips were washed and stained 
with SAPE (Streptavidin Phycoerythrin) according to the manufacturer’s 
recommendations and then scanned. GeneChip Operating System software was used to 
read image files and to convert them into workable .CEL intensity files. 
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Figure 2.1. Schematic representation of the whole transcript sense target labelling assay. 
To increase the assay sensitivity, most of the ribosomal RNA was removed from the total RNA samples. 
The remaining RNA was reverse-transcribed into double-stranded cDNA using short random 
oligonucleotide primers linked to a T7 promoter. Antisense RNA (cRNA) was generated by in vitro 
transcription, before a second cycle of cDNA synthesis was carried out through random priming and 
addition of dUTP to the nucleotide substrates. The cRNA template was digested by RNase H treatment, 
and the remaining sense strand cDNA was fragmented using a combination of uracil-DNA glycosylase 
and human apurinic/apyrimidinic endonuclease, which cut the DNA where dUTP has been incorporated. 
Finally, DNA fragments were terminally labelled with biotin molecules and hybridised to the Affymetrix 
chip. Unbound DNA was washed from the chip and Streptavidin Phycoerythrin was added followed by 
biotinylated anti-streptavidin antibody to stain the hybridised DNA molecules before scanning.  
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2.2.2. Affymetrix Human Exon 1.0 ST array 
The Affymetrix Human Exon arrays consist of approximately 5.5 million 
probes, targeting the whole length of protein coding transcripts across the entire 
genome. The expression signals obtained from these probes are summarised into probe 
set signals, which provide a measure of expression of individual exons. The collection 
of probe sets mapping to the same gene structure constitutes a transcript cluster (gene). 
By combining the expression signals of all of the probe sets that belong to one transcript 
cluster, it is possible to calculate an accurate estimate of gene expression as well as to 
identify events of differential exon inclusion or skipping (Figure 2.2).  
  Statistical analysis of exon array data was carried out at two levels: firstly, at the 
gene level, to identify genes differentially expressed between normal and tumour 
samples; secondly, at the exon level, to investigate patterns of alternative splicing.  
 
2.2.3. Exon array analysis software 
Exon array data analysis was performed with the help of two main tools: the 
Affymetrix Expression Console software, which is freely available from the Affymetrix 
website; and Bioconductor, an open source software project primarily based on the R 
programming language. I used Expression Console to read .CEL files and generate gene 
and exon expression values, whereas I used R and Bioconductor for the subsequent 
statistical analysis.  
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Figure 2.2. Affymetrix Exon array design.  
Probes are distributed along the entire length of the gene. On average, four different probes map to each 
individual exon and their expression signals are summarised into a single probe set signal (exon 
expression value). Probe sets, in turn, can be assembled into virtual transcript clusters to provide the 
expression signal of all the transcripts encoded by the same gene (gene expression value). Two levels of 
analysis can be performed: one at the probe set level, to provide information about alternative splicing; 
and one at the transcript cluster level, to investigate differential gene expression. Green boxes represent 
exons. Grey boxes are introns which are removed during mRNA splicing. Adapted from the Affymetrix 
datasheet [143].   
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2.2.4. Gene level summary, quality control and analysis 
Gene-level signal estimates were calculated by applying the PLIER (Probe 
Logarithmic Intensity Error) algorithm [144], and including only those probe sets that 
map to well-annotated exons (core probe sets). Variance
 stabilisation was obtained by 
adding the small constant 16
 to all the data points, followed by log2 transformation 
[144]. 
As a quality control analysis, I drew box plots and density plots which described the 
overall signal distribution of every individual sample within the dataset. Samples whose 
intensity signals deviated from the common distribution of the set were excluded from 
further analysis. 
Prior to statistical analysis, a filter based on expression was applied to remove 
any genes not expressed across the entire dataset. I used the detection above background 
(DABG) algorithm, which is implemented in Expression Console, to generate a 
detection p-value for every individual probe set based on the background signal 
distribution of control probes on the array. I considered a gene to be expressed in any 
given sample if at least 75% of its targeting probe sets had a detection p-value < 0.05. 
Genes considered to be expressed in less than three samples were filtered out. 
Once filtered, the gene-level dataset was analysed to identify differentially 
expressed genes (DEGs) between sample subgroups, using the moderated t-statistic of 
the LIMMA package [145] and applying False Discovery Rate (FDR) to correct for 
multiple testing. The LIMMA moderated t-statistic differs from the ordinary Student’s 
t-statistic in the way it estimates a moderated standard error for every gene by taking 
into account information from all other genes. This procedure shrinks estimated 
standard errors towards a pooled estimate, relatively increasing and decreasing small 
and large sample variances respectively, to reduce the likelihood that significant  
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statistics arise merely from under-estimated sample variances. Moderated statistics such 
as the one in the LIMMA package have been reported to work particularly well with 
small microarray datasets [145]. FDR controls the expected proportion of false positives 
within the collection of significant observations. For example, if 100 observations were 
considered to be significantly different between two sample groups with a maximum 
FDR value of 0.05, we would expect 5 of these observations to be false positives.  
Lists of significantly up- and down-regulated genes obtained from statistical 
comparisons were subjected to functional enrichment analysis using DAVID functional 
annotation tools [146].  
 
2.2.5. Alternative splicing analysis 
Alternatively spliced exons were identified by Dr. Sonia Shah at the 
Bloomsbury Centre for Bioinformatics, UCL. Following the removal of cross-
hybridising probe sets, as according to Affymetrix annotation, exon- and gene-level 
signal estimates were generated through the Robust Multichip Average (RMA) 
algorithm [147]. To reduce false positives caused by non-expressed genes or non-
expressed exons across all samples, background noise was filtered out. This was 
achieved by excluding probe sets and transcript clusters from the dataset which fell into 
the lowest quartile of the expression signal distribution in all samples.  
The Splicing Index algorithm was applied to identify alternative splicing events 
between sample subgroups. This method aims to identify those exons that show 
significantly different inclusion rates between two groups of samples. It assumes that in 
the absence of splicing, the observed signal from each exon would have a constant ratio 
with the observed signal from its gene across all samples. A ratio that differed 
significantly between two groups of samples would be indicative of differential  
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splicing. For every probe set a gene-level normalized intensity (NI) value (probe set 
signal / gene signal) was calculated and NI average values across sample subgroups 
were compared through the LIMMA moderated t-statistic and FDR correction to 
identify statistically significant differences. A splicing index value was also calculated 
as the log2 ratio between NI values in different subgroups. 
Statistical analysis of differential splicing has been reported to be particularly 
prone to the generation of false positives [148, 149]. Filtering of potential false 
positives was done through manual inspection of the data using expression plots. For 
example, I discarded probe sets whose expression value strongly and uniformly 
deviated from the profile of adjacent probe sets, as they most probably indicated cross-
hybridising, poorly performing probes or non-expressed exons [150]. Finally, I selected 
the most promising splicing patterns by visualising probe sets in their genomic context 
using the publicly available annotation database X:MAP [151]. This database provides 
information about the location of each exon within the gene, known alternative splicing 
events, presence of overlapping transcripts and potential artefacts of Affymetrix 
transcript annotations, such as multiple genes being combined into a single transcript 
cluster. I evaluated all of this information and selected a subset of most promising 
alternative splicing events for further analysis.  
 
2.3. Cell biology 
2.3.1. Cell lines 
2.3.1.1. Daoy 
  The Daoy cell line was established in 1985 by Jacobsen et al. from a portion of a 
desmoplastic medulloblastoma of a 4-year-old boy [152]. Daoy cells are adherent in 
culture and display a polygonal shape with prominent nuclei and multiple nucleoli. The  
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Daoy cell line is hyper-tetraploid, with the majority of cells possessing between 93 and 
99 chromosomes. We purchased the Daoy cell line from the American Type Culture 
Collection.  
 
2.3.1.2. UW228-2 
  The UW228-2 cell line was established by Keles et al. in 1995 from the surgical 
specimen of a primary medulloblastoma in the posterior fossa of a 9-year-old female 
patient [153]. UW228-2 cells are adherent in culture and are not sensitive to cell-contact 
inhibition. They display multiple chromosomal aberrations, among which is the loss of 
heterozygosity for a distal sequence on the short arm of chromosome 17. The UW228-2 
cell line was the kind gift of Professor Silvia Marino from Barts and The London 
School of Medicine and Dentistry, London.  
 
2.3.1.3. D425 Med 
  The D425 Med cell line was established in the late 1980s by Friedman et al. 
from the resected tumour tissue of a 5-year-old boy with medulloblastoma [23]. 
Chromosomal analysis revealed that the D425 Med cell line is near-diploid and displays 
some of the structural abnormalities most commonly described in human 
medulloblastoma, such as isochromosome 17q and abundant double minutes, which 
have been associated with amplification of the c-Myc gene [23]. D425 Med cells are 
semi-adherent in culture and display spheroid morphology. The D425 Med cell line was 
the kind gift of Professor Silvia Marino from Barts and The London School of Medicine 
and Dentistry, London.  
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2.3.1.4. 293FT 
  The 293FT cell line is a fast growing variant of the HEK 293 cell line, a 
permanent line established by Graham et al. in 1977 by exposing primary human 
embryonic kidney cells to sheared fragments of adenovirus type 5 DNA [154]. 293FT 
cells constitutively express the SV40 large T antigen under the control of the human 
cytomegalovirus promoter. Overexpression of the large T antigen favours the 
replication of packaging and lentiviral expression plasmids containing the SV40 origin 
of replication and generally enhances lentiviral production [155]. The 293FT cell line is 
therefore an ideal host for the production of non-replicating lentiviral particles. We 
purchased the 293FT cell line from Invitrogen.  
 
2.3.2. Cell culture conditions 
  Unless otherwise stated, cells were cultured in complete culture medium 
consisting of Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine and 1% penicillin-streptomycin (all from 
Invitrogen). Cell cultures were kept in an incubator at 37 
oC in an atmosphere of 5% 
CO2.  
  Cell cultures were regularly checked for mycoplasma contamination using a 
MycoProbe mycoplasma detection assay (R&D Systems) according to the 
manufacturer’s instructions. The MycoProbe assay detects approximately 95% of all of 
the mycoplasma contaminants using a colorimetric signal amplification system which 
targets the mycoplasma 16S ribosomal RNA.  
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2.3.3. Subculture 
  When cells reached approximately 80% confluence, the culture medium was 
discarded and the cells were rinsed with PBS to remove any residual serum and 
incubated for a few minutes at 37 
oC with 1 ml of trypsin-EDTA per 10 cm dish. When 
starting to detach from the dish, the cells were harvested in fresh complete medium and 
centrifuged at 1,200 rpm in an Eppendorf 5810 R bench-top centrifuge (Eppendorf UK 
Ltd) for 5 minutes. The resulting cell pellet was resuspended in culture medium and 
replated at 1:4 to 1:20 dilutions, depending on cell density.  
 
2.3.4. Freezing cultured cells  
  Cells were harvested and pelletted as described in section 2.3.3. The cell pellet 
was resuspended in a small volume of culture medium and cells were counted using a 
Neubauer haemocytometer. Cells were diluted in freezing medium (culture medium 
plus 10% cell culture grade DMSO) at a concentration of 1 x 10
6 cells/ml and 1ml 
aliquots were dispensed into cryovials and transferred to a -80 
oC freezer in a Nalgene 
freezing container (Nalgene Labware) to assure the optimal cooling rate of -1
 oC per 
minute which avoids the formation of intracellular ice crystals. After 24 hours, cells 
were transferred to liquid nitrogen for longer storage. 
 
2.3.5. Recovery of frozen cells 
  A vial of frozen cells was rapidly thawed in a water bath at 37 
oC. The cells 
were then transferred to a centrifuge tube containing 10 ml of culture medium and 
centrifuged at 1,200 rpm for 5 minutes to remove the DMSO. Cells were resuspended in 
complete culture medium, plated in a 10 cm dish and maintained in an incubator at 37 
oC with 5% CO2. Cells were re-fed with fresh complete medium after 24 hours.     
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2.3.6. Isolation and culture of mouse granule cell precursors 
2.3.6.1. Granule cell precursor preparation 
Granule cell precursors (GCPs) were isolated from 7 or 8-day-old C57Bl/6 mice 
according to the procedure described by Wechsler-Reya et al. [43]. Cerebella were 
dissected, stripped of their meninges, cut into small pieces, and digested for 30 minutes 
at 37 
oC in a solution containing 10 U/ml of papain (Lorne Laboratories Ltd), 200 μg/ml 
L-cysteine (Sigma Aldrich) and 250 U/ml of DNase I (Sigma Aldrich). A single-cell 
suspension was obtained by triturating the cerebella in PBS containing 8 mg/ml of 
chicken egg white trypsin inhibitor (Roche Diagnostics Corporation), 8 mg/ml of 
bovine serum albumin (BSA, Sigma Aldrich) and 250 U/ml of DNase I. The cells were 
then centrifuged, resuspended in PBS containing 200 µg/ml of BSA (PBS-BSA), and 
passed through a cell strainer to remove debris. GCPs were selectively isolated by 
centrifugation through a step gradient of 35% and 65% Percoll (Sigma Aldrich) and 
harvested from the 35%-65% interface. After a wash in PBS-BSA, the cells were 
resuspended in neurobasal medium supplemented with 2% B-27 serum free supplement, 
1 mM sodium pyruvate, 2 mM L-glutamine and 1% penicillin/streptomycin (all from 
Invitrogen). GCPs were plated on poly-D-lysine-coated plasticware or glass coverslips 
at a density of 1 x 10
6 cells/ml and incubated at 37 C in 5% CO2.  
To maintain the precursor state, 3 µg/ml of recombinant ShhN (R&D Systems) 
was added to the cell culture medium immediately after plating. Alternatively, ShhN 
supernatant, generated as described in section 2.3.6.3  was added to the cell culture 
medium at 20% v/v. A similar amount of mock supernatant was used for the control 
culture.  
 
  
 
73
2.3.6.2. Poly-D-lysine coating of culture plates  
  To favour the adhesion of mouse GCPs to culture surfaces, glass coverslips 
(placed in 24-well plates) and plastic culture plates were treated with a solution of 70-
150 kDa poly-D-lysine (Sigma Aldrich) at a concentration of 0.2 mg/ml and 0.02 mg/ml 
respectively. A suitable volume of poly-D-lysine solution was used to completely coat 
the culture surface. After two hours, the solution was removed by aspiration and the 
surface was washed three times with tissue culture grade water. Coated plates were air-
dried, sealed with parafilm and stored at 4 C until needed.  
 
2.3.6.3. Preparation of Shh and mock supernatants 
293FT cells were cultured in 10 cm dishes in antibiotic-free medium until they 
reached 40-60% confluence. To prepare the transfection mixture, 25 μl of FuGene 6 
reagent (Roche Diagnostics Corporation) was added to 600 μl of DMEM and incubated 
at room temperature for five minutes. Nine μg of plasmid DNA, either rat ShhN 
expression plasmid (described in section 2.5.1.1) or pcDNA 3.1 control plasmid 
(Invitrogen), was added to the mixture and incubated at room temperature for a further 
30 minutes. The transfection mixture was then added to the cells in culture in a drop-
wise fashion. After 24 hours, culture medium was discarded and replaced with 8 ml of 
fresh complete culture medium. Culture medium was then harvested every 24 hours for 
72 hours and stored at 4 C. After each harvest 8 ml of fresh medium was added to the 
culture and the cells were discarded on the third day. ShhN supernatants from the three 
consecutive harvests were combined, filtered through 0.45 μm filters and stored at -80 
C in 5 ml aliquots. Similarly, frozen aliquots were generated for the mock supernatant. 
To confirm the presence of ShhN in the ShhN supernatant, western blots were carried  
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out using serial dilutions of ShhN and mock supernatants, and recombinant ShhN as a 
control.  
 
2.3.7. Producing lentivirus in 293FT cells 
  To produce lentiviral particles, 6 x 10
6 293FT cells were plated in a 10 cm dish 
in 10 ml of culture medium and co-transfected with 5 µg of lentiviral transgene 
expression plasmid, 3.75 µg of packaging plasmid and 1.5 µg of envelope expression 
plasmid, using 36 µl of Lipofectamine 2000 reagent (Invitrogen) diluted in Opti-MEM I 
medium without serum (Invitrogen). Transfection was carried out overnight at 37 C 
with 5% CO2. The following day, the transfection supernatant was replaced with 8 ml of 
fresh complete culture medium. 48 hours after transfection, the virus-containing 
supernatant was harvested and cells were discarded. Floating cells and cell debris were 
removed by filtering the supernatant through 0.45 µm filters and 1 ml viral aliquots 
were prepared and stored at -80 C until use.  
  To determine viral titre, serial dilutions of the viral preparations were used to 
transduce 293FT cells seeded in 6-well plates. Transduction was carried out as 
described in section 2.3.8. The cell culture medium was changed every 24 hours for 72 
hours, at which time, the proportion of transduced cells (i.e. EGFP expressing cells) was 
measured on a BD FACSArray bioanalyser system as described in section 2.3.9.1 and 
data corresponding to the viral dilution factor yielding about 10-15% of transduced cells 
was used to calculated viral titre as follow: 
T = (F x C0 / V) x 1000 
where T is the titre (number of infectious particles per ml of viral preparation), F is the 
frequency of transduced cells, C0 is the number of cells at the time of transduction and 
V is the volume of virus added to the cells [μl].   
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2.3.8. Lentiviral transduction of immortalised cell lines 
  Target cells were plated in 6-well plates at a density of 50,000 cells/well (Daoy 
and UW228-2 cell lines) or 100,000 cells/well (D425 Med cell line) and allowed to 
grow overnight. Typically cells were inoculated with defrosted viral aliquots at a 
multiplicity of infection (MOI) of 0.1 (Daoy and UW228-2) or 0.5 (D425 Med) in a 
final volume of 2 ml. This would normally give a transduction efficiency ranging 
between 50% and 80%. Cells were spin-infected by centrifuging the plates at 1,800 rpm 
for 45 minutes at room temperature and then incubated overnight at 37 C / 5% CO2. 
After 24 hours, the culture medium was replaced with fresh complete medium. 48 hours 
after transduction, the cells were ready to be assayed for transgene expression and 
functional studies.  
  When a 100% proportion of transgene-expressing cells was required, a 
puromycin selection protocol was applied to remove the non-transduced cells from the 
culture. At least 48 hours post-transduction, cell culture medium was replaced with 
fresh medium containing 0.5 μg/ml (D425 Med cells) or 1 μg/ml (Daoy and UW228-2 
cells) of puromycin antibiotic (Sigma Aldrich). Puromycin treatment was carried out for 
four to five days, using a sample of non-transduced cells to monitor how efficiently the 
antibiotic caused cell death. Following puromycin treatment, the percentage of 
transduced cells was measured by flow cytometry as the proportion of EGFP expressing 
cells. Cultures were kept in puromycin-free medium for an additional week before 
performing any other assays.  
 
2.3.9. Flow cytometry 
  Flow cytometry assays were performed at the flow cytometry core facility at the 
UCL Institute of Child Health using either the BD LSRII or the BD FACSArray  
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bioanalyser system (both from BD Biosciences). Fcs files generated by cytometry 
analysis were analysed using the Summit v4.3 software (Beckman Coulter).  
 
2.3.9.1. Detection of EGFP-positive cells 
  Transduced cells were washed in PBS, incubated in Trypsin-EDTA at 37 C for 
2 minutes and harvested in 1 ml of complete medium directly into flow cytometry 
tubes. A non-transduced sample was used to set up voltage parameters and define a 
threshold for the autofluorescence signal. A gate was applied to include only live cells 
and at least 10,000 events/sample were recorded. A histogram showing EGFP signal on 
the x-axis and cell count on the y-axis was used to visualise the distribution of EGFP 
fluorescence.  
 
2.3.9.2. Cell cycle analysis 
  Flow cytometry cell cycle analysis was performed by labelling nuclear DNA 
with Propidium Iodide (PI). PI is a fluorescent dye which intercalates between nucleic 
acid bases and is commonly used to quantitatively assess cellular DNA content. The 
assay is based on the principle that as cells progress through the cell cycle their DNA 
content doubles from 2n in G1, gradually increasing through the S phase, up to 4n in 
G2/M. PI labelling of fixed cells can therefore be used to analyse the cell cycle 
distribution of whole cell populations. Because PI can also bind to RNA, an RNase 
treatment is necessary to allow the selective labelling of nuclear DNA.  
  Cells were harvested, washed in PBS and pelleted through centrifugation. One 
ml of ice-cold 70% ethanol was added dropwise to the cell pellet while vortexing to 
ensure homogeneous fixation of all cells. The sample was incubated for at least 30 
minutes at 4 C and spun at 2,000 rpm for 5 minutes. The supernatant was discarded  
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and cells were washed twice in PBS. The cell pellet was treated with 50 μl of 
ribonuclease A (Sigma Aldrich) at 100 µg/ml to get rid of RNA. 400 μl of a 50 µg/ml PI 
solution (Sigma Aldrich) in PBS was added to the pellet and the sample was incubated 
in the dark for 30 minutes prior to flow cytometry analysis.  
  A dot plot showing PI signal area versus PI signal width was used to gate on 
single cells and filter out doublets and cell clumps. A second plot representing PI signal 
on the x-axis and cell count on the y-axis was then used to estimate the percentage of 
cells in each cell cycle phase.  
 
2.3.9.3. Bromodeoxyuridine staining for flow cytometry analysis 
  Bromodeoxyuridine (BrdU) is a thymidine analogue which is readily 
incorporated into DNA by cells undergoing DNA synthesis during the S phase of the 
cell cycle. Flow cytometry analysis of BrdU incorporation allows cell cycle studies to 
be performed which add a dynamic dimension to the PI analysis described above, since 
only cells that are actively cycling will incorporate BrdU.  
  For the last 30 minutes to 3 hours of culture, cells were incubated with fresh 
medium containing 10 µM BrdU (Roche Diagnostics Corporation). Cells were then 
harvested using trypsin, washed in PBS and fixed in 1 ml of ice cold 70% ethanol. After 
30 minutes at 4 C, cells were centrifuged at 2,000 rpm for 5 minutes and washed twice 
in 1 ml of PBS. To unwind the DNA, cells were resuspended in 1 ml of 2N 
hydrochloric acid and left at room temperature for 30 minutes with occasional mixing. 
Two more washes in PBS were performed, followed by a third wash in PBS-T (PBS, 
0.2% Tween 20, 1% BSA). Two μl of anti-BrdU antibody (Abcam) was added directly 
to the cell pellet and incubated for 30 minutes at room temperature. Following one wash 
in PBS-T, cells were incubated in a 1:10 dilution of fluorescein-conjugated anti-rat-IgG  
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antibody (Roche Diagnostics Corporation) for 30 minutes at room temperature, in the 
dark. Cells were then washed in PBS-T and incubated for 30 minutes in 50 μl RNase A 
(100 µg/ml) and 400 μl of PI (50 µg/ml) prior to flow cytometry analysis.  
Single cells were gated on a dot plot graph showing PI signal area versus PI signal 
width. A second dot plot showing PI signal on the x-axis and BrdU signal on the y-axis 
was used to visualise cell cycle distribution. The cell scatter plot formed a characteristic 
horseshoe profile, allowing the distinction of G1, S and G2/M phases.  
 
2.3.10. Immunocytochemistry 
2.3.10.1. Coverslip preparation 
  Glass coverslips were placed in a centrifuge tube containing 2N NaOH for 
sterilisation and incubated for two hours on a tube roller to assure constant rotation. 
Coverslips were rinsed thoroughly with tissue culture grade water and stored in sterile 
70% ethanol. Before use, coverslips were allowed to air dry inside a class I tissue 
culture hood.  
 
2.3.10.2. Intracellular antigen staining 
  For immunocytochemistry analysis, cells were cultured on sterilised glass 
coverslips in 24-well plates and then fixed with 4% paraformaldehyde (PFA) at room 
temperature for 15 minutes. Following three washes in PBS, cells were blocked and 
permeabilised for an hour in a solution of 10% sheep serum (Sigma Aldrich) and 0.1% 
Triton X-100 (Sigma Aldrich) in PBS. Cells were incubated with primary antibodies 
diluted in 1% sheep serum in PBS overnight at 4 C. A negative control was incubated 
in 1% sheep serum in PBS in the absence of primary antibody to check for any auto-
fluorescence of the secondary antibody. Three more washes in PBS were performed  
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before incubating cells with fluorochrome-conjugated secondary antibodies diluted in 
1% sheep serum in PBS for 2 hours at room temperature. Cells were carefully rinsed 
with PBS and coverslips were mounted on slides using ProLong Gold antifade reagent 
with DAPI (Invitrogen). All antibodies used for immunocytochemistry analysis are 
listed in Table 2.1. 
 
Table 2.1. Antibodies used for immunocytochemistry. 
 
Antibody  Company/Cat. number  Source  Working dilution 
Anti‐NeuN  Millipore/Chemicon 
MAB377 
Mouse  1:250 
Anti‐GFAP  Millipore/Chemicon 
MAB360 
Mouse  1:250 
Anti‐Brn2 (Pou3F2)  Santa Cruz Biotechnology 
sc‐28594 
Rabbit  1:250 
Anti‐Ube2C (UbcH10)  Boston Biochem 
A‐650 
Rabbit  1:400 
Anti‐BrdU  Abcam  
Ab6326 
Rat  1:400 
Fluorescein‐conjugated 
anti‐rat IgG 
Jackson ImmunoResearch 
Laboratories 
712‐095‐153 
Donkey  1:500 
Rhodamine‐conjugated 
anti‐mouse IgG 
Jackson ImmunoResearch 
Laboratories 
715‐025‐150 
Donkey  1:500 
Rhodamine‐conjugated 
anti‐rabbit IgG 
Jackson ImmunoResearch 
Laboratories 
711‐025‐152 
Donkey  1:500 
 
 
2.3.10.3. Bromodeoxyuridine staining for immunocytochemistry 
  Cells growing on coverslips were incubated with 10 µM bromodeoxyuridine 
(BrdU, Roche Diagnostics Corporation) for the last 30 minutes to 3 hours of culture 
depending on the experiment. Cells were washed and fixed in 4% PFA as described in 
section 2.3.10.2. Cells were permeabilised in ice-cold methanol for 1 minute at -20 C, 
before being incubated for one hour in a blocking solution containing 10% sheep serum, 
0.1% Triton X-100 and DNaseI at 10 µg/ml (Roche Diagnostics Corporation) to unwind 
the DNA. Cells were then stained and mounted as described in section 2.3.10.2.   
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  This same protocol was applied for both single-labelling of BrdU and double-
labelling of intracellular antigens and BrdU. 
 
2.3.10.4. Image capture and processing 
Fluorochrome-labelled cells mounted on slides were visualised on a Zeiss 
Axioplan fluorescence microscope (Carl Zeiss Ltd) using a x63 objective with Immersol 
oil, and images were captured using a Quantix digital camera and Smart Capture VP 
software. Image files were processed using the ImageJ software. 
 
2.4. Molecular biology 
2.4.1. Total RNA isolation 
2.4.1.1. RNA isolation from frozen tissues using the RNeasy mini kit 
  Up to 30 mg of frozen tissue was disrupted in 600 µl of RLT buffer (RNeasy 
mini kit, QIAGEN) using a disposable plastic pestle. The suspension was finely 
homogenised through a QIAshredder homogenizer (QIAGEN) and transferred to an 
RNeasy spin column for total RNA isolation with an RNeasy mini kit, according to the 
manufacturer’s instructions. An on-column DNase digestion was performed to eliminate 
genomic DNA contamination. RNA was stored at -80 °C. 
 
2.4.1.2. RNA isolation using the TRIzol reagent 
Up to 5 x 10
6 cells growing in culture were washed with ice-cold PBS and 
harvested in 1ml of TRIzol reagent (Invitrogen). Alternatively, up to 30 mg of frozen 
tissue was ground up in 1ml of TRIzol reagent using a disposable plastic pestle. 
Homogenised samples were incubated at room temperature for 5 minutes to allow the 
complete dissociation of nucleo-protein complexes before adding 200 µl of chloroform.  
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Tubes were vigorously shaken for 15 seconds and centrifuged at 11,000 rpm in an 
Eppendorf tabletop centrifuge for 15 minutes at 4 °C. The upper aqueous phase was 
collected in a fresh tube and RNA was precipitated with isopropanol. After 10 minutes 
at room temperature, RNA was pelleted by centrifuging at 11,000 rpm for 10 minutes at 
4 °C, washed in ice-cold 70% ethanol, and resuspended in 20 l of RNase-free water.  
  To remove contaminating DNA, up to 1 µg of total RNA was incubated for 15 
minutes at room temperature with 1 unit of DNase I (Invitrogen). The reaction was 
stopped by adding EDTA to 2.5 mM and heating at 65 °C for 10 minutes. RNA was 
stored at -80 °C. 
 
2.4.1.3. RNA quality control 
  RNA purity and concentration were assessed by measuring sample absorbance 
at 260 and 280 nm using the NanoDrop spectrophotometer (Thermo Fisher Scientific). 
An A260/A280 ratio higher than 1.8 was considered indicative of highly purified RNA.  
RNA samples to be used for the exon array study were profiled using the Agilent 
Bioanalyser (Agilent Technologies) to assess total RNA integrity.  
 
2.4.2. First strand cDNA synthesis  
Total RNA was reverse transcribed into first strand cDNA using SuperScript II 
reverse transcriptase (RT, Invitrogen), a modified version of the Moloney Murine 
Leukemia Virus RT, and oligo(dT).  
  Up to 1 g of DNAse-treated total RNA was heated to 65 °C for 5 minutes in 
the presence of oligo(dT) at a final concentration of 25 g/ml and dNTPs, each at a final 
concentration of 0.5 mM. 5X RT buffer and DTT (10 mM final concentration) were 
then added and a pre-incubation at 42 °C for 2 minutes was carried out. Finally, 200  
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units of SuperScript II RT were added to the reaction before incubating at 42 °C for 50 
minutes. The enzyme was then heat-inactivated at 70 °C for 15 minutes and samples 
were stored at -20 °C. 
 
2.4.3. Polymerase Chain Reaction (PCR) 
2.4.3.1. Primer design 
  PCR primers were designed using the online open access Primer3 software 
developed at the Whitehead Institute for Biomedical Research [156]. Whenever 
possible, forward and reverse primers were chosen to selectively amplify cDNA 
templates. As a general rule, primer pairs with no or very low self-complementarity 
were chosen to reduce the probability of primer dimer formation. 
  For the validation of cassette-exon splicing events, primers were designed to 
recognise sequences located upstream and downstream of the candidate cassette exon, 
so as to generate PCR products of different sizes depending on the inclusion or 
exclusion of the target exon from the spliced transcript. Alternative ends of the 
transcript were discriminated using two independent pairs of primers, each specifically 
targeting one individual splicing variant. Primers for whole gene expression analysis 
were chosen to amplify regions of the target gene common to all Ensembl-annotated 
transcript variants (http://ensembl.genomics.org.cn/index.html). 
  To confirm target specificity, primer sequences were aligned against whole 
organism nucleotide databases using the NCBI nucleotide blast program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). A complete list of the primer sequences used 
for this project can be found in Appendix 1.  
Desalted primer oligonucleotides were purchased from Sigma Aldrich.  
  
 
83
2.4.3.2. Semi-quantitative PCR  
  Approximately 5 ng of cDNA template was mixed with 1X CoralLoad PCR 
buffer (QIAGEN), a mix of dNTPs (Promega) at 200 μM each, 0.5 μM of forward and 
reverse primers and one unit of Taq DNA polymerase (QIAGEN). Following an initial 
5-minute heating step at 95 °C, the PCR reaction was performed for 26 to 34 cycles, 
each of which consisted of a 30 second denaturation step at 95 °C, followed by a 30 
second annealing step at 60 °C and a 30 second extension step at 72 °C. The reaction 
was completed with a final elongation step at 72 °C for 5 minutes before cooling down 
to 4 °C. For cDNA amplicons of more than 600 base pairs, the extension step was 
prolonged to 45 seconds.  
Generally, PCR products were analysed at least twice, at increasing numbers of cycles. 
Each time 5 µl of PCR product was directly loaded on a 2% agarose gel and DNA 
electrophoresis was performed as described in section 2.5.4. 
 
2.4.3.3. Estimation of the ratio between cassette-exon splice variants  
After electrophoresis, agarose gels were photographed using a UVI-doc gel 
documentation system and the PCR-amplified DNA bands corresponding to the two 
alternatively spliced transcript forms were quantified using the ImageQuant TL v2005 
software (GE Healthcare).  
A simple formula was developed to quantify the prevalence of one or the other 
form in each individual sample. The formula computes the ratio between the difference 
and the average of the signal intensities of the two alternative splice forms (Splicing 
Indicator). The outcome is a number which only ranges from -2 to 2. A Splicing 
Indicator value of 2 is obtained when only the band corresponding to target exon  
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inclusion is visible on the gel. Conversely, a value of -2 indicates the exclusive 
amplification of the splice form in which the target exon is excluded.  
 
2.4.3.4. Real Time PCR  
  To validate alternative end of transcript splicing events, Real Time PCR was 
performed using the SYBR Green chemistry. Reactions containing 1X SYBR Green 
PCR master mix (Applied Biosystems), 0.5 μM of forward and reverse primers and 
approximately 5 ng of cDNA template were run in triplicate or quadruplicate on a 
7900HT Fast Real-Time PCR System (Applied Biosystems). The amplification protocol 
included an initial step at 95 °C for 10 minutes, followed by 40 cycles of both a 
denaturation step at 95 °C for 15 seconds and an annealing/extension step at 60 °C for 1 
minute. To confirm the absence of primer-dimers, a dissociation curve analysis was 
performed at the end of the run.  
  To verify the equal amplification efficiency of different primer pairs, an initial 
optimisation protocol was carried out to generate standard curves based on increasing 
concentrations of a cDNA template. Amplification rates for the different primer pairs 
were compared through the ΔCt method and PCR efficiencies were calculated based on 
the slope of the standard curves [157]. Following this initial analysis, the 2
-ΔΔCt relative 
quantitation method could be applied to measure the relative abundance of one 
transcript form relative to the other, using one of the samples as the internal calibrator.  
  TaqMan chemistry was used for Real Time PCR analysis of whole gene 
expression. Optimised individual assays containing gene specific primers and probe 
were purchased from Applied Biosystems. Reaction mixes contained 1X TaqMan PCR 
master mix (Applied Biosystems), 1X primer/probe solution and approximately 5 ng of 
cDNA template. A fast PCR protocol was performed, consisting of 40 cycles of  
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denaturation at 95 °C for 1 second followed by annealing/extension at 60 °C for 20 
seconds. Transcript abundance relative to housekeeping gene expression was calculated 
by applying the 2
-ΔΔCt method. 
 
2.4.4. Preparation of protein extracts from cells in culture 
Cells growing in culture were rinsed in ice-cold PBS and harvested using a cell 
scraper. Following one more wash in ice-cold PBS, cells were pelleted by 
centrifugation, lysed in SDS buffer containing 10 mM Tris-HCl, 150 mM NaCl, 0.5 
mM EDTA, 1 mM EGTA, 1% SDS, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) 
and 2% v/v of a mammalian protease inhibitor cocktail (Sigma Aldrich) and incubated 
for 20 minutes at 90 °C. Cell debris was pelleted by high speed centrifugation for 20 
minutes, the protein-containing supernatant was collected in a fresh tube and protein 
concentration was determined using a Bio-Rad protein assay (Bio-Rad Laboratories) 
with known concentrations of gamma globulin protein to generate a standard curve.  
  
2.4.5. Western blotting 
Protein samples were mixed with 5X SDS sample buffer to obtain a final 
concentration of 62.5 mM Tris-Cl pH 6.8, 10% glycerol, 2% SDS, 0.1% β-
mercaptoethanol and 0.0005% bromophenol blue. Samples were then boiled for 5 
minutes, vortexed and spun before loading on the gel. 
Denatured proteins were separated by SDS polyacrylamide gel electrophoresis 
on gels cast with concentrations of acrylamide ranging from 8% to 13% depending on 
the size of the protein to be resolved (for a detailed composition of stacking and 
resolving gels, see Table 2.3, on page 94). Acrylamide gels were usually run at 80 Volts 
for two hours in SDS running buffer (Table 2.3), in a Mini-PROTEAN electrophoresis  
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chamber (Bio-Rad Laboratories). Proteins were then transferred to an Immobilon-P 
membrane (Millipore Ltd), by electroblotting in 1X transfer buffer (Table 2.3) using a 
Mini-PROTEAN blotting module (Bio-Rad Laboratories) and applying a constant 
voltage of 35 Volts for 3 hours. To prevent non-specific binding, the membrane was 
incubated for 45 minutes in a blocking solution of 5% non-fat dry milk and 0.05% v/v 
Tween 20 in TBS (Table 2.3).  
  Primary antibody incubation was carried out at 4 °C overnight in blocking 
solution. The membrane was then washed thoroughly in TBS containing 0.05% v/v 
Tween 20 (TBS-T) and incubated with a peroxidise-conjugated secondary antibody in 
5% non-fat dry milk in TBS-T for one hour at room temperature. Following a 60-
minute long series of washes in TBS-T, proteins were detected using the ECL Plus 
Western Blotting detection system (GE Healthcare) and protein bands were visualised 
by exposing the blot to an ECL hyperfilm (GE Healthcare). For protein quantitation, 
films were scanned and analysed using the Bio-Rad Quantity One analysis software 
(Bio-Rad Laboratories).  
  Membranes to be re-probed were dipped in methanol to drive out the water and 
allowed to dry on a paper sheet before being re-activated by soaking in methanol for 15 
seconds and washing in water for 2 minutes. A list of the primary antibodies used for 
western blotting experiments can be found in Table 2.2. 
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Table 2.2. Antibodies used for western blotting. 
 
Antibody  Company/Cat. number  Source  Working dilution 
Anti‐Gli1  Santa Cruz Biotechnology 
sc‐20687 
Rabbit  1:1000 
Anti‐Shh  Cell Signaling Technology 
2287 
Rabbit  1:1000 
Anti‐Brn2 (Pou3F2)  Santa Cruz Biotechnology 
sc‐28594 
Rabbit  1:1000 
Anti‐Pttg1 (Securin)  Abcam 
Ab3305 
Mouse  1:1000 
Anti‐Bmi  Abcam 
Ab14389 
Mouse  1:500 
Anti‐Ube2C (UbcH10)  Boston Biochem 
A‐650 
Rabbit  1:1000 
Anti‐Gapdh  Cell Signaling Technology 
2118 
Rabbit  1:1000 
Anti‐β‐actin  Cell Signaling Technology 
3700 
Mouse  1:1000 
 
 
2.5. Molecular cloning 
2.5.1. Plasmid vectors 
2.5.1.1. Rat ShhN expression plasmid 
  The rat ShhN expression plasmid was kindly provided by Dr. Robert Wechsler-
Reya, Duke University Medical Center, Durham, North Carolina. The DNA sequence 
encoding amino acid residues Met 1 – Gly 198 of rat Sonic hedgehog (Shh) is cloned 
within the pMT21 parent plasmid. The 198 amino acid residue protein encoded by the 
plasmid corresponds to the 20 kDa N-terminal domain of rat Shh, which is generated 
through an autocatalytic reaction required for Shh signalling activity. The Shh N-
terminal domain (ShhN) is secreted from the cell and is responsible for all known Shh 
signalling functions.  
 
2.5.1.2. pGIPZ lentiviral vector  
  The pGIPZ lentiviral vector was developed by Open Biosystems in collaboration 
with Dr. Gregory Hannon (Cold Spring Harbour Laboratory, NY) and Dr. Stephen  
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Elledge (Harvard University Medical School, Boston, MA), with the aim to achieve 
effective messenger-RNA silencing in a wide variety of cell types, including primary 
and non-dividing cells. The pGIPZ vector is designed to express short hairpin RNA 
constructs (shRNAs) within the context of the human microRNA-30 (miR30). The 
shRNA consists of a 22-nucelotide double-stranded RNA (sense and antisense strands) 
and a 19-nucleotide loop from human miR30, embedded in 125 nucleotides of miR30 
flanking sequence on either side (Figure 2.3A). This design allows the expression of the 
shRNA from an RNA polymerase II promoter and was shown to increase the ability of 
shRNAs to down-regulate their target genes, by enhancing shRNA processing by the 
RNase III enzymes Drosha and Dicer [158].  
The shRNA is transcribed as part of a multicistronic mRNA for the co-expression of the 
EGFP reporter gene and a mammalian selectable marker (puromycin resistance gene), 
thereby allowing the tracking and selection of shRNA producing cells (Figure 2.3B).  
  In order to generate replication-defective lentiviral particles, pGIPZ vectors 
expressing the shRNA of interest were co-transfected into 293FT cells together with the 
psPAX2 vector, expressing the gag and pol viral packaging proteins, and the pMD2.G 
vector, containing the VSV-G viral envelope expression cassette (both vectors were a 
kind gift from Professor Didier Trono, Ecole Polytechnique Federale de Lausanne, 
Lausanne, Switzerland). 
 
2.5.1.3. pGIPZ-SFFV lentiviral vector  
  The pGIPZ-SFFV lentiviral vector is a modified version of the pGIPZ vector in 
which the cytomegalovirus (CMV) promoter was substituted for the spleen focus 
forming virus (SFFV) long terminal repeat (LTR) sequence. A pGIPZ recipient vector 
was generated by removing the CMV-EGFP cassette by XbaI restriction digestion  
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followed by 5' overhang blunting and NotI digestion. Similarly, an SFFV-EGFP insert 
was generated from the pHR-SIN-CSGW vector [159] by EcoRI digestion, 5' overhang 
blunting and NotI digestion. Finally the SFFV-EGFP insert was subcloned into the 
pGIPZ recipient vector.  
 
2.5.2. Restriction digestion 
A reaction mix containing up to 3 µg of plasmid DNA, restriction enzymes at 10 
units per µg of DNA and 1X optimal restriction buffer was incubated at 37 °C for 2-4 
hours. Digested products were then mixed with 6X orange loading dye (15% Ficoll, 
0.25% Orange G in distilled water) and analysed by agarose gel electrophoresis as 
described in section 2.5.4.  
 
2.5.3. Blunting reaction 
  Following restriction enzyme digestion, 5 units of T4 DNA polymerase/µg of 
plasmid DNA was added to the reaction tube, together with dNTPs at a final 
concentration of 100 µM and a compatible restriction enzyme 10X buffer in a final 
volume of 50 µl. The reaction was incubated at 37 °C for 10 or 5 minutes to blunt 5'- or 
3'-overhangs respectively.  
 
2.5.4. Agarose gel electrophoresis 
Plasmid DNA from restriction enzyme digestion were resolved on 1% agarose 
gels, whilst PCR products, normally within the range of 100-700 bps, were resolved on 
2% agarose gels. Molecular biology grade Agarose (Invitrogen) was weighed out and 
then microwaved in1X TAE buffer (Table 2.3). Ethidium bromide was added to a final 
concentration of 0.5 μg/ml. Once set, the gel was placed in a Horizon 11.14  
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Figure 2.3. Schematic representation of the pGIPZ shRNAmir lentiviral vector.  
 
(A) Secondary structure fold of endogenous miR30 microRNA and miR30-based shRNAs. In pGIPZ, the 
mature miR30 coding sequence (upper hairpin) is replaced with sequences encoding shRNAs which 
target any gene of choice (lower hairpin). Adapted from Stegmeier et al. [160].  
 
(B) A diagram of the pGIPZ lentiviral vector and its main features. Adapted from the Open Biosystem 
website [161].  
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electrophoresis chamber (Biometra) filled with 1X TAE buffer and DNA samples 
containing 1X loading buffer were loaded into the wells. One well was loaded with a 
DNA ladder of known size, 1 kb Plus DNA ladder (Invitrogen) or GeneRuler 50 bp 
DNA ladder (Fermentas Life Sciences) for restriction enzyme digests or PCR products 
respectively. Typically, a constant voltage of 100 Volts was applied to the gel for 30-60 
minutes. After electrophoresis, the DNA bands were visualised under UV light. 
 
2.5.5. Purification of DNA from agarose gels 
Following electrophoresis, the DNA bands of interest were excised from the 
agarose gel using a disposable scalpel. DNA was purified from the gel using a 
QIAquick Gel Extraction kit (QIAGEN) according to the manufacturer’s guidelines. 
 
2.5.6. Ligation of DNA fragments 
Typically, 100 ng of plasmid vector DNA was mixed with insert DNA at 1:3 
and 1:1 molar ratios. Three units of T4 DNA ligase and 2X rapid ligation buffer (both 
from Promega) were added to the ligation mix to give a 10 µl final volume. The ligation 
reaction was incubated at room temperature for 15 minutes. 
 
2.5.7. Bacterial transformation 
  For routine molecular cloning, I used subcloning efficiency DH5α competent 
cells (Invitrogen). Briefly, 50 µl of E.coli DH5α cells were mixed in a tube with 4 µl of 
ligation reaction or 1 ng of plasmid DNA and incubated on ice for 30 minutes. Cells 
were then heat shocked for precisely 20 seconds at 42 °C and cooled on ice for 2 
minutes. Each sample was diluted in 900 µl of pre-warmed LB medium (Table 2.3) and 
incubated for 1 hour at 37 °C with constant shaking. Up to 200 µl from each  
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transformation was spread on pre-warmed LB-agar plates (Table 2.3) containing the 
appropriate selection antibiotic (either ampicillin at 100 μg/ml or kanamycin at 50 
μg/ml, depending on the plasmid). Plates were incubated overnight at 37 °C. 
  For transformation of large or problematic plasmids, I used library efficiency 
DH5α competent cells (Invitrogen), following the protocol described above except that 
there was a 45-second heat shock step. 
 
2.5.8. Isolation of Plasmid DNA 
  Small scale preparations of plasmid DNA (mini preps) for colony screening 
were obtained by picking single well-isolated transformation colonies from an agar 
plate and transferring them to individual tubes containing 5 ml of LB medium with the 
appropriate antibiotic for selection. The small cultures were grown overnight at 37 °C 
with constant shaking. Bacterial cells were harvested by centrifugation at 4,000 rpm for 
15 minutes at room temperature and plasmid DNA was purified using a QIAprep spin 
miniprep kit (QIAGEN) and a microcentrifuge, according to the manufacturer’s 
instructions. 
  For transfection experiments, larger preparations of purified plasmid DNA 
(maxi preps) were generated. A single transformation colony containing the plasmid of 
interest was transferred to a starter 5 ml culture of LB medium containing the selective 
antibiotic. The culture was allowed to grow for 7-8 hours at 37 °C in a shaking 
incubator after which it was transferred to a larger flask containing 400 ml of selective 
LB medium and was incubated for 14-16 hours at 37 °C with constant shaking. 
Bacterial cells were centrifuged in a Sorvall RC5B plus ultra-centrifuge at 10,000 rpm 
for 20 minutes at 4 °C. Plasmid DNA was purified using a Genopure plasmid maxi kit  
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(Roche Diagnostics Corporation) following the procedure for high copy number 
plasmids as per manufacturer’s instructions.  
 
2.5.9. PCR subcloning 
  PCR products were subcloned into the pGEM-T Easy vector (Promega). The 
pGEM-T Easy vector is a linearised vector with 3' thymidine-overhangs at both ends 
which facilitate the insertion of 3' adenine-tailed PCR products generated by some 
thermostable DNA polymerases. Briefly, the PCR fragment of interest was purified 
from the agarose gel as described in section 2.5.5. A 10 µl ligation reaction was set up 
containing 3 µl of PCR insert, 25 ng of plasmid vector, 3 units of T4 DNA ligase and 
2X rapid ligation buffer (both from Promega). After 1 hour incubation at room 
temperature, 4 µl of the reaction was used to transform subcloning efficiency DH5α 
competent cells as described in section 2.5.7. To allow for blue/white colony selection,  
100 µl of 0.1 M IPTG (Insight Biotechnology Ltd) and 50 µl of 20 mg/ml Xgal 
(Promega) were spread on top of the ampicillin agar plates before seeding the bacteria. 
 
2.5.10. Sequencing 
  To confirm the DNA sequence of plasmid constructs or PCR products, a small 
amount of purified DNA was sent to The Wolfson Institute for Biomedical Research 
DNA sequencing facility at UCL to be analysed on an Applied Biosystems 3730xl 
Genetic Analyser. Sequencing results were provided in the form of .ab1 files which 
were then examined using FinchTV analysis software (Geospiza). Sequence comparison 
was performed using the NCBI nucleotide BLAST tools.  
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2.6. Statistics 
  Unless otherwise stated, data were analysed using two-tailed Student's t-test and 
comparisons were considered statistically significant for p-values < 0.05. In cases where 
other statistical tools were more appropriate, details of the analysis were described in 
the individual figure legends.  
 
2.7. Buffers and solutions 
  The composition of all buffers and solutions used for this project are listed in 
Table 2.3. 
 
Table 2.3. Buffers and solutions. 
 
Buffer/Solution  Components 
LB (Luria‐Bertani) medium  1% w/v bacto‐tryptone (BD Biosciences) 
0.5% w/v bacto‐yeast extract (BD Biosciences) 
17 mM NaCl 
LB agar   1.5% w/v bacto‐agar (BD Biosciences) in LB medium 
TAE (Tris‐acetate‐EDTA 
electrophoresis buffer) 
40 mM Tris‐acetate 
1 mM EDTA 
Stacking gel   13% v/v 30% acrylamide/0.8% bis‐acrylamide solution (National 
Diagnostics) to obtain a final concentration of 3.9% acrylamide 
125 mM Tris‐HCl pH 6.8 
0.1% SDS 
0.05% ammonium persulfate 
0.2% TEMED 
Resolving gel  33% v/v 30% acrylamide/0.8% bis‐acrylamide solution (National 
Diagnostics) for a 10% acrylamide gel 
375 mM Tris‐HCl pH 8.8 
0.1% SDS 
0.05% ammonium persulfate 
0.2% TEMED 
SDS running buffer   25 mM Tris Base 
250 mM glycine 
0.1% SDS 
Transfer buffer  25 mM Tris Base 
250 mM glycine 
20% v/v methanol 
TBS (Tris Buffered Saline)  100 mM Tris‐HCl pH 7.6 
150 mM NaCl 
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Chapter 3 
Exon array analysis of paediatric medulloblastomas 
 
 
 
3.1. Introduction 
  During the past decade, a few seminal papers have described the use of genome-
wide approaches to classify large cohorts of medulloblastomas into discrete molecular 
subgroups characterised by alterations in specific signalling pathways [20, 92, 100]. 
These studies largely contributed to the notion that medulloblastoma is a heterogeneous 
disease and that different clinical outcomes might be associated with particular tumour 
molecular fingerprints.  
  In the light of these findings, it became interesting to look at the molecular 
profile of medulloblastoma patients treated at GOSH, and to generate a novel 
expression data set providing an additional level of analysis of the molecular 
complexity of human medulloblastoma.  
  Within our group, we decided to use the novel Affymetrix Human Exon 1.0 ST 
array platform to measure the expression level of more than one million exons in human 
medulloblastoma and normal cerebellum. With more than 5.5 million individual probes 
mapping to both cDNA-supported transcripts (e.g. RefSeq mRNAs) and in silico 
predicted gene structure sequences (e.g. from Ensembl), Affymetrix exon arrays are 
among the most powerful expression tools currently available (Figure 2.2). At the gene 
level, an average of 40 probes are distributed across the entire length of the gene, 
generating a more sensitive and robust measurement of gene expression compared to 
traditional 3'-based approaches where probes exclusively cover the 3'-end of genes. At  
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the exon level, approximately four probes per exon provide an estimate of individual 
exon expression and support the detection of alternative splicing.  
  This chapter contains a description of the samples used for microarray profiling 
and a summary of low level data analysis, including sample molecular classification 
according to specific gene signatures.  
 
3.2. Histopathological classification and sample processing 
A total of 14 snap-frozen paediatric medulloblastoma samples (median age of 
7.3 years) were obtained from the Histopathology Department of GOSH and the 
original H&E stains were evaluated by a clinical neuropathologist (Dr. Thomas 
Jacques) as described in section 2.1.3. On review, four cases were classified as classic 
medulloblastoma and ten as anaplastic medulloblastoma. The spectrum of histology is 
shown in Figures 3.1 and 3.2.  
  H&E staining performed on frozen tissue sections confirmed that all of the 
medulloblastoma samples used in this project consisted predominantly of tumour cells 
and that they were representative of the diagnosed tumours (two examples are shown in 
Figure 3.3). Sections of the normal cerebellum sample obtained from GOSH did not 
show evidence of neoplasia, except for a small area at the periphery where astrocytoma 
cells were detectable, and that was eventually cut off before RNA extraction. Table 3.1 
summarises histological and clinical features of the 19 samples included in the array 
study.  
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Table 3.1. Patients and tumour features of the sample series used for the exon array 
study. 
Medulloblastoma samples 
Sample Id  Sex 
Age at 
surgery 
(years) 
Pathology              
(CLA, classic;           
ANA, anaplastic) 
Nodularity  Desmoplasia 
Anaplasia 
Grade 
Anaplasia 
Extent 
T1  F  6.5  ANA  Slight ‐  Severe  Diffuse 
T3  F  2.7  CLA  Slight ‐  None  ‐‐ 
T7  M  14.7  ANA  None ‐  Severe  Diffuse 
T8  F  5.7  ANA  Slight  +  Severe  Diffuse 
T9  M  5.8  CLA  None  +  Slight  Focal 
T10  M  5.7  CLA  None  +  Slight  Focal 
T11  F  8.1  ANA  None ‐   Moderate  Diffuse 
T12  M  1.9  ANA  None ‐  Severe  Diffuse 
T13  M  10.3  ANA  None ‐   Moderate  Focal 
T15  M  8.3  ANA  None ‐   Moderate  Focal 
T16  F  9.7  ANA  Slight ‐  Severe  Diffuse 
T17  M  7.8  ANA  None ‐   Moderate  Focal 
T18  F  6.8  ANA  None ‐  Severe  Diffuse 
T19  M  11.3  CLA  Slight ‐  Slight  Focal 
Normal cerebellar samples 
Sample Id  Sex  Age (years)  Source  Notes 
CB1  na  na  GOSH  
CB2  F/M  16‐70  Clontech  pool of 24 individuals 
CB3  M  63  Ambion  
CBF1  F  Fetus (37 weeks gestation)  BioChain  
CBF2  F  Fetus (40 weeks gestation)  BioChain    
             
The table illustrates histological and clinical parameters for the 19 samples used in the exon array study. 
The upper part lists medulloblastoma samples; the lower part describes normal cerebellar samples.  
F, female; M, male; GOSH, Great Ormond Street Hospital; na, not available.   
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Figure 3.1. Histopathological grading of anaplasia in medulloblastoma.  
Anaplasia was graded as none (A), slight (B), moderate (C) or severe (D) according to increasing levels 
of nuclear enlargement and pleomorphism, extensive mitosis, extensive apoptosis and cell wrapping. A-D 
show H&E stains performed on paraffin-embedded sections of medulloblastoma samples. Insets are 
enlarged to the right of each panel.  
 
(A) The medulloblastoma with no anaplasia is composed of small, morphologically uniform cells with a 
high nuclear-cytoplasmic ratio.  
 
(B) A representative field of a medulloblastoma with slight anaplasia showing nuclear enlargement. 
Patterns resembling Homer-Wright rosettes are formed in this tumour (inset).   
 
(C) Large areas of abundant apoptosis and polyhedral cell morphology are typical features of 
medulloblastomas with moderate anaplasia. Arrow heads point to apoptotic cells.    
 
(D) Severely anaplastic medulloblastomas feature larger, pleomorphic cells with high mitotic index and 
occasional cell wrapping (arrow head).  
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Figure 3.2. Medulloblastoma features of nodularity and desmoplasia, and normal cerebellum.  
A-B show H&E stains performed on paraffin-embedded sections of medulloblastoma samples. C is a 
stained section of snap frozen normal cerebellum. Insets are enlarged to the right of each panel. 
 
(A) An example of a classic medulloblastoma showing a slight degree of nodularity. The nodular area (N) 
contains small neurocytic cells with abundant cytoplasm and is surrounded by moderately pleomorphic 
cells with higher nuclear-cytoplasmic ratios.  
 
(B) A region of desmoplasia characterised by abundant pericellular collagen deposition.  
 
(C) A section of normal adult cerebellum showing a fine structured cortex with a completely formed 
mature internal granule layer (IGL), a Purkinje cell layer (PL) and a molecular layer (ML). P, Purkinje 
neuron.   
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Figure 3.3. Histology of medulloblastoma frozen sections.  
H&E staining performed on frozen tissue sections confirmed that the specimens used for the exon array 
study consisted predominantly of tumour cells and were representative of the diagnosed 
medulloblastomas. Two examples are shown. Insets are enlarged to the right of each panel. 
 
(A) Frozen section H&E stain of the classic medulloblastoma with no anaplasia described in Figure 3.1A.  
 
(B) Frozen section H&E stain of the medulloblastoma with severe anaplasia described in Figure 3.1D. An 
example of cell wrapping is indicated by the arrow head.   
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3.3. Exon array quality control and filtering 
  Total RNA was extracted from all tissue samples (14 medulloblastomas and one 
normal cerebellum obtained from GOSH). One μg of each RNA sample, including the 
four samples of normal cerebellum obtained from commercial sources, was then 
processed and hybridised to the exon array. 
  Low level array analysis was initially applied to assess the overall experiment 
performance and to identify potential sample outliers. Briefly, gene level signal 
estimates were generated and box plots were drawn to visualise signal variation among 
different arrays. As shown in Figure 3.4, individual array signal distributions largely 
overlapped, which excluded any general hybridisation problems. A filter based on 
expression was applied to remove genes with very low expression across the entire data 
set and which contributed to the background signal noise potentially affecting 
subsequent analysis. This led to the generation of a final data set consisting of 12,160 
genes, which appeared to be significantly expressed in at least three out of the 19 total 
samples. Figure 3.5 represents a schematic overview of the initial analysis workflow 
while in Figure 3.6 density curves illustrate the effect of the filtering step on signal 
distribution.  
  I used unsupervised clustering as an explorative method to assess the overall 
quality of the microarray experiment. Samples with the most similar expression profiles 
are grouped together; therefore, biological replicates belonging to the same histological 
category are expected to cluster together. As expected, normal and tumour samples 
segregated into two discrete clusters (Figure 3.7). Within the normal cerebellum cluster, 
it was possible to distinguish fetal from adult samples. The four medulloblastomas 
designated as classic clustered in the same tumour subgroup, together with four 
anaplastic medulloblastomas, mostly characterised by lower degrees of anaplasia. A  
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second tumour cluster contained six anaplastic medulloblastomas, five of which 
displayed severe anaplasia (Figure 3.7). Although clinical and histological parameters 
did not completely explain the molecular variability observed within the data set, 
normal and malignant tissues significantly diverged (p-value < 0.0001), and I could see 
a trend for more anaplastic tumours to cluster together (p-value = 0.057), which 
strongly supported the good quality of the data.   
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Figure 3.4. Sample signal distribution.  
Box plots were used to describe the overall gene signal distribution for each individual sample within the 
dataset. The left and right edges of each box correspond to the 25th percentile and 75th percentile, 
respectively. The median value is shown as a vertical line through each box. Whiskers extend to 1.5 times 
the inter-quartile range (defined as the difference between the 75th and 25th percentiles), and outliers are 
marked with circles. Individual signal distributions appeared to consistently overlap, which indicated an 
overall good performance of the microarray experiments. Red, medulloblastoma samples; blue, normal 
cerebellum samples.   
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Figure 3.5. Schematic overview of low level analysis and filtering of the exon array data. 
Intensity files (.CEL files) were generated with the GeneChip Operating System software following exon 
array hybridisation and scanning and were loaded into the Expression Console software for low-level 
analysis. The probe logarithmic intensity error estimate (PLIER) algorithm was used to summarise probe 
intensities into gene-level signal estimates for the 22,011 genes represented on the array. Background 
noise was detected with the detection above background (DABG) algorithm and the resulting probe set 
signal detection p-values were used to assign a detection call to each gene. Following the removal of all 
control features, a filter based on gene expression was applied to the remaining 17,817 genes, generating 
a final dataset of 12,160 genes to be used for the subsequent gene-level analysis.   
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Figure 3.6. Filter on gene expression.  
A filter based on expression was applied to remove genes not expressed across the entire dataset. A gene 
was considered expressed if at least 75% of its targeting probe sets had a detection p-value < 0.05. Only 
genes expressed in at least three out of 19 samples were selected for further analysis. The density plots 
illustrated above show the dataset signal distribution before (black) and after (red) applying the filter. 
Each line corresponds to an individual sample. After filtering, the minor peak on the left of the graph 
corresponding to genes expressed at a low level disappeared.     
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Figure 3.7. Unsupervised hierarchical cluster analysis.  
The dendrogram was computed on the expression levels of 624 genes with a variance value across all 
samples higher than 2. Distances between samples were calculated using the Euclidean distance metric 
and are measured on the graph along the vertical axis. The shorter the bar to the junction node between 
two samples, the more similar the samples are. The three major clusters are colour-coded as follows: blue 
bars, normal cerebella; green bars, anaplastic medulloblastomas, mainly characterised by severe 
anaplasia; brown bars, a mix of classic and mostly moderate anaplastic medulloblastomas. The Pearson 
Chi-Square test was used to assess the significance of clinical differences across clustering subgroups. 
Differences in age distributions were tested using the Kruskal-Wallis test. The Pearson Chi-Square test on 
histology performed on the two tumour clusters only (i.e. testing classic vs anaplastic histology) generated 
a significant p-value of 0.04. NS, non significant, NA, not available.  
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3.4. Sample subgrouping based on the Shh gene expression signature 
  Before performing statistical analysis for differential gene expression, I used 
gene-level expression profiles to identify samples expressing gene signatures 
characteristic of previously described medulloblastoma molecular subgroups. I 
performed an unsupervised hierarchical clustering of the 523 genes corresponding to the 
Shh-signature genes reported in Thompson’s data series [20], as supported by the 
Affymetrix Best Match array comparison spreadsheet (www.affymetrix.com). Three 
anaplastic medulloblastoma samples segregated in a discrete cluster (Figure 3.8) and, 
when compared to the other samples, showed significant overexpression of genes 
typically belonging to the Shh signalling pathway or associated with a cerebellar 
granule cell precursor state, such as GLI1, MYCN and ATOH1 (Figure 3.8). These three 
samples were therefore classified as Shh-driven tumours (SHH).  
  Similarly, I applied cluster analysis using the other gene lists identified by 
Thompson  et al., but none of the samples seemed to express any distinctive gene 
signatures, therefore I grouped all of the remaining tumour samples together as 
medulloblastoma subset 2 (MB2). 
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Figure 3.8. A medulloblastoma subgroup is characterised by the Shh-gene signature.  
The clustering was computed on the expression levels of 523 genes which corresponded to the Shh-
signature genes in Thompson’s data series. The Euclidean distance metric was used as a measure of 
distance between samples. Three medulloblastoma samples formed a discrete cluster and were classified 
as Shh-driven medulloblastomas (SHH). Abnormal activation of the Shh signalling pathway in these 
samples was confirmed by the significant overexpression of Shh-related genes (FDR adjusted p-value < 
0.01), as shown in the heatmap. Two different transcript clusters for the MYCN gene are shown. All 
remaining medulloblastoma samples were subgrouped together for further analysis (MB2). A summary of 
the major clinical parameters is reported at the bottom. Histology: white = normal CB, grey = classic MB, 
orange = anaplastic MB; Age: white = fetal, yellow = <3 years, grey = >3 years, orange = adult; Sex: 
white = female, grey = male, orange = pool.  
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3.5. Discussion 
  In this chapter I have described the collection, processing and hybridisation of a 
set of paediatric medulloblastomas and normal cerebellar samples to the Affymetrix 
Human Exon arrays, and the initial steps of array data analysis.  
  Tumour samples displayed features of either classic or anaplastic histological 
subtype and were classified accordingly. Following array hybridisation and an initial 
assessment of experiment performance, I applied a filter on gene expression level and 
obtained a workable data set for subsequent analysis (Figure 3.5). Unsupervised 
hierarchical clustering of the most informative genes confirmed that samples from the 
same biological classification shared similar expression profiles (normal cerebellum vs 
tumour, p-value < 0.0001; classic vs anaplastic medulloblastomas, p-value = 0.04). 
However, histological features of nodularity, desmoplasia and anaplasia extent did not 
appear to affect the overall clustering results (Figure 3.7). Although previous studies 
had described specific molecular subgroups to strongly associate with the infant patient 
population (< 3 years) [20, 92], I did not find any significant correlation between age 
and clustering subgroups (Figure 3.7). Still, this result might have been biased due to 
the limited number of younger patients in my medulloblastoma cohort.  
  I performed one more unsupervised cluster analysis using a well characterised 
list of Shh-associated genes (Figure 3.8). Remarkably, although none of the tumours in 
my cohort belonged to the desmoplastic histological subtype, which is significantly 
over-represented among Shh-driven medulloblastomas; three samples of anaplastic 
medulloblastoma formed a discrete cluster and expressed significantly higher levels of 
genes involved in Shh signalling, such as PTCH2,  GLI1,  BOC, and HHIP. Known 
targets of the Shh signalling pathway such as MYCN, FOXM1 and MELK were also 
overexpressed in this cluster, as well as the GCP marker ATOH1 (Figure 3.8). Of note,  
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these three Shh-activated tumour samples were also subgrouped together in the previous 
analysis, in which samples were clustered according to the expression profile of the 
most variable genes (samples T7, T8 and T16 in Figure 3.7). 
  The percentage of Shh-activated tumours in my sample set (21%) was in line 
with previously published studies (24% in Kool et al. [92], 19.5% in Thompson et al. 
[20], 30% in Northcott et al. [107]). Even so, I failed to identify tumours matching any 
of the other four gene signatures described in Thompson et al., probably because of the 
relatively small size of my sample set. Since several studies agree on a few genetic 
features characterising medulloblastomas with activated WNT signalling pathway, such 
as mutations in the CTNNB1 gene encoding the β-catenin protein [19], it would be 
interesting to perform mutation analysis as an alternative method to identify samples 
belonging to the WNT medulloblastoma subtype. It will also be important to update 
patients’ clinical information with details regarding their clinical course, as 
medulloblastoma patients’ outcome significantly differs as a function of the tumour 
molecular features [9].  
  To summarise, initial array data analysis showed evidence of good experimental 
performance and a significant association between the biological classification of the 
samples and similarities in gene expression. A group of three Shh-driven 
medulloblastomas was identified based on the expression profile of well characterised 
Shh-related genes, which would allow the investigation of Shh-mediated differential 
gene expression and splicing. On the other hand, the remaining medulloblastoma 
samples did not demonstrate a similarly distinct gene signature and were therefore 
grouped together for subsequent analysis.  
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Chapter 4 
Analysis of differential gene expression in paediatric 
medulloblastoma 
 
 
 
4.1. Introduction 
  In recent years, the use of sophisticated microarray technologies has greatly 
improved our understanding of the molecular alterations underlying human cancer 
[106]. The use of integrated genomic approaches has led to significant advances in the 
molecular characterisation of human medulloblastoma. These approaches provide a 
more accurate classification of tumour subtypes when compared to histological analysis 
alone. Furthermore, they can also identify additional genes involved in 
medulloblastoma pathogenesis and this will lead to the development of new therapeutic 
regimens, specifically designed to address a heterogeneous patient population [7, 25, 
162].  
  Because medulloblastoma originates from immature precursor cells in the 
cerebellum, functional analysis of putative tumour-associated genes typically involves 
the investigation of gene-regulated biological processes in the context of normal 
cerebellar development [27, 28, 163]. Primary cultures of mouse granule cell precursors 
(GCPs) constitute one of the best characterised in vitro models for the analysis of 
candidate gene function [163]. In a seminal paper published in 1999, Wechsler-Reya 
and Scott described the in vitro culture of Shh-dependent mouse GCPs [43]. While 
granule cell cultures had been used for a long time to study cerebellar cell biology [164, 
165], the use of Shh to promote cell proliferation and maintain an undifferentiated state 
represented a fundamental step forward in our understanding of the mechanisms  
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regulating growth and oncogenesis in the cerebellum. Since then, GCP cultures have 
been used in numerous studies investigating the role of candidate genes in the regulation 
of cell cycle progression [44-46, 48, 53, 54, 59, 66, 166], leading to the generation of 
genetically engineered mice in which specific genetic alterations targeting the GCP 
lineage favour the development of cerebellar tumours [36, 81, 82, 85].  
  The functional characterisation of putative tumour genes also relies on the use of 
human medulloblastoma cell lines [167]. Because these cells can be indefinitely 
propagated in vitro and injected into the flank or brain of immuno-compromised mice to 
recapitulate the tumour of origin, human tumour cell lines constitute a useful model of 
human cancer and are used in the majority of preclinical studies [168]. In contrast to 
other cancer types which are readily established as immortalised cell lines, only a small 
percentage of human medulloblastomas successfully give rise to cell lines in culture 
[169, 170]. In addition, a recent study by Sasai et al. showed that medulloblastoma cell 
cultures established from Shh-dependent tumours developed in Ptch
+/-  p53
-/-  mice 
down-regulate Shh pathway activity and are therefore unable to respond to hedgehog 
antagonists [171]. The authors suggested that the propagation of tumour cells in culture 
leads to permanent epigenetic changes which induce Shh pathway silencing [171]. 
Based on these findings, caution should be used when working with medulloblastoma 
cell lines as models of the primary tumours from which they are derived. Nevertheless, 
several studies have successfully used a variety of well characterised cell lines to gain 
insights into the molecular pathogenesis of human medulloblastoma, highlighting the 
value of medulloblastoma cells as an in vitro model for the preliminary functional 
analysis of candidate genes [172-177].   
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  For my project, I cultured both mouse primary GCPs and human 
medulloblastoma cell lines to assess the importance of candidate gene expression for the 
proliferation of normal cerebellar precursor and medulloblastoma cells, respectively.  
  In this chapter, I compared gene-level expression profiles of medulloblastoma 
and normal cerebellar tissues and identified a selection of genes overexpressed in Shh-
driven medulloblastomas. As an initial step in the characterisation of the selected genes, 
I analysed their expression patterns in in vitro cultures of GCPs maintained in the 
presence or absence of Shh, as well as in human medulloblastoma cell lines. This 
chapter also describes preliminary studies in which I used a lentiviral expression system 
to study the biological effects of candidate gene knockdown in medulloblastoma cell 
lines.  
 
4.2. Identification of genes differentially expressed in Shh-driven 
medulloblastomas 
  Following the identification of a subset of Shh-driven medulloblastoma samples 
within my data set (SHH tumours), I was interested in characterising their gene 
expression profile in more detail. I therefore compared gene expression values between 
the SHH tumour subset and three other sample subgroups, that is the entire set of five 
normal cerebellar samples (all CB), the subset of adult normal cerebella (adult CB), or 
the remaining subset of non-Shh-associated tumours (MB2), as shown in Figure 4.1A. 
Each individual comparison generated a list of differentially expressed genes (DEGs), 
which were either up- or down-regulated in SHH tumours. Figure 4.1A shows a 
schematic description of gene-level analysis, including the number of DEGs identified 
for each individual comparison. As expected, SHH and MB2 tumours shared more 
similar expression profiles compared to normal cerebella. As a result, I obtained a  
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workable number of DEGs for the SHH versus MB2 comparison at the higher 
significance threshold of 0.01, as opposed to the 0.001 significance level applied for the 
other two comparisons (Figure 4.1A). In total, 278 and 300 unique genes were 
identified as being respectively up- and down-regulated in SHH tumours. The 50 most 
significantly differentially expressed genes for each list are shown in Figure 4.2. The 
complete lists can be found in Appendices 2 and 3. In Figure 4.1B a Venn diagram was 
drawn representing the intersections between the three lists of DEGs identified. Of note, 
six genes were significantly deregulated in all three comparisons. These include the 
MYCN gene, one of the best characterised Shh-driven medulloblastoma signature genes.  
  For a general description of the biological relevance of DEGs, I performed 
functional enrichment analysis of Gene Ontology (GO) terms and tissue annotations 
(Figures 4.3 and 4.4). This type of analysis identifies annotation terms which are 
significantly over-represented in any individual gene list with reference to a background 
list, generally consisting of all of the annotated genes represented on the array platform 
in use. I analysed the two lists of genes that were up- and down-regulated in SHH 
tumours independently. Genes overexpressed in SHH tumour samples appeared to be 
involved in cell cycle related processes corresponding to GO terms such as spindle 
organisation, chromosome segregation, DNA replication and mitosis (Figure 4.3, right 
bars). In contrast, the down-regulated genes were typical of a more differentiated 
phenotype, being implicated in specialised cell functions such as synaptic transmission 
and cell-cell signalling (Figure 4.3, left bars). I then looked at the enrichment in tissue 
annotation terms and found that genes up-regulated in SHH tumours were expressed at 
higher levels in normal embryonic and malignant tissues, including medulloblastomas 
(Figure 4.4, right bars). In contrast, down-regulated genes were mostly expressed in 
normal brain tissues, including cerebellum and cerebral cortex (Figure 4.4, left bars).  
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Figure 4.1. Schematic overview of gene-level analysis. 
 
(A) Statistical analysis of differential gene expression was carried out using the moderated t-statistic of 
the LIMMA package in R, and applying false discovery rate (FDR) to correct for multiple testing. Shh-
driven medulloblastomas (SHH) were compared to the five normal cerebellar samples (all CB), the adult 
cerebellar samples (adult CB), or the second tumour subset (MB2). In each case, a significance threshold 
was set based on FDR adjusted p-values, as detailed in the flow chart. Numbers in boxes refer to the 
number of genes which were selected at any particular step of the analysis. In total, 278 and 300 unique 
genes were identified as being respectively up- and down-regulated in SHH tumours. Functional 
enrichment analysis was performed on the two lists of up- and down-regulated genes. Candidate genes for 
following studies were selected from the up-regulated gene set.    
  
(B) Venn diagram of DEG lists identified by different subgroup comparisons.    
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Figure 4.2. Top 50 genes up- and down-regulated in Shh-driven medulloblastomas.  
Two heatmaps show the expression of the 50 most significantly up- (A) and down-regulated genes (B) in 
SHH tumours compared to the other sample groups. Both samples and genes were clustered according to 
their expression profiles and the corresponding dendrograms are shown to the top and to the left of the 
heatmaps, respectively. Samples subgroups are colour-coded as follows: dark blue, normal fetal CB; light 
blue, normal adult CB; red, SHH; green, MB2. A green-red colour palette was used to illustrate gene 
expression values, with green corresponding to low and red corresponding to high expression.  
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Figure 4.3. Functional enrichment analysis of Gene Ontology terms. 
Gene Ontology (GO) annotation terms were used to perform functional enrichment analysis using the 
DAVID tools. Briefly, a statistical measure of the likelihood that any individual GO term would appear in 
the DEG list at the observed frequency (as compared to its frequency across the entire population of 
genes represented on the exon array) is calculated together with a p-value indicating the significance of 
the enrichment. Each bar represents a significantly enriched term and is colour-coded according to its 
corresponding p-value. The bar length represents the fold-enrichment, and the figure at the end of each 
bar refers to the number of DEGs described by that term. Genes up- and down-regulated in SHH tumours 
were analysed as separate gene lists and are depicted with bars pointing to the right and to the left, 
respectively. The three major GO categories are specified on the sides: BP, biological process; CC, 
cellular component; MF, molecular function.   
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Figure 4.4. Functional enrichment analysis of tissue annotation. 
DAVID tissue annotation category is based on the data obtained by Serial Analysis of Gene Expression 
(SAGE) of several normal and malignant tissues within the context of the Cancer Genome Anatomy 
Project (CGAP, http://www.ncbi.nlm.nih.gov/ncicgap/). A tissue annotation term is assigned to a gene if 
its expression level is higher in that given tissue as compared to the collection of all other tissues. Since 
several SAGE libraries are taken into account, the same annotation term can occur more than once. For a 
description of histogram features, see figure legend 4.3.  
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They also appeared to be expressed in brain tumours of glial origin, possibly indicating 
the presence of a smaller glial component in SHH tumour samples as opposed to the 
other profiled samples. 
  The DEGs identified in my study included genes differentially expressed in 
SHH tumours compared to either MB2 tumours or normal cerebella. Genes identified 
by medulloblastoma subset comparison are those which contribute to the Shh gene 
expression signature (e.g.  ATOH1,  HHIP,  BOC, etc.); whereas genes selected in 
reference to normal samples are expected to be associated with a more general 
malignant cerebellar phenotype, and were indeed frequently expressed at a rather 
uniform level across all medulloblastoma samples. One of the most highly down-
regulated genes obtained from the SHH versus MB2 comparison was OTX2 (Appendix 
3, page 242), which encodes a critical homeodomain-containing transcription factor 
implicated in brain morphogenesis [178]. Recurrent OTX2 gene amplification and/or 
overexpression were observed both in medulloblastoma cell lines and primary tumours, 
particularly in those of anaplastic histology [179]. Interestingly, by performing genome-
wide screening of differential gene expression, Kool et al. found a significant increase 
in  OTX2 expression levels in primary medulloblastomas that did not express a 
molecular signature of Shh pathway activation [92]. Further evidence of selective 
abnormal expression of OTX2 in Shh-independent tumours came from Adamson et al., 
who also associated gain of OTX2 copy number with a worse prognosis for 
medulloblastoma patients and suggested a role for OTX2 in promoting medulloblastoma 
progression by regulating MYC expression [180]. 
  Compared to normal cerebella, SHH tumours expressed lower levels of several 
genes playing important roles in cerebellar development. Some interesting examples are 
FAT2, GAS7 and GABRA6 (Figure 4.2). The FAT2 gene encodes a member of the well  
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conserved Fat subfamily of protochaderins, which are commonly involved in the 
regulation of cell-cell interactions during morphogenesis [181]. Within the subfamily, 
FAT2 is unique in its restricted expression pattern: in the developing cerebellum, the 
mouse Fat2 protein is specifically detected in non-proliferating granule neurons in the 
inner external germinal layer and in migrating granule neurons, but not in granule cell 
precursors in the outer external germinal layer. Fat2 protein levels peak in differentiated 
granule neurons during the third post-natal week and remain high throughout adulthood 
[182]. It has been suggested that FAT2 could contribute to the regulation of granule cell 
axon organisation in the molecular layer of the cerebellar cortex through its engagement 
in homophilic interactions [182].  
  Growth arrest specific 7 (GAS7) is predominantly expressed in terminally 
differentiating neuronal cells in the mature cerebral cortex, hippocampus and 
cerebellum. It has putative roles in transcriptional regulation, neuronal differentiation 
and neurite formation [183]. GAS7 maps to chromosome 17p, in the proximity of a 
highly unstable chromosomal region putatively involved in the formation of 
isochromosome 17q, the most common chromosomal aberration in medulloblastomas 
[25]. It has therefore been suggested that GAS7 might represent a putative 
medulloblastoma tumour suppressor gene, which is disrupted as a result of i(17q) 
formation. However, GAS7 gene expression has been detected independently of i(17q) 
in a series of childhood medulloblastomas [184] and its potential implication in 
medulloblastoma tumorigenesis remains uncertain.  
  GABRA6 encodes the α6 subunit of the GABA receptor. GABA is the major 
inhibitory neurotransmitter in the mammalian brain and the GABA receptor α6 subunit 
is primarily expressed in cerebellar granule neurons following their terminal  
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differentiation. Its expression is modulated by nuclear factor 1 as part of a neuronal 
lineage specification program [185].  
  Genes significantly up-regulated in the SHH tumour subtype will be discussed 
in the following section.  
 
4.3. Selection of medulloblastoma-associated candidate genes 
  Alongside very well characterised genes which critically define the molecular 
signature of Shh-driven medulloblastomas (e.g. ATOH1, FOXM1, MELK; see Figure 
3.8), I identified several other genes whose expression level was higher in tumour 
samples, particularly in the SHH tumour subset, and whose biological function 
suggested that they may represent interesting tumour candidate genes. Based on their 
expression profiles and on biological information retrieved from the literature, I selected 
14 of these genes for further analysis (Figure 4.5). All of the 14 selected genes were 
expressed at higher levels in SHH tumours compared to normal adult cerebellar 
samples. Several candidate genes were equally overexpressed in all tumour samples 
(e.g.  PLK1,  TROAP), while others were significantly more expressed in the SHH 
tumour subgroup (e.g. POU3F2, DLG7, BAZ1A). In most cases, normal fetal cerebellar 
samples showed higher expression levels than their adult counterpart (e.g. EZH2, 
PTTG1, TEAD2). 
  Most of the selected genes encode spindle related proteins which are normally 
involved in regulating correct chromosome segregation during mitosis (CHEK1, 
UBE2C,  KIF4A,  DLG7,  CASC5,  NUSAP1,  PLK1,  TROAP, and PTTG1). Being 
involved in cell cycle specific processes, these genes typically show a characteristic 
expression profile in which their expression level peaks at the time when they are 
needed for their particular functions [186]. Regardless of whether their observed  
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overexpression in medulloblastoma simply reflects the high proliferation rate of tumour 
cells compared to differentiated normal cerebellar cells, or is actively contributing to the 
tumorigenesis process, these genes represent valuable candidates differentiating 
between normal and tumour cells and they are potential targets for clinical anticancer 
therapies that strategically aim to interfere with checkpoint signalling pathways [187-
191].  
  Other selected genes encode transcription factors implicated in neuronal 
development (POU3F2 and TEAD2) or chromatin-associated proteins participating in 
the chromatin-dependent regulation of transcription (BAZ1A and EZH2). Because 
processes that modulate gene expression within a cell ultimately control cell behaviour, 
defects in both transcription regulation and chromatin have been long associated with 
cancer and a considerable interest is emerging in the development of novel therapies 
targeting these key cellular processes [192, 193].  
  Finally, I selected candidate genes implicated in DNA replication and repair 
(EXO1, CHEK1 and KIF4A). Alterations affecting DNA repair genes are major drivers 
of both hereditary and sporadic cancer [194]. Furthermore, since many of the existing 
chemo- and radiotherapy agents function through their ability to induce DNA damage, 
pharmacological inhibition of DNA repair mechanisms has been explored as a valuable 
approach to enhance drug sensitivity [187, 195].  
  More details of the selected genes’ function and possible role in tumorigenesis 
can be found in Table 4.1.   
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Figure 4.5. Selection of candidate genes up-regulated in Shh-driven medulloblastomas. 
The heatmap show the expression of the 14 selected candidate genes. Samples subgroups are colour-
coded as follows: dark blue bars, normal fetal CB; light blue bars, normal adult CB; red bars, SHH; green 
bars, MB2. A green-red colour palette was used to illustrate gene expression, with green corresponding to 
low and red corresponding to high expression values.   
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Table 4.1. Biological functions and potential tumorigenic roles of selected genes 
significantly up-regulated in Shh-driven medulloblastomas. 
 
 
Gene 
Symbol 
Description  Function(s)/ Role(s) in tumorigenesis  Reference(s) 
CHEK1  Cell cycle checkpoint kinase   Regulatory component of cell cycle check points; DNA 
damage response. Potential drug target.  
[187, 196] 
UBE2C  Ubiquitin‐conjugating 
enzyme 
Required for the destruction of mitotic cyclins and for 
cell cycle progression. Overexpressed in several human 
cancers; associated with tumour progression. 
[191, 197‐199] 
KIF4A  Microtubule‐based motor 
protein 
Maintenance of chromosome integrity during mitosis; 
DNA damage response. 
[200, 201] 
EXO1  5′‐3′ exonuclease  Implicated in DNA replication, recombination, and 
mismatch repair. 
[202] 
BAZ1A  ATP‐dependent chromatin 
assembly factor subunit 
Chromatin‐dependent regulation of transcription.  [203] 
DLG7  Microtubule‐associated 
protein 
Involved in microtubule polymerization 
and mitotic spindle stabilisation. Potential oncogenic 
target of Aurora‐A. 
[204‐206] 
CASC5  Kinetochore protein  Required for the localisation of outer kinetochore 
proteins and chromosome segregation. 
[207] 
TEAD2  Transcription factor  Contributes to neural tube closure; required for YAP‐
induced cell growth. 
[208] 
NUSAP1  Nucleolar‐spindle associated 
protein 
Mitotic spindle organization.  [209] 
PLK1  Polo‐like kinase  Involved in the control of spindle dynamics and 
chromosome segregation. Overexpressed in several 
human tumours. 
[210, 211] 
TROAP  Trophinin associated protein  Participates in early embryo implantation; required for 
spindle assembly during mitosis. 
[212] 
POU3F2  Transcription factor  Involved in Schwann cell development; regulator of 
melanocytic growth; neuronal‐fate‐inducing factor. 
[213, 214] 
PTTG1  Mitotic checkpoint securin  Prevents premature chromosome separation through 
inhibition of separase activity. Tumorigenic.  
[190, 215] 
EZH2  Member of the Polycomb‐
group family 
Involved in the transcriptional silencing of differentiation 
genes. Potential role in tumorigenesis. 
 [216] 
 
The table lists the 14 selected candidate genes together with a summary of their function in normal cells 
and their possible role in tumorigenesis.  
 
     
 
128
4.4. In vitro culture of mouse cerebellar granule cell precursors 
  GCPs are the proposed cells of origin of Shh-driven medulloblastomas and an 
increasing number of studies have shown that genes which contribute to 
medulloblastoma pathogenesis are also implicated in GCP proliferation [163]. As a 
result, GCPs constitute the best characterized cell culture model to study the regulation 
and function of medulloblastoma candidate genes in vitro [45, 53, 54, 65, 166]. I 
therefore set up a mouse cerebellar granule cell precursor (GCP) culture model to 
investigate the possible role of Shh in regulating the expression of selected candidate 
genes (Figure 4.6). Cells isolated from mouse post-natal cerebellum initially include a 
mixture of mature granule neurons and GCPs at different stages of the cell cycle which 
are committed to differentiate unless their specific mitogen (Shh) is added to the cell 
culture medium [43]. I observed that the addition of ShhN (the biologically active NH2-
terminal peptide of Shh) induced a change in the overall culture morphology within 48 
hours of plating, with cells visibly projecting fewer processes than their control 
counterparts and forming clumps of clonal expansion (Figure 4.6C). Cell clumping in 
GCP cultures has been previously described [69, 165], and in my experiments it was 
significantly accentuated in the presence of ShhN.  
  I assessed the activation of the Shh signalling pathway in ShhN-treated cultures 
by measuring the expression of well characterised Shh-associated genes (Atoh1, Gli1, 
Foxm1 and Melk) by western blotting or RT-PCR. As expected, all of the analysed 
genes were expressed at remarkably higher levels in ShhN-treated cultures compared to 
the controls (Figure 4.7A-B).  
  Using a BrdU incorporation assay to label proliferating cells, I confirmed that 
the addition of ShhN maintained GCP proliferation at 48 hours after plating: whereas 
control cultures showed almost no positivity for BrdU, as measured both by 
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Figure 4.6. In vitro culture of mouse cerebellar granule cell precursors (GCPs). 
 
(A) Schematic overview of in vitro GCP cultures. GCPs were isolated from mouse cerebella at post-natal 
days 7 or 8 and cultured for at least 48 hours in the presence or in the absence of Shh. Without Shh, GCPs 
begin to differentiate upon plating, so that within 48 hours the culture consists of a homogeneous 
population of post-mitotic, mature granule neurons. However, the addition of Shh to the culture medium 
prolongs GCP proliferation giving rise to a mixed population of precursors and mature granule neurons. 
 
(B) Serial dilutions of the ShhN supernatant produced by transfecting 293FT cells were analysed by 
western blotting. The blot was probed with an anti-Shh antibody to confirm that the supernatant contained 
the ShhN polypeptide. Different amounts of recombinant ShhN were loaded as a control. Control 
supernatant did not generate any Shh signals.  
 
(C) Phase contrast microscopy of cerebellar cell cultures (48 hours after plating). The two panels on the 
left show representative fields of mature granule neurons cultured in the absence of ShhN (control 
culture). On the right, two fields of cerebellar neuron cultures in the presence of ShhN are shown.  
 
(D) Immunocytochemistry staining of astrocytes in cerebellar cell cultures. Forty-eight hours after 
plating, cells were stained with an antibody specific for astrocytes (GFAP).   
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immunocytochemistry and flow cytometry (Figure 4.7C-D), ShhN-treated cultures 
showed a considerably higher BrdU uptake, which further increased with prolonged 
BrdU pulses (Figure 4.7D). Interestingly, following a 15-hour BrdU incubation, the 
percentage of BrdU-positive cells in ShhN-treated cultures reached 64%, indicating that 
far more than half of the overall cell population consisted of proliferating GCPs.  
  To further validate the effects of ShhN-treatment on my GCP cultures, I carried 
out an immunocytochemistry assay using an antibody against NeuN, a nuclear antigen 
specifically expressed in post-mitotic neurons [217]. In line with previous reports, I 
found that cells cultured in the absence of ShhN were largely positive for NeuN, while a 
consistent proportion of ShhN-treated cells was NeuN-negative (Figure 4.8) [43, 218]. 
In addition, by performing NeuN and BrdU double staining, I verified that ShhN-
cultures were a mixture of two distinct cell populations: NeuN-positive, BrdU-negative 
differentiated granule neurons coexisted with NeuN-negative, BrdU-positive granule 
cell precursors (Figure 4.8). 
  Although granule neurons and granule precursors represent the predominant cell 
populations in the early post-natal mouse cerebellum, other cell types are present during 
this period, including glial cells, such as astrocytes and oligodendrocytes, and Purkinje 
neurons. To minimise the contribution of non-granule neuronal types to the cell culture, 
the protocol for the generation of GCP cultures includes a Percoll gradient separation 
step [43, 164]. I confirmed that my GCP cultures were enriched in neuronal cell types 
by staining the cultures for glial fibrillary acidic protein (GFAP), a marker specific for 
astrocytes. I found that only a small minority of cells expressed GFAP (<1%). In 
addition, GFAP-positive cells were mostly located at the edges of the culture surface, 
perhaps as an effect of coverslip coating. Some examples of GFAP staining are shown 
in Figure 4.6D.  
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Figure 4.7. ShhN induces expression of granule precursor markers and proliferation of GCPs. 
 
(A-B) Treatment of cerebellar cultures with ShhN for 48 hours induced the expression of well known 
markers of granule cell precursor state, as measured by western blotting (A) and RT-PCR (B). Preps A-C 
are independent GCP preparations. β-actin and β2-microglobulin (β2m) were used as housekeeping 
controls. NTC, non-template control. 
 
(C) ShhN induction of BrdU uptake by GCPs measured by immunocytochemistry. Cells were incubated 
with BrdU for the last 3 hours of a 48-hour culture, then fixed and stained. Representative fields are 
shown at two different magnifications.    
 
(D) ShhN induction of BrdU uptake by GCPs measured by flow cytometry. At the end of a 48-hour 
culture, cells were pulsed with BrdU for the indicated amount of time. They were then harvested, fixed 
and stained.   
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Figure 4.8. ShhN-treated cultures are a mixture of mature granule neurons and granule cell 
precursors.  
Cerebellar cells were cultured for 48 hours in the absence or in the presence of ShhN, and pulsed with 
BrdU for the last 3 hours of culture. Cells were then fixed and double-stained with anti-NeuN and anti-
BrdU antibodies.   
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4.5. Analysis of candidate gene expression in GCP cultures 
  Following the identification of a set of genes that were significantly 
overexpressed in SHH tumours (section 4.3), I was interested to test whether their 
expression levels were also modulated by Shh in cultured GCPs. To investigate this 
possibility, I performed semi-quantitative RT-PCR to measure gene expression in GCP 
cultures maintained in the presence or absence of ShhN for 48 hours. As shown in 
Figure 4.9, ShhN was able to induce a significant increase in the level of expression of 
the entire set of candidate genes. In most cases (e.g.  Dlg7,  Kif4,  Chek1), I found 
minimal or no expression in control cultures, as opposed to a strong expression signal 
observed in ShhN-treated cultures. In a few other cases (e.g. Ezh2,  Pou3f2), the 
difference in expression level between control and ShhN-treated cultures was more 
modest, but still significant (Figure 4.9).  
  For two genes, Pou3f2 and Ube2c, I confirmed differential expression at the 
protein level by western blotting and immunofluorescence analysis (Figures 4.10 and 
4.11).  Pou3f2 encodes a transcription factor implicated in the development of the 
nervous system. Targeted mutagenesis of Pou3f2 in mouse embryonic stem cells 
resulted in the loss of specific neuronal lineages in the hypothalamus and mortality 
before post-natal day 10 [219]. Recently, Pou3f2 was used in combination with two 
other transcription factors (Ascl1 and Myt1l) to reprogramme mouse embryonic and 
post-natal fibroblasts into functional neuronal cells in vitro [213]. Besides being an 
important player in neuronal development, there is evidence that Pou3f2 plays a role in 
oncogenesis, and particularly in melanoma growth and survival [214]. In their study of 
the expression pattern of transcription factors in the mouse post-natal cerebellum, 
Schüller et al. observed widespread Pou3f2 protein expression in both the EGL and the 
IGL [220]. Accordingly, I found that Pou3f2 was expressed both in ShhN-treated and in  
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Figure 4.9. Genes overexpressed in Shh-driven medulloblastomas are also up-regulated in GCPs in 
the presence of Shh. 
Treatment of cerebellar cultures with ShhN for 48 hours induced the expression of medulloblastoma-
associated genes, as measured by RT-PCR. Preps A-C are independent GCP preparations. The 
housekeeping  β2-microglobulin (β2m) gene was used as a control. NTC, No-template control. The 
intensity of the agarose gel bands was quantified by densitometry. The bar chart shows average fold 
changes in gene expression between ShhN-treated and control cultures with 95% confidence intervals. All 
of the candidate genes examined were expressed at significantly higher levels in ShhN-treated cultures, 
while β2m gene expression did not differ between the two conditions (average fold change = 1.0; 95% CI 
0.9, 1.1).    
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control GCP cultures, however its expression was significantly higher in the presence of 
ShhN (Figure 4.9). In the series of human samples used for my microarray experiment, 
the expression profile of POU3F2 correlated extremely well with that of the ATOH1 
gene (correlation coefficient = 0.9), which suggested that they may be co-expressed in 
Shh-responsive cells.  
  To further test this hypothesis, I measured Pou3f2 protein expression in mouse 
GCP cultures. I found that Pou3f2 protein levels were more than four fold higher in 
ShhN-treated cultures compared to controls as measured by western blotting (p-value = 
0.002, Figure 4.10A). Immunostaining for Pou3f2 showed the presence of a small 
number of positive cells in control cultures, whereas a much larger proportion of 
Pou3f2-expressing cells was observed in ShhN-treated cultures (Figure 4.10B). 
Typically, the cells which stained positive for Pou3f2 were NeuN-negative, suggesting 
that Pou3f2 expression was restricted to immature GCPs (Figure 4.10B). 
  Ube2c is a ubiquitin-conjugating enzyme responsible for the polyubiquitination 
and consequent destruction of mitotic cyclins prior to anaphase initiation and cell cycle 
progression. Its expression is modulated during the cell cycle, with Ube2c transcript 
levels increasing in mitosis and dropping during telophase and G1. Ube2c was found to 
be expressed at relatively high levels in many different types of human cancer, 
including breast, lung, ovary and bladder carcinomas, and glioblastomas [191]. Its 
causative role in tumorigenesis has recently been established through the use of 
transgenic mice, in which Ube2c overexpression induced whole chromosome instability 
and spontaneous tumour formation [199].  
  I carried out western blotting to measure Ube2c protein levels in GCP cultures 
(Figure 4.11). In control cells, Ube2c was undetectable, as should be the case for 
differentiated neurons. However, in ShhN-treated GCPs the level of Ube2c expression  
 
138
 
Figure 4.10. Shh induces the expression of Pou3f2 in GCP cultures.  
 
(A) Western blot showing a significant increase in the level of the Pou3f2 protein in GCPs cultured for 48 
hours in the presence of ShhN. β-actin was used as a loading control. A quantitation of the protein bands 
is shown to the right. Since basal levels of Pou3f2 were comparable across the three independent 
experiments, I normalised the intensity of each individual protein band to the same control band (Prep A). 
 
(B) Analysis of Pou3f2 and NeuN expression by immunostaining.   
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Figure 4.11. Shh induces the expression of Ube2c in GCP cultures.  
 
(A) Western blot showing a very significant increase in Ube2c protein expression level in GCPs cultured 
for 48 hours in the presence of ShhN. β-actin was used as a loading control.  
 
(B) Analysis of Ube2c and NeuN expression by immunostaining. In control cells Ube2c expression was 
extremely low, and the very few positive cells displayed glial cell morphology (arrow). In contrast, Ube2c 
was expressed at higher levels in ShhN-treated GCP cultures and its expression was specifically detected 
in NeuN-negative cells.  
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was remarkably higher (Figure 4.11A). A similar pattern of expression was observed in 
immunostaining experiments, in which the only positive cells in control GCP cultures 
clearly displayed a glial morphology, suggesting that they might be contaminating 
astrocytes or oligodendrocytes that maintained the ability to proliferate in culture 
(Figure 4.11B).  
 
4.6. Analysis of candidate gene expression in human medulloblastoma cell lines 
  Human medulloblastoma cell lines have been successfully employed for the 
functional characterisation of putative tumour-associated genes. Aiming to address the 
possibility that some of the identified candidate genes were required to sustain tumour 
cell proliferation, I initially assessed candidate gene expression in three commonly used 
medulloblastoma cell lines, Daoy, D425 Med and UW228-2, by semi-quantitative RT-
PCR. Three samples of normal adult cerebellum and two samples of normal fetal 
cerebellum were also analysed for comparison. The FOXM1 gene, which is known to 
promote Shh-dependent cell cycle progression and is overexpressed in 
medulloblastomas [166], was used as a control. I also studied MYC gene expression as 
an additional control, because MYC is amplified in the D425 Med cell line. 
  As suggested from gene expression patterns in cultured GCPs and from the array 
analysis, most of the genes examined were expressed at higher levels in fetal cerebellar 
samples compared to adult cerebellar samples (Figure 4.12A). Importantly, the majority 
of genes also appeared to be expressed at considerably higher levels in the three 
medulloblastoma cell lines compared to both adult and fetal normal cerebellum. These 
genes included FOXM1, UBE2C (whose expression was also analysed at the protein 
level, Figure 4.12B) and many others. Only two genes, POU3F2 and TEAD2, were 
expressed at similar levels in medulloblastoma cells and normal cerebellum (Figure  
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Figure 4.12. Expression of selected candidate genes in human medulloblastoma cell lines. 
 
(A) Semi-quantitative RT-PCR analysis of candidate gene expression in adult normal cerebellum (light 
blue bar), fetal normal cerebellum (dark blue bar) and human medulloblastoma cell lines (Daoy, D425 
Med and UW228-2, purple bar). The housekeeping β2-microglobulin (β2m) gene was used as a control. 
Gels are representative of at least two independent experiments. NTC, No-template control. 
 
(B) Immunocytochemistry analysis of UBE2C expression in human medulloblastoma cell lines.  
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4.12A). In accordance with its amplification pattern, MYC transcript levels were much 
higher in D425 Med cells compared to all of the other samples. Overall, the RT-PCR 
results indicated that the medulloblastoma cell lines expressed all of the candidate genes 
identified in primary tumours and could be considered useful models for subsequent 
analysis. 
 
4.7. Functional analysis of candidate genes by shRNA-mediated knockdown in 
medulloblastoma cell lines 
  To investigate the potential contribution of the selected candidate genes to 
medulloblastoma pathogenesis, and in particular their role in tumour growth and cell 
proliferation, I used shRNA expression constructs to inhibit their expression. ShRNAs 
have been widely used to knock down target genes in mammalian cells. Following 
transcription, shRNAs are cleaved by endogenous nucleases to generate short double 
stranded RNAs which are recognised by the RNA-induced silencing complex (RISC) 
and used to target complementary mRNAs for destruction [221]. ShRNAs can be easily 
delivered to target cells using viral vectors which are specifically designed to express 
the desired shRNA sequences [221]. In my experiments, I used the pGIPZ lentiviral 
vector system described in section 2.5.1.2, in which individual shRNAs are transcribed 
under the control of the CMV promoter and are co-expressed with the EGFP reporter 
gene and the gene encoding puromycin resistance [161]. Following viral transduction, I 
was therefore able to track and select for shRNA-expressing cells by monitoring EGFP 
expression and applying puromycin selection. 
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4.7.1. Initial characterisation of the shRNA expression system 
  Cells were inoculated with the appropriate viral preparation at a suitable MOI to 
obtain an efficiency of transduction in the range between 40% and 80% (unless 
otherwise stated, an MOI of 0.1 was used for both the Daoy and the UW228-2 cell 
lines). In general, for each target gene, three individual shRNAs were used which were 
complementary to different regions in the target mRNA. A scrambled shRNA sequence 
designed not to cause the specific degradation of any known human mRNAs was used 
in each experiment to control for non-specific changes in gene expression which may 
result from the shRNA delivery method. As shown in Figure 4.13A, at three days 
following transduction, the percentage of cells which expressed EGFP, and therefore the 
shRNA of interest, was measured by flow cytometry and cells were divided into two 
aliquots. One aliquot was subjected to a five-day puromycin selection protocol to 
remove all of the non-transduced cells (Figure 4.13B). Once a > 98% population of 
shRNA-expressing cells was obtained, total RNA and proteins were isolated for an 
assessment of shRNA-mediated gene knockdown efficiency by Real Time PCR or 
western blotting. The same cell population was also used to perform cell cycle analysis 
by BrdU or Propidium Iodide (PI) staining.  
  A second aliquot of transduced cells was maintained in culture for three to four 
weeks without applying any treatment. At every cell passage, the percentage of EGFP-
positive cells was measured by flow cytometry. Any significant decrease in the 
proportion of EGFP-positive cells would indicate a growth disadvantage for the 
transduced cells relative to the non-transduced ones. This could be due to either a 
decrease in the cell proliferation rate or an increase in apoptosis or cellular senescence. 
In any case, by using scrambled shRNA-transduced cells as a reference, the screening 
would provide information about any alterations of the overall cell growth rate caused  
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Figure 4.13. Experimental outline for the screening of candidate genes by shRNA silencing.  
 
A) On day 1, medulloblastoma cells were inoculated with the appropriate viral preparations. Following 
the assessment of transduction efficiency, cells were divided into two aliquots. One aliquot was used to 
monitor changes in the proportion of EGFP-positive cells in culture, over a three to four-week time 
period. This would provide information about the effect of shRNA-mediated gene knockdown on cell 
proliferation/apoptosis. A second aliquot was put under puromycin selection to obtain a > 98% population 
of shRNA-expressing cells which would be used to assess the efficiency of shRNA-mediated gene 
knockdown and to perform cell cycle analysis.  
 
B) A five-day puromycin selection period applied to a mixed population of < 100% transduced cells 
results in the restricted survival of transduced cells. Here I show an example of UW228-2 cells 
transduced with a scrambled shRNA-expressing lentiviral vector.   
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by the expression of gene-specific shRNAs. This technical approach has been 
successfully used by other groups in our department to identify putative tumour 
oncogenes in a variety of cell systems (unpublished data). 
  Before performing transduction experiments to knock down some of the putative 
target genes that I identified in my microarray study, I wanted to validate the overall 
approach by knocking down the expression of a control gene known to be important for 
medulloblastoma cell proliferation. I decided that the BMI1 gene, encoding a member of 
the Polycomb group of transcriptional repressor proteins, was an appropriate control 
gene. Polycomb group proteins are responsible for a variety of epigenetic programmes 
which regulate critical developmental mechanisms, including cell progenitor 
proliferation and stem cell self-renewal [222]. The BMI1 gene is expressed in the 
developing mouse and human cerebellum, where it regulates Shh-induced GCP 
proliferation [54], mainly through the repression of genes such as p16
INK4a, p19
Arf and 
p21
Waf1/Cip1 [55]. BMI1 is also overexpressed in human and mouse medulloblastomas 
and is required for tumour formation in a mouse model of Shh-induced 
medulloblastoma [223]. In addition, a study by Wiederschain et al. showed that 
shRNA-mediated  BMI1 knockdown in Daoy cells resulted in the inhibition of cell 
proliferation, as measured by MTS assay, as well as an increase in apoptotic cell death 
[224].  
  I transduced Daoy cells with three individual lentiviral shRNA constructs 
targeting the BMI1 mRNA. Levels of BMI1 mRNA and protein were significantly 
reduced by 70% to 90% in BMI1  shRNA-expressing Daoy cells compared to non-
transduced Daoy cells or cells transduced with the control scrambled shRNA (Figure 
4.14A-B). Despite causing a significant reduction in BMI1 protein levels, BMI1 
knockdown did not seem to affect Daoy cell proliferation, as assessed by monitoring  
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Figure 4.14. BMI1 knockdown in Daoy cells. 
 
A-B) BMI-shRNAs efficiently reduced the levels of BMI1 mRNA (A) and protein (B) in Daoy cells, as 
assessed by semiquantitative RT-PCR and western blotting. A scrambled shRNA was used as a control, 
and three individual shRNAs targeting the BMI1 mRNA were tested (BMI1 shRNA 1-3). B, Protein 
bands were quantified by densitometry. The histogram shows GAPDH-normalised BMI1 protein levels as 
the averages of two experiments.  
 
C) Percentage of EGFP-expressing Daoy cells, as assessed by flow cytometry analysis over a three-week 
time period following viral transduction.  
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EGFP-expression in transduced Daoy cell cultures over time (Figure 4.14C). In 
agreement with this result, cell cycle analysis by BrdU staining did not reveal any 
significant changes in the overall cell cycle distribution of BMI1-depleted Daoy cells 
relative to control cells (Figure 4.15A-B). My results contrasted with the BMI1 
knockdown effects I was expecting based on published data. One of the possible 
explanations is that the level of BMI1 protein knockdown I obtained was not good 
enough to elicit a biological effect. My decision to use an MOI of 0.1 for Daoy cell 
transduction experiments was intended to minimise the number of viral construct 
integration sites within the target cell genome. However, by increasing the MOI, I 
should obtain a better knockdown, and indeed BMI1 protein levels further decreased 
when I transduced Daoy cells with lentiviral shRNAs at the higher MOI of 0.5 (Figure 
4.14B). In the future, it would also be interesting to perform additional assays to 
measure alternative biological readouts, as in my hands BMI1 might not be essential for 
cell proliferation but could affect other cellular functions. Importantly, BMI1 
knockdown in Daoy cells has been recently shown to alter cell adhesion and to favour 
the formation of cellular aggregates through the deregulation of the bone morphogenetic 
protein pathway, rather than affect cell proliferation or apoptosis (oral communication, 
[225]).  
  While this initial experiment was not completely conclusive, it did demonstrate 
that I could use shRNAs to target genes in the Daoy cell line. I therefore moved on to 
perform knockdown analysis of some of the medulloblastoma-associated candidate 
genes.  
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Figure 4.15. Cell cycle analysis of Daoy cells transduced with BMI1 shRNAs. 
 
A) Daoy cell lines expressing specific BMI1 shRNAs were obtained by lentiviral transduction followed 
by five days of puromycin selection. Following 1 hour of BrdU incubation, cells were harvested and 
stained with an anti-BrdU antibody and Propidium Iodide (PI). Cell cycle distribution was analysed by 
flow cytometry.  
 
B) Percentage of cells in each cell cycle phase as determined by the flow cytometry analysis shown 
above.  
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4.7.2. Screening of candidate genes 
  I initiated a screening of medulloblastoma-associated candidate genes by 
looking at the effects of shRNA-mediated knockdown of four target genes: DLG7, 
UBE2C, KIF4A and PLK1. I performed DLG7 knockdown analysis in Daoy cells only, 
whereas I analysed the other three genes in both the Daoy and the UW228-2 cell lines.  
  DLG7 is a microtubule-associated protein which plays a critical role in 
controlling mitotic spindle stability and dynamics throughout mitosis [204]. DLG7 is 
phosphorylated by and shares a similar expression profile across a variety of normal and 
malignant human tissues with Aurora-A, a mitotic kinase with oncogenic properties 
[206]. It has been suggested that DLG7 may represent a potential oncogenic target of 
Aurora-A [206]. Daoy cells expressing DLG7 shRNAs showed a 45% to 85% decrease 
in DLG7 mRNA levels compared to control cells, as measured by Real Time PCR 
(Figure 4.16A). This level of knockdown did not affect the overall cell growth rate, as 
confirmed by the steady proportion of EGFP-positive cells in transduced Daoy cell 
cultures, measured over a three-week time period (Figure 4.16B).  
  The ubiquitin-conjugating enzyme UBE2C has been the focus of an increasing 
number of studies in which UBE2C depletion in cancer cell lines was shown to inhibit 
cell proliferation and sensitise cells to apoptosis [191, 226, 227]. In my experiments, I 
obtained a modest UBE2C knockdown, with only one of the three UBE2C shRNAs 
tested being able to reduce UBE2C mRNA level by more than 50% in both the Daoy 
and the UW228-2 cell lines (Figure 4.17A). Possibly as a result of inefficient UBE2C 
silencing, I did not observe any changes in the growth rate of either Daoy or UW228-2 
transduced cells (Figure 4.17B). Similarly, cell cycle analysis by PI staining did not 
reveal any differences in cell cycle distribution in UBE2C shRNA-expressing cells 
relative to non-transduced and scrambled shRNA-expressing control cells (Figure 4.18).  
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Figure 4.16. Analysis of DLG7 knockdown in Daoy cells. 
 
A) Real Time PCR analysis of DLG7 gene expression in Daoy cells transduced with a scrambled shRNA 
or three individual shRNAs targeting the DLG7 mRNA. The β2M and HPRT genes were used as 
housekeeping controls. The experiment was performed in triplicate. Bars correspond to averages +/- 
standard errors.   
 
B) Percentage of EGFP-expressing Daoy cells over a three-week time period following viral transduction.  
  
 
151
 
 
 
Figure 4.17. Analysis of UBE2C knockdown in Daoy and UW228-2 cells. 
 
A) Real Time PCR analysis of UBE2C gene expression in Daoy (left) and UW228-2 (right) cells 
transduced with a scrambled shRNA or three individual shRNAs targeting the UBE2C mRNA. The β2M 
and HPRT genes were used as housekeeping controls. The experiment was performed in triplicate. Bars 
correspond to averages +/- standard errors.   
 
B) Percentage of EGFP-expressing Daoy (left) and UW228-2 (right) cells over a four-week time period 
following viral transduction.   
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Figure 4.18. Cell cycle analysis of Daoy and UW228-2 cells transduced with UBE2C shRNAs. 
 
A) Cell lines expressing UBE2C shRNAs were obtained by lentiviral transduction followed by five days 
of puromycin treatment. Cell cycle analysis was performed by flow cytometry using Propidium Iodide 
(PI) to label nuclear DNA. For each sample, gates were drawn to measure the proportion of cells in each 
cell cycle phase, based on PI signal area. Results of the analysis performed on UW228-2 cells are shown 
as an example.  
 
B) Summary of cell cycle analysis by PI staining in Daoy and UW228-2 cells. The histograms show the 
proportion of cells in each cell cycle phase.   
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  Kinesin family member 4A (KIF4A) is a microtubule-based motor protein 
implicated in chromosome condensation and segregation as well as in the regulation of 
cell cytokinesis [228, 229]. A role for KIF4A has also been described in modulating cell 
survival in post-mitotic neurons during brain development [230]. KIF4A has been found 
to be a prognostic biomarker in human lung cancer, with its overexpression being 
associated with increased patient mortality [231]. In vitro studies showed that KIF4A 
siRNA-mediated knockdown in lung cancer cell lines caused a significant decrease in 
cell viability [231]. I transduced the Daoy and UW228-2 cell lines with three individual 
viral shRNAs targeting human KIF4A mRNA and obtained a 40% to 70% decrease in 
KIF4A mRNA levels as measured by Real Time PCR (Figure 4.19A). However, neither 
Daoy nor UW228-2 KIF4A shRNA-expressing cells showed any significant changes in 
overall cell growth rate (Figure 4.19B), nor in cell cycle distribution (Figure 4.19C) 
relative to non-transduced and scrambled shRNA-expressing control cells.  
  PLK1  encodes a Polo-like kinase which plays multiple roles during mitosis, 
including regulating the G2/M transition, via the activating phosphorylation of the 
FOXM1 transcription factor [232, 233]. PLK1 is overexpressed in several human 
tumour types and has therefore been proposed as a potential target in anticancer 
strategies [234]. PLK1 depletion in human cancer cell lines has indeed shown an 
essential role for PLK1 in sustaining cancer cell proliferation and survival [189]. Daoy 
cells transduced with PLK1-specific viral shRNAs showed an extremely modest 
decrease in PLK1 mRNA levels (15% to 40%, Figure 4.20A). PLK1 knockdown was 
more efficient in UW228-2 cells, reaching up to 80% (Figure 4.20A). Nonetheless, I did 
not observe any important variations in the proportion of EGFP-expressing cells or in 
cell cycle distribution of either the Daoy or the UW228-2 medulloblastoma cells 
compared to control cells (Figure 4.20B and C).   
 
154
Figure 4.19. Analysis of KIF4A knockdown in Daoy and UW228-2 cells. 
Daoy and UW228-2 cells were transduced with either a scrambled shRNA or three individual shRNAs 
targeting the KIF4A mRNA, at an MOI of 0.1. For the experiments shown in A and C, cells were treated 
with puromycin to obtain a homogeneous population of EGFP-expressing cells.  
 
A) Real Time PCR analysis of KIF4A gene expression. The β2M and HPRT genes were used as 
housekeeping controls. The experiment was performed in triplicate. Bars correspond to averages +/- 
standard errors.   
 
B) Percentage of EGFP-expressing cells over a four-week time period following viral transduction. 
 
C) Cell cycle analysis by PI staining. 
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Figure 4.20. Analysis of PLK1 knockdown in Daoy and UW228-2 cells.  
Daoy and UW228-2 cells were transduced with either a scrambled shRNA or three individual shRNAs 
targeting the PLK1 mRNA, at an MOI of 0.1. For the experiments shown in A and C, cells were treated 
with puromycin to obtain a homogeneous population of EGFP-expressing cells.  
 
A) Real Time PCR analysis of PLK1 gene expression. The β2M and HPRT genes were used as 
housekeeping controls. The experiment was performed in triplicate. Bars correspond to averages +/- 
standard errors.   
 
B) Percentage of EGFP-expressing cells over a four-week time period following viral transduction. 
 
C) Cell cycle analysis by PI staining.  
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4.7.3. Optimisation of a viral transduction protocol for the D425 Med cell line 
  Unlike both the Daoy and UW228-2 medulloblastoma cell lines, which 
comprise large, polygonal-shaped adherent cells, D425 Med cells exhibit spheroid 
morphology, are semi-adherent in culture and display some of the structural 
abnormalities most commonly described in human medulloblastoma, such as 
isochromosome 17q and amplification of the MYC oncogene. Transduction of both the 
Daoy and UW228-2 cell lines using pGIPZ lentiviral constructs successfully induced 
long-term transgene expression, as monitored by flow cytometry analysis of EGFP-
expressing cells. In contrast, when I transduced D425 Med cells with pGIPZ 
lentiviruses, I obtained extremely weak EGFP signal intensities, even when increasing 
the MOI, as shown in the upper panels of Figure 4.21. Importantly, the EGFP signal 
intensity further decreased over time, suggesting that the CMV promoter, which drives 
the expression of the EGFP gene as well as the puromycin resistance gene and the 
shRNA included in the pGIPZ vector, was inactivated, possibly as a consequence of 
epigenetic regulation [235, 236]. To optimise the expression of these sequences in D425 
Med cell, I replaced the CMV promoter region in the pGIPZ vector with the SFFV-LTR 
promoter sequence. The lower panels in Figure 4.21 show flow cytometry analysis of 
EGFP expression achieved by transducing D425 Med cells with the modified pGIPZ-
SFFV vector: by plotting cell count versus EGFP signal intensity, I could distinguish 
two discrete subpopulations of EGFP-positive and negative cells, corresponding to 
transduced and non-transduced cells respectively. 
  To confirm that the pGIPZ-SFFV viral construct could be used for the 
successful delivery of gene-specific shRNAs to target cells, I transduced D425 Med 
cells with pGIPZ-SFFV lentiviral constructs expressing an shRNA targeting the 
GAPDH mRNA, which had been used in previous experiments in our department to  
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induce at least a 40% decrease in GAPDH mRNA in human tumour cell lines. I also 
transduced cells with a scrambled shRNA as a control. D425 med cells expressing the 
GAPDH shRNA displayed a 40% decrease in GAPDH transcript levels compared to 
control cells. By increasing the MOI, the reduction in the level of GAPDH expression 
increased to 60% (Figure 4.22). These results confirmed the usefulness of modified 
pGIPZ-SFFV lentiviruses as an efficient tool to achieve target gene knockdown in the 
D425 Med cell line.  
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Figure 4.21. Transduction of D425 Med cells with different lentiviral constructs. 
D425 Med cells were transduced with either the original pGIPZ lentiviral construct (CMV promoter, top 
panels), or the modified pGIPZ-SFFV lentiviral construct (SFFV-LTR promoter, bottom panels). In both 
cases two MOIs of 0.5 and 1 were tested.  
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Figure 4.22. GAPDH knockdown in D425 Med cells.  
Real Time PCR analysis of GAPDH gene expression in D425 Med cells transduced with a scrambled 
shRNA or an shRNA targeting the GAPDH mRNA. The  β2M and HPRT genes were used as 
housekeeping controls. The experiment was performed in triplicate. Bars correspond to averages +/- 
standard errors.   
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4.8. Discussion 
  In recent years, the advent of high-resolution microarray platforms has allowed a 
significant improvement in our understanding of the tumour transcriptome. Genome-
wide studies of human medulloblastomas have revealed an increasing number of 
putative cancer-associated genes whose deregulation during cerebellar development 
could contribute to the origin and growth of cerebellar malignancies [20, 92, 99-103, 
107, 237]. Similarities in gene expression profiles between normal and tumour 
cerebellar tissues have provided additional support to the notion that GCPs represent the 
cell of origin of a molecular subset of medulloblastomas [20, 92, 105, 107]. Although 
little is known about the possible alternative origins of the remaining medulloblastoma 
subgroups, the investigation of the mechanisms and pathways which drive normal 
cerebellar development has proven to be an indispensible approach for the 
understanding of medulloblastoma pathogenesis [27, 28, 163, 238]. 
  In this part of my project, I used the exon array data described in the previous 
chapter to perform a statistical analysis of differential gene expression between normal 
cerebellum and different medulloblastoma molecular subgroups. I identified a total of 
278 and 300 unique genes as being respectively up- and down-regulated in Shh-driven 
tumours relative to either normal cerebellum or Shh-independent medulloblastoma 
samples. Several of the differentially expressed genes which I identified had already 
been described in association with medulloblastoma in general, such as TOP2A [101], 
MELK [239], or with Shh-driven medulloblastomas specifically, including MYCN, 
BOC, HHIP [20, 92], NHLH1 [44], FOXM1 [166].  
  I also identified a number of less characterised medulloblastoma candidate 
genes, many of which are implicated in spindle organisation, cell cycle control, 
epigenetic modification of chromatin structures and neuronal specification. I selected a  
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number of candidate genes which were overexpressed in Shh-driven tumours and 
showed that their level of expression also increased in the presence of Shh in primary 
cultures of mouse GCPs. These genes represent interesting candidates which may play a 
role in precursor cell proliferation as well as in medulloblastoma formation and 
maintenance. I therefore wanted to explore their role in sustaining cell proliferation and 
survival by using human medulloblastoma cell lines as in vitro models of 
medulloblastoma pathogenesis.  
  I decided to investigate the effects of target gene depletion by transducing 
medulloblastoma cell lines with lentiviral constructs designed to express gene-specific 
shRNAs. In preliminary experiments, I showed that pGIPZ lentiviruses could transduce 
the Daoy and UW228-2 medulloblastoma cell lines, leading to the expression of the 
EGFP reporter gene. I could also specifically select for the transduced cells by treating 
cell cultures with puromycin to obtain a uniform population of shRNA-expressing cells.  
  As an initial step, I performed shRNA-based knockdown analysis on four of the 
selected candidate genes: DLG7, UBE2C, KIF4A and PLK1. All four genes have been 
critically implicated in the survival and expansion of different types of human cancer 
cell lines and represent promising targets for anticancer therapies. Despite obtaining 
efficient transductions, I found that in most cases, shRNA-based target gene knockdown 
was not optimal. In addition, I did not observe any significant biological effects of gene-
specific shRNA-expression in the tested medulloblastoma cell lines, such as changes in 
cell growth rate and cell cycle distribution.  
  One of the main technical problems with my experiments was that, in general, I 
did not achieve a high level of target mRNA knockdown, which could explain why 
there were no clear effects in the functional assays. In most of the studies that I 
reviewed from the literature, target gene knockdown was obtained by siRNA  
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transfection [189, 191, 226, 231]. Typically siRNAs can achieve more efficient 
reductions in mRNA/protein levels but they only allow transient in vitro studies. To 
improve shRNA-based gene silencing the MOI could be increased. Indeed, I obtained a 
more significant reduction in the level of target gene expression by performing higher 
MOI transductions. I could also increase the selection pressure on shRNA-expressing 
cells by increasing puromycin concentration, selecting only those transduced cells that 
expressed the transgenes at higher levels, including the puromycin resistance gene. The 
disadvantage of these approaches is that they cause an increase in the number of viral 
particles that integrate in the host cell DNA, raising the possibility of toxicity due to 
multiple integration sites. In my experiments, I used individual shRNA-expressing 
constructs to knock down candidate genes in medulloblastoma cell lines. It would be 
useful to transduce cells with a pool of two or more shRNA-constructs directed against 
the same target gene, as different shRNAs can act synergistically to significantly 
improve the efficiency of gene knockdown.  
   An alternative approach to the use of shRNAs is the overexpression of dominant 
negative mutant forms of the proteins of interest. For example, a dominant negative 
form of the UBE2C protein has been developed, in which the catalytic cysteine is 
converted into a serine. This single amino acid change disrupts UBE2C ubiquitination 
activity and prevents the destruction of cyclins during mitosis [240]. When transfected 
into mammalian cells, mutant UBE2C was shown to arrest cells in mitosis, consistent 
with other reports in which UBE2C was depleted by siRNA-mediated gene silencing 
[191]. It will be interesting to test whether expression of the UBE2C dominant negative 
protein in medulloblastoma cell lines induces growth arrest and triggers tumour-specific 
TRAIL-mediated cell killing, as has been described for other tumour cell lines [191]. 
Dominant negative forms have also been described for the DLG7 and PLK1 proteins  
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[206, 241]. In both cases, overexpression of the mutant forms in human cancer cell lines 
impaired their ability to grow and in some tumour cell lines was enough to induce 
tumour-specific cell death [241].  
  In my initial experiments I decided to evaluate the potential role of candidate 
genes in sustaining medulloblastoma cell growth. In the same plate, I co-cultured 
transduced cells expressing gene-specific shRNAs and non-transduced cells. Any 
changes in the relative proportions of the two cell subpopulations in culture would be 
indicative of a difference in their growth rates. This assay has the potential to detect 
very subtle changes in the ability of target cells to survive and proliferate. I also 
performed cell cycle analysis by flow cytometry to detect any differences in cell cycle 
distribution. However, it will be necessary to perform additional assays for a 
comprehensive investigation of the biological consequences of target gene knockdown. 
Cell colony forming and neurosphere assays are commonly used to test the ability of 
cancer cells to self renew [174, 242]. In some cases migration and invasion assays could 
be used to study the possible role of target genes in regulating tumour cell migration and 
invasiveness [176, 243]. Furthermore, I will set up gene-specific functional assays to 
confirm the efficiency of gene knockdown. For example, a significant reduction in the 
level of the UBE2C protein causes an increase in the level of cyclin B protein [191, 
240]. Therefore by measuring cyclin B protein expression I would get an indication of 
residual UBE2C activity.   
  The efficient silencing of any individual target gene might induce different cell 
responses in different medulloblastoma cell lines. In agreement with the literature, my 
own experiments showed that the three human medulloblastoma cell lines that I used 
differed in terms of morphology, gene expression and in their biological response to 
viral transduction. While the Daoy and the UW228-2 cell lines strongly expressed  
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transgenes which were under the transcriptional control of the CMV promoter, I had to 
develop an alternative transduction protocol to be able to successfully express lentiviral 
shRNAs in the D425 Med cell line. It will be interesting to study any cell-specific effect 
of target gene depletion, which may be related to the specific gene signature of the three 
individual cell lines, such as the MYC oncogene amplification in the D425 Med cells.  
  The use of medulloblastoma cell lines as a model of tumour pathogenesis is 
rather controversial [171]. Several commercially available human cell lines have been 
extensively used in studies that have investigated the effect of putative 
medulloblastoma-associated genes in sustaining tumour growth and survival. However, 
these cells have been shown to be no longer responsive to Shh [58], and evidence has 
suggested that propagation of tumour cells in culture irreversibly inhibits Shh pathway 
activity [171]. These observations raise the issue of whether the available 
medulloblastoma cell lines represent an adequate tool for the study of the biological role 
of candidate genes whose level of expression is regulated by the Shh signalling 
pathway.  
  An appropriate investigation of the effects of Shh-dependent genes in a 
pathological context requires the use of an in vitro system in which cells retain their 
ability to respond to stimuli which enhance or antagonise the Shh signalling pathway. 
There is scarce evidence of the level of activity of the Shh pathway in human 
medulloblastoma cell lines. However, it has been reported that cyclopamine, a plant-
derived Shh antagonist which acts at the level of the Smoothened receptor [244], 
induces a decrease in the level of expression of the GLI1 gene, which is a direct target 
of Shh signalling, and increases apoptosis in DAOY and UW228 medulloblastoma cells 
[245]. Given more time, I would like to further investigate how the manipulation of the 
Shh signalling pathway can affect the survival and proliferation of human  
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medulloblastoma cell lines in order to assess whether they represent appropriate models 
of Shh-dependent medulloblastomas and, eventually, whether SMO or GLI1 could be 
used as control genes in my knockdown experiments.  
  Murine medulloblastoma allograft cell lines have been used to model Shh-
mediated proliferation events and represent a useful alternative to commercially 
available tumour cell lines. Berman et al. described the generation of the PZp53MED 
medulloblastoma cell lines from allografts grown in athymic mice following the 
subcutaneous injection of tumour cells obtained from Ptc
+/-;  p53
-/- mice [246]. 
Following a 72 hour-long treatment with cyclopamine, the authors observed a 60 to 
80% reduction in cell proliferation [246]. Moreover, addition of cyclopamine to the cell 
culture induced a significant decrease in the expression level of genes typically 
regulated by Shh, including Mycn and Cyclins D1 and D2, whereas the expression of 
NeuroD1, a marker of post-mitotic granule cells, increased. The effects of cyclopamine 
could be reversed by over-expressing the Shh effector Gli1  [246]. It would be 
interesting to test whether human medulloblastoma allograft cell lines could be 
established in the same way. This cell model could be readily manipulated in vitro to 
silence the genes of interest. Any resulting changes in the ability of cells to progress 
through the cell cycle would be compared to the effects of cyclopamine treatment (i.e. 
inactivation of the Shh pathway) or Gli1 gene knockdown.  
  Finally, mouse GCP primary cultures could be used to investigate the potential 
role of Shh-related genes in promoting cell proliferation during normal cerebellar 
development. In my future experiments, I would like to use lentiviral vectors to 
overexpress some of the selected medulloblastoma candidate genes in GCPs cultured in 
the presence or absence of ShhN. Measuring BrdU incorporation as a read-out for cell 
proliferation, I could assess whether the forced expression of candidate genes leads to  
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an increase in the cellular response to ShhN, and if it is sufficient to promote cell cycle 
progression in the absence of the ShhN stimulus. In this setting, overexpression of the 
Mycn gene would represent a valid control, as its role in mediating Shh-dependent GCP 
proliferation has been clearly established [45, 48]. Conversely, I could inactivate a gene 
of interest by expressing its dominant negative mutant form in ShhN-treated GCPs. A 
decrease in the proportion of proliferating cells would suggest a role for the candidate 
gene in the positive regulation of the cell cycle.  
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Chapter 5 
Analysis of differential splicing in paediatric medulloblastoma 
 
 
 
5.1. Introduction 
  Alterations in mRNA splicing are commonly found in a variety of human cancer 
types and can result in the production of novel transcript variants or in an imbalance 
between normal mRNA isoforms. In both cases the global protein expression within a 
cell can be altered in ways that have the potential to sustain tumour growth [116, 118, 
119]. Individual candidate gene approaches have been used to characterise alternative 
transcript variants whose expression is enriched in cancer and which may display 
oncogenic potential (reviewed in [117, 118]). However, these studies can only reveal a 
minority of the splicing aberrations which occur during oncogenesis. During the past 
few years, an increasing number of computational and microarray-based studies have 
been carried out to explore genome-wide patterns of differential splicing between 
cancer tissues and their normal counterparts (reviewed in [117]). These studies 
demonstrated that the comprehensive analysis of cancer splicing patterns could improve 
cancer diagnostic classification and provide useful prognostic markers [247-250].  
  Since their development four years ago, Affymetrix exon arrays have been used 
in a variety of studies for the unsupervised discovery of alterations in the global patterns 
of alternative splicing (AS) associated with a range of conditions, including human 
cancer. In the first published exon array analysis of cancer-associated differential 
splicing, Gardina et al. identified nine genes undergoing differential splicing between 
paired tumour-normal colon cancer samples [148]. Interestingly, several of these genes 
were implicated in cell-cell interactions and cytoskeleton organisation, suggesting that  
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splicing alterations in colon cancer may affect cell mobility and extracellular 
interactions. French et al. applied exon array technology for the identification of splice 
variants whose expression differed between histological subgroups of glial tumours 
[249]. Through the unsupervised analysis of exon expression levels, the authors were 
able to classify glioma subgroups according to their histological appearance. In 
addition, they identified splice variants that appeared to be differentially regulated 
between low and high grade gliomas, and a collection of novel exons which were 
expressed as part of well annotated mRNAs but had not been previously described in 
the NCBI Reference Sequence (RefSeq) database. More recently, Dutertre et al. 
performed an exon array analysis of mouse primary mammary tumours with different 
metastatic potentials [248]. They identified several differentially expressed exons, many 
of which corresponded to genes implicated in cell migration and morphology. They also 
validated a selection of the candidate exons as being differentially expressed in human 
primary breast cancers associated with different metastatic capabilities, suggesting that 
alterations in splicing patterns were often conserved between mouse and human. 
Finally, they were able to associate the expression pattern of a subset of tumour-
associated splice variants with poor prognosis in a large cohort of breast cancer patients. 
Overall these findings emphasise the important role that splicing programmes may play 
during oncogenesis and the increasing value of differential splice form expression in the 
clinical management of cancer. 
  Medulloblastoma originates from the cerebellum, which is known to undergo 
extensive splicing regulation [251, 252]. A few studies of human medulloblastomas 
have described alternative splice forms of individual genes which are associated with 
specific molecular subsets of medulloblastoma [128], normal cerebellar development 
[131] or tumour recurrence [130]. I wanted to explore on a wider scale whether changes  
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in splicing patterns occurred frequently in medulloblastomas and if such changes could 
be related to defects in the normal development of the cerebellum.  
 
5.2. Identification of tumour-associated splicing events 
  To identify splicing patterns associated with either medulloblastoma in general 
or SHH tumours specifically, I compared exon/gene expression ratios between different 
sample subgroups, as illustrated in Figure 5.1. A total of 1,262 genes containing at least 
one potential differentially spliced exon were identified.  
  Probe set expression plots were used to evaluate the likelihood that candidate 
events represented true positive hits (as an example, expression pots for the TJP1 and 
DAAM1 genes are shown in Figure 5.2). Probe sets with very high or very low 
expression across all samples were discarded as they were suggestive of cross-
hybridising probes or non-expressed exons respectively (e.g. probe set 3329727 
mapping to exon 1 of the MADD gene, Figure 5.3). In a few cases, inspection of 
candidate gene expression plots allowed the identification of probe sets whose profile 
was indicative of differential splicing even though they did not meet the requirements 
for statistical significance (e.g. probe set 2680331 mapping to exon 15 of the MAGI1 
gene, Figure 5.3). I therefore considered these probe sets as false negatives and retained 
them for subsequent analysis. 
  Following the filtering of strong candidate events based on expression profiles, I 
used the X:Map database to inspect probe set location in annotated transcript structures 
and to verify whether they mapped to known alternatively spliced exons. I was able to 
classify candidate events into a variety of AS mechanisms, including alternative starting 
or ending of the transcript and mutually exclusive exon usage (Figure 5.4). However, I 
chose to initially focus on cassette exon events as they could be more easily validated  
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Figure 5.1. Schematic overview of exon-level analysis. 
Exon- and gene-level signal estimates were generated through the Robust Multichip Average (RMA) 
algorithm using the Expression Console software. To identify differential splicing events, gene-level 
normalized intensity values (exon signal / gene signal) were calculated for each individual exon and 
compared across sample subgroups through the LIMMA moderated t-statistic and FDR multiple testing 
correction. Several comparisons were carried out as shown in the figure. Numbers in boxes refer to the 
number of genes containing at least one exon with differential inclusion rate across different sample 
subgroups. In total, 1,262 unique genes were predicted to generate splice variants associated with specific 
sample subgroups. The possibility that these genes represented true positive hits was investigated using 
expression plots and annotation databases and a collection of 95 strong candidate genes was obtained, 
from which a smaller set of events was selected for further analysis. SHH, SHH tumours; MB, 
medulloblastomas (including SHH and MB2); CB, normal cerebella (including adult and fetal samples).  
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Figure 5.2. TJP1 and DAAM1 probe set expression plots.  
Expression plots show the signal distribution of each core probe set mapping to the TJP1 gene (top graph) 
or the DAAM1 gene (bottom graph). Each whisker plot represents the probe set average log2 expression in 
each subgroup with standard error bars. Probe sets are sorted by genomic location. Horizontal lines 
represent the average gene expression signal within each sample subgroup. Red asterisks indicate 
differentially expressed probe sets identified by statistical analysis. Black arrows point to the probe sets 
that I selected for RT-PCR validation. Probe set 3615612 mapping to exon 20 in the TJP1 gene appeared 
to be significantly overexpressed in normal cerebella (CB) compared to medulloblastomas (SHH and 
MB2 tumours), suggesting differential splicing of exon 20 between the two sample subgroups (i.e. 
preferential retention of exon 20 in CB samples and skipping in MB2 and SHH samples). Similarly, the 
expression pattern of probe set 3538263 mapping to the DAAM1 gene was indicative of DAMM1 exon 16 
being more frequently skipped in SHH tumours compared to all of the other samples examined. 
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Figure 5.3. MADD and MAGI1 probe set expression plots.  
Expression plots were drawn as described in figure legend 5.2. Probe set 3329727 mapping to exon 1 in 
the MADD gene is an example of a probe set discarded upon visual inspection of expression plots: its 
expression profile is suggestive of non-responsive/uniformly non-expressed probes. Despite not passing 
the statistical significance filter, probe sets 3329783 mapping to exon 34 of the MADD gene and 2680331 
mapping to exon 15 of the MAGI1 gene were selected for RT-PCR analysis because their profile was 
indicative of differential expression between sample subgroups.  
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Figure 5.4. Differential splicing of the WHSC1, TRRAP and WASF3 genes. 
Heatmaps summarise probe set expression profiles across the sample set: expression values were 
normalised first on gene signals and then on the average probe set expression across all samples. 
Normalised values were then averaged for each sample subgroup: normal cerebella (CB), Shh-driven 
medulloblastomas (SHH), and Shh-independent medulloblastomas (MB2). A green-red colour palette 
illustrates normalised probe set expression values, with green corresponding to low and red corresponding 
to high expression. Probe sets are sorted by genomic location, with red asterisks underlying putative 
differentially spliced probe sets as identified by statistical analysis. Schematic representations of 
alternative transcript exon structures are shown for each gene, with red and grey boxes corresponding to 
protein coding exons and untranslated regions, respectively. Transcript IDs refer to EnsEMBL release 56.  
 
A) Alternative splicing of the WHSC1 gene generates splice forms with alternative 3΄ ends. Exon array 
analysis suggested that medulloblastomas, and particularly SHH tumours, expressed more of the longest 
transcript form (top transcript), as opposed to normal cerebellar samples which predominantly expressed 
the two shorter forms (middle and bottom transcripts).  
 
B) Alternative splicing of the TRRAP gene generates splice forms with alternative exon inclusion. Probe 
set 3014461 maps to a cassette exon in the TRRAP gene which is predicted to be skipped in SHH tumour 
transcripts, as opposed to normal cerebella and MB2 tumours.  
 
C) Alternative splicing of the WASF3 gene generates splice forms with mutually exclusive exons. One 
pair of alternative exons, 7A and 7B, is found in the WASF3 gene; they are spliced in a mutually 
exclusive manner. Compared to medulloblastomas, normal cerebellar samples appeared to express 
significantly higher levels of the transcript form containing exon 7B (bottom transcript).  
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by RT-PCR. In total, 14 cassette exon splicing events were selected to be validated on a 
representative subset of the profiled samples (training set). Primers were designed to 
match constitutive exons flanking the candidate cassette exon, so as to generate PCR 
products of different sizes depending on the inclusion or exclusion of the target exon 
from the spliced transcript. For 11 of the 14 examples examined I observed 
amplification of both transcript forms (as confirmed by sequence analysis), indicating 
that the corresponding exons were genuinely undergoing alternative splicing (Figure 
5.5). In the three non-confirmed cases, only one PCR product was detected, suggesting 
that only one transcript form was expressed. These events were not analysed further.  
  I quantified alternative PCR product intensities and calculated differences in 
their log2 ratios between sample subgroups to confirm the presence of significant 
differential splicing (Table 5.1). As predicted by the array analysis, three of the 11 
experimentally validated genes (DAAM1,  EHBP1 and TRRAP) generated splicing 
patterns which distinguished between SHH tumours and all of the other samples (Figure 
5.5 and Table 5.1). In all of the remaining cases, all of the medulloblastomas shared 
similar splicing patterns which differed from those of normal adult cerebellar samples. 
Interestingly, normal fetal cerebellar samples generally produced splicing patterns 
which were more similar to the tumours than to the normal adult samples (Figure 5.5).  
  To efficiently visualise patterns of differential splicing I performed hierarchical 
cluster analysis using Splicing Indicator values calculated for each one of the 11 
validated events (the Splicing Indicator formula is summarised in Figure 5.6A). In cases 
where more than two transcript forms were amplified, the two most prominent were 
taken into account. Tumour and normal adult cerebellar samples were divided into two 
discrete clusters, with the latter mostly expressing splice forms retaining the candidate 
exons. An exception to this was the MADD gene, whose exon 34 appeared to be evenly  
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underexpressed in adult cerebella compared to medulloblastomas. One of the two fetal 
cerebellar samples (CBF1) clustered together with SHH tumours, while the second one 
(CBF2) subgrouped with the normal adult cerebella, but clearly exhibited an 
intermediate profile between normal and tumour samples (Figure 5.6B). This suggested 
the possibility that tumours retained splicing patterns characteristic of an 
undifferentiated cerebellar phenotype. 
 
 
 
Table 5.1. Genes alternatively spliced in medulloblastoma identified by exon array 
analysis and validated by RT-PCR 
                           
              
Exon Array    
RT‐PCR 
validation** 
Probe 
set ID 
Gene 
Symbol 
Probe set 
Location† 
Transcript ID  Comparison‡  Adj        
p‐value 
Probe 
set FC§ 
Gene 
FC|| 
Training 
set 
Test set 
3464995  ATP2B1   Ex 20  ENST00000359142  MB vs CB  0.003 ‐ 3.73  1.44  < 0.001  < 0.001 
3329783  MADD   Ex 34  ENST00000311027  MB vs CB  > 0.01*  1.57 ‐ 1.74  0.01  < 0.001 
2680306  MAGI1   Ex 24  ENST00000330909   MB vs CB  < 0.001 ‐ 3.61 ‐ 1.09  < 0.001  < 0.001 
3323129  NAV2   Ex 6  ENST00000360655  MB vs CB  0.009 ‐ 5.50 ‐ 3.42  0.02  0.008 
2507435  R3HDM1   Ex 15  ENST00000264160  MB vs CB  0.004 ‐ 1.86 ‐ 1.12  0.04  < 0.001 
3615612  TJP1   Ex 20  ENST00000346128  MB vs CB  0.002 ‐ 5.13  1.15  0.007  < 0.001 
3789479  WDR7   Ex 17  ENST00000254442   MB vs CB  < 0.001 ‐ 5.46 ‐ 1.14  < 0.001  < 0.001 
2680331  MAGI1   EX 15  ENST00000330909   SHH vs CB  > 0.01* ‐ 1.70 ‐ 1.56  0.03  0.004 
3538263  DAAM1   Ex 16  ENST00000351081   SHH vs CB & MB2  0.009 ‐ 5.17  1.96  0.01  < 0.001 
2485003  EHBP1   Ex 8  ENST00000263991  SHH vs CB & MB2  0.005 ‐ 8.88  1.11  0.003  0.006 
3014461  TRRAP   Ex 22  ENST00000456197  SHH vs CB & MB2  0.003 ‐ 2.62 ‐ 1.10  0.004  < 0.001 
                 
† Exons are numbered according to the Ensembl transcripts listed to the right (EnsEMBL release 56). ‡
 In 
several cases probe sets were identified as differentially spliced for more than one comparison. Here I 
report the comparison that generated the most significant difference. §
 Fold change in gene-normalised 
probe set signal values. || Fold change in gene signal values. ** P-values were calculated on the log2 ratio 
between skipped and retained transcript forms as quantified from the agarose gels. MB, medulloblastoma 
(including both SHH and MB2); SHH, Shh-driven medulloblastoma; MB2, Shh-independent 
medulloblastoma, CB, normal cerebellum. * Events with an adjusted p-value > 0.01 but a profile 
suggestive of AS (Figure 5.3).  
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Figure 5.5. RT-PCR validation of differentially spliced cassette exons.  
RT-PCR validation of candidate splicing events was performed on 13 of the 19 original samples profiled 
using exon arrays. PCR amplicons are listed below gene names. Exon structures corresponding to each 
amplified band are shown to the right of each gel. Pink arrows point to heteroduplexes of alternatively 
spliced forms. NTC, No-template control.  
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Figure 5.6. Visualisation of splicing patterns using the Splicing Indicator formula.  
 
A) The Splicing Indicator formula was used to better visualise patterns of differential splicing. It 
corresponds to the ratio between difference and average of the signal intensities of the two alternative 
splice forms. Splicing Indicator values range between -2 and 2, where -2 and 2 correspond to exclusive 
amplification of the skipped exon isoform or the retained exon splice form respectively.  
 
B) Cluster analysis was performed on the Splicing Indicator values corresponding to the 11 splicing 
events analysed by RT-PCR (see Figure 5.5). The Euclidean distance metric was used as a measure of 
distance between genes/samples. A blue-red colour palette was used to represent Splicing Indicator 
values, with blue corresponding to negative values (i.e. exon skipping, S); and red corresponding to 
positive values (i.e. exon retention, R). Sample subgroups are colour-coded as follow: light blue = adult 
normal cerebellum; dark blue = fetal normal cerebellum, green = MB2 tumours, red = SHH tumours.  
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5.3. Identification of novel splice forms 
  For some genes, I observed additional PCR products to those predicted by the 
exon array analysis. In two cases (ATP2B1 and R3HDM1) I found that an extra 
transcript variant was generated via an alternative 5' splice site located within the 
candidate cassette exon (ATP2B1 sequence analysis is shown in Figure 5.7A). Both 
novel transcript forms have been eventually annotated in EnsEMBL release 56 
(September 2009). In the case of the TRRAP gene, the unexpected PCR product 
corresponded to a previously unreported splice form in which exon 22 is excluded and 
exon 23 is retained (see Figure 5.5 for a schematic illustration of exon structures). I also 
identified a novel 9 nucleotide-long exon inserted upstream of cassette exon 34 in the 
MADD gene (Figure 5.7B). Direct sequencing showed that this novel mini-exon was 
heterogeneously expressed across the sample-set.  
  All of the other extra bands detected corresponded to heteroduplexes forming 
between alternative PCR products (also described in [148, 250]), as confirmed by PCR 
subcloning and sequencing. 
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Figure 5.7. Examples of splice variant sequence analysis.  
 
A) Sequence analysis of ATP2B1 exons 19-21 PCR products. Amplification of the ATP2B1 amplicon 
generated PCR products corresponding to three alternative splice forms. The upper and the lower gel 
bands corresponded to the transcript forms in which ATP2B1 exon 20 is retained and skipped, 
respectively; the middle gel band corresponded to an additional transcript variant generated via an 
alternative 5' splice site within cassette exon 20.   
 
B) Sequence analysis of MADD exons 33-35 PCR products. Sequencing of several PCR subclones of the 
MADD upper gel band revealed the presence, in most cases, of an additional 9 nucleotide-long exon 
located upstream of the candidate cassette exon.  
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5.4. Validation of differential splicing in an independent set of primary 
medulloblastomas and in medulloblastoma cell lines 
  To confirm that the splicing patterns of the selected genes were characteristic of 
medulloblastoma in general, I performed RT-PCR analysis of the 11 experimentally 
validated splice events using an independent set of ten normal cerebella and 20 
medulloblastoma samples (test set). The clinical features of this novel sample series are 
presented in Table 5.2. The tumour samples had been previously classified into either 
the SHH or the MB2 subgroup according to whether or not they showed a gene 
expression signature indicative of Shh signalling pathway activation [92]. The novel 
independent set of samples replicated the same patterns of splicing identified in the 
initial set of samples (Figure 5.8), as confirmed by statistically significant differences in 
log2 ratios of transcript forms between sample subgroups (Table 5.1). It was interesting 
to see that the three genes previously shown to generate SHH-tumour specific splice 
forms (DAAM1, EHBP1 and TRRAP) were also undergoing differential splicing in the 
SHH-tumours of the novel sample series, with only one exception (Figure 5.8). 
  I also analysed splicing patterns in three human medulloblastoma cell lines 
(Daoy, D425 Med and UW228-2) and found that they were similar to those of primary 
medulloblastomas, with the cell lines highly expressing tumour-associated transcript 
forms, including those characteristic of SHH-tumours (Figure 5.8).  
  To effectively visualise alternative transcript expression, I performed an 
unsupervised cluster analysis using Splicing Indicator values generated for each 
individual sample analysed by RT-PCR, including both training and test sets shown in 
Figure 5.5 and 5.8, respectively. Most of the adult normal cerebellar samples formed a 
homogeneous cluster and predominantly expressed transcript forms in which the 
candidate exons were retained. An exception to this was the CB1 sample, which showed   
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Table 5.2. Patients and tumour features of the sample series used for independent 
validation of differential splicing. 
 
Medulloblastoma samples    Normal cerebellar samples 
Sample 
Id 
Sex 
Age at 
diagnosis 
(years) 
Pathology 
Shh 
Status 
 
Sample 
Id 
Sex 
Age 
(years) 
Source  Notes 
                   
T20  M  5.3  CLA  ‐   
T23  M  10.4  CLA  ‐   
CB4  F/M  22‐68  Clontech  pool of 10 
individuals 
T24  M  4.9  CLA  ‐   
T25  M  4.7  CLA  ‐   
CB5  M  22  BioChain    
T26  M  19.8  CLA  ‐   
T27  F  9.7  CLA  ‐   
CB6  M  26  BioChain    
T28  F  6.5  CLA  ‐   
T29  F  9.8  LCA  ‐   
CBF3  M  Fetus        BioChain   26 weeks 
T30  M  8.9  LCA  ‐   
T32  M  14.0  CLA  ‐   
CB7  F  68  QSBB  Breast cancer 
T33  M  8.0  CLA  ‐   
T34  M  3.7  CLA  ‐   
CB8  M  38  QSBB  Gastric 
cancer 
T35  F  8.6  CLA  ‐   
T21  F  35.0  CLA  +   
CB9  M  43  QSBB  Heart attack 
T22  F  43.0  CLA  +   
T31  M  8.3  D  +   
CB10  M  76  QSBB  Lung cancer 
T36  F  1.3  D  +   
T37  F  39.6  D  +   
CB11  F  53  QSBB  Intra‐cerebral 
haemorrhage 
T38  M  0.2  D  +   
T39  F  1.4  D  +   
CB14  M  63  QSBB  Congestive 
heart disease 
                   
 
The table illustrates the major clinical features of medulloblastoma (left) and normal cerebellar samples 
(right) used for the independent validation of differential splicing. Pathology: CLA, classic; LCA, large 
cell/anaplastic; D, desmoplastic. Sex: F, female; M, male. QSBB, Queen Square Brain Bank. In the note 
section, patients’ cause of death is reported for samples obtained from QSBB.   
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Figure 5.8. RT-PCR analysis of differential splicing in an independent set of samples and in 
medulloblastoma cell lines.  
Left panel gels show RT-PCR results for an independent set of ten normal cerebellar and 20 
medulloblastoma samples, including seven samples belonging to the SHH subgroup (red bar). Asterisks 
indicate two normal fetal cerebellar samples that were included in the initial validation (CBF1 and 
CBF2). Right panel gels show RT-PCR results for two adult normal cerebellar samples (light blue bar) 
and three human medulloblastoma cell lines (purple bar). PCR amplicons are listed below gene names. 
Exon structures corresponding to each amplified band are shown to the right of each gel. Pink arrows 
point to heteroduplexes of alternatively spliced forms. NTC, No-template control.  
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a splicing profile more similar to fetal cerebellar samples, and therefore slightly related 
to medulloblastomas. The CB1 tissue sample was obtained from a juvenile patient with 
a cerebellar glial tumour, so it may be that either the age of the patient or the undetected 
presence of a minor contamination of tumour cells could have contributed to the results.  
  Interestingly, the majority of SHH tumours shared similar splicing patterns, 
including a unique profile for those genes which were initially identified as undergoing 
SHH-associated splicing (DAAM1, EHBP1 and TRRAP). As observed in Figure 5.8, 
only one SHH-tumour sample (T36) did not match this profile. Because sample T36 
was also the only tumour sample which appeared to generally express transcript forms 
characteristic of normal adult cerebellum, it could be that the original tissue specimen 
from which RNA was isolated contained a large proportion of normal tissue which 
eventually affected the RT-PCR analysis. Furthermore, three tumour samples classified 
as MB2 tumours shared their overall splicing profiles with SHH-tumours. One of these 
samples was originally classified as a SHH-tumour on the basis of unsupervised 
clustering of gene expression; however, it did not show aberrant activation of the Shh 
signalling pathway and was therefore reclassified as a Shh-independent tumour 
(personal communication by Prof. Steve Clifford). As for the other two samples, they 
genuinely belonged to the Shh-independent molecular subgroup. It would be interesting 
to explore whether these ‘irregular’ splicing profiles could be informative of specific 
tumour characteristics or indicative of mis-classification.  
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Figure 5.9. Cluster analysis of normal and tumour samples based on splicing patterns.  
Unsupervised hierarchical clustering was performed on the Splicing Indicator values generated for each 
of the 45 individual samples analysed by RT-PCR (13 samples from the training set, 30 samples from the 
test set and CBF1 and CBF2 replicates, indicated above as CBF1.1 and CBF2.1) and using the Euclidean 
distance metric. Grey and yellow boxes at the bottom indicate samples analysed in the first (training set) 
and second (test set) RT-PCR validation experiments, respectively. S, Skipped exon splice form; R, 
Retained exon splice form.  
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5.5. Tumour-associated splicing patterns are observed during the normal 
development of mouse cerebellum 
  Cerebellar GCPs are the proposed cells of origin of Shh-driven 
medulloblastomas. I therefore investigated whether transcripts which showed 
characteristic splicing patterns in medulloblastomas were also differentially spliced in 
cultured GCPs. I analysed splicing variations in GCP cultures for seven of the candidate 
genes whose genomic organization was conserved between human and mouse 
(according to the X:Map database version 2.4, Table 5.3). In the presence of Shh, the 
splicing patterns for five out of the seven genes analyzed by RT-PCR (Damm1, Ehbp1, 
Magi1,  Trrap and Wdr7) recapitulated the patterns observed in the human tumour 
samples (Figure 5.10). That is, Shh caused a decrease in candidate exon inclusion rate, 
similarly to what I observed in medulloblastoma when compared to normal adult 
cerebellum. In the two remaining cases (Madd and Nav2), both transcript forms were 
expressed independently of Shh treatment (Figure 5.10).  
  The analysis of different stages of early post-natal mouse cerebellar 
development showed that the switch between the two alternative transcript forms of the 
five validated mouse genes occurred between post-natal days 7 and 14, at the time when 
GCPs mature into post-mitotic neurons (Figure 5.10). Thus, during the post-natal 
development of the mouse cerebellum, the amount of cassette exon inclusion that occurs 
falls as the number of proliferating GCPs decreases.  
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Table 5.3. Mouse cassette exons analysed by RT-PCR and their human equivalents.  
 
Mus musculus  Homo sapiens 
Gene 
Name 
Exon 
Ensembl  
Transcript ID 
Gene 
Name 
Exon 
Ensembl 
Transcript ID 
Daam1  Ex 16  ENSMUST00000085299  DAAM1  Ex 16  ENST00000351081  
Ehbp1  Ex 7  ENSMUST00000045167  EHBP1   Ex 8  ENST00000263991 
Magi1   Ex 21  ENSMUST00000055224  MAGI1   Ex 24  ENST00000330909  
Trrap   Ex 31  ENSMUST00000094120  TRRAP   Ex 22  ENST00000456197 
Wdr7  Ex 17  ENSMUST00000072726   WDR7   Ex 17  ENST00000254442  
Nav2  Ex 5  ENSMUST00000050869  NAV2   Ex 6  ENST00000360655 
Madd  Ex 33  ENSMUST00000077941  MADD   Ex 34  ENST00000311027 
 
The table shows the mouse cassette exons analysed by RT-PCR and their human equivalent. Exons are 
numbered according to the corresponding Ensembl transcript IDs (EnsEMBL release 56).  
 
192
Figure 5.10. Splicing variants characteristic of human medulloblastomas are expressed during 
normal mouse cerebellar development.  
 
A) RT-PCR analysis of differential splicing in mouse GCP cultures maintained in the presence or in the 
absence of Shh for 48 hours (left panel) and in total mouse cerebellum during early post-natal 
development (right panel). Red arrows point to PCR bands corresponding to the predominant transcript 
forms observed in human medulloblastomas. Gels are representative of three independent experiments. 
NTC, No-template control.  
 
B) Quantitation of transcript isoform ratios based on the Splicing Indicator formula. In both mouse 
systems, the top five represented genes were found to be differentially spliced, with medulloblastoma-
associated variants being significantly more expressed in the presence of ShhN (left panel) and prior to 
GCP maturation in the post-natal cerebellum (P1-P7, right panel). In contrast, Madd and Nav2 splice 
patterns were not modulated by ShhN in in vitro GCP cultures. *, ShhN-treated GCPs versus control, p-
value , 0.05; ***, Total cerebellum at post-natal days 1-7 versus 14-21, p-value < 0.0001. S, Skipped 
exon splice form; R, Retained exon splice form.  
.  
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5.6. Analysis of MADD differential splicing 
  The  MADD gene (also known as IG20) encodes a death domain-containing 
adaptor protein which is believed to contribute to the propagation of apoptotic signals 
through its interaction with tumour necrosis factor receptor 1 (TNFR1). MADD has 
been implicated in cancer cell survival and apoptosis [253-256], as well as 
neurotransmission and neurodegeneration [257]. Evidence suggests that these 
contrasting effects are due to the differential expression of MADD alternative splice 
forms. Five different exons in the MADD gene are alternatively spliced to generate 
seven transcript forms (Figure 5.11), four of which (IG20pa, MADD, IG20-SV2 and 
DENN-SV) have been reported to be commonly expressed across a variety of human 
tissues [255, 258]. In a series of papers published over the past ten years, Prabhakar et 
al. defined a critical role for the DENN-SV and MADD splice variants in promoting cell 
survival in HeLa and ovarian teratocarcinoma PA-1 cell lines, possibly via the 
activation of NF-kappa-B and of the Mitogen-Activated Protein Kinase (MAPK) 
cascade, respectively [254, 255, 259-261]. In contrast, expression of the IG20pa splice 
variant was shown to suppress cell replication and favour both spontaneous and drug-
induced apoptosis in cancer cells [255]. Of interest, malignant tissues often express 
higher levels of the MADD and DENN-SV transcripts compared to the other two splice 
forms [255]. Recently, Li et al. described enriched expression of the IG20-SV4 and 
KIAA0358 splice forms in human neuronal tissues, and in neuroblastoma cell lines in 
particular [258]. Down-modulation experiments using splice form specific siRNAs 
showed that the two neuron-enriched transcripts elicited opposite cellular effects, with 
KIAA0358 exerting potent anti-apoptotic functions and IG20-SV4 enhancing caspase-8 
activation and apoptosis.  
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  In the RT-PCR validation experiments described in sections 5.4 and 5.5, I found 
that  MADD exon 34 was expressed both in normal and in malignant cerebellum 
(Figures 5.5 and 5.8), in agreement with its expression being characteristic of neuronal 
cell types (MADD exon 34 is only retained in the two neuron-enriched splice forms 
IG20-SV4 and KIAA0358, therefore it is not expressed in non-neuronal tissues). 
However I observed significantly higher inclusion rates of exon 34 in medulloblastoma 
samples compared to normal adult cerebellum. Since the analysis of exon 34 alone can 
not discriminate between all of the different splice variants of the MADD gene, I further 
investigated the alternative splicing profile of MADD exons 13L and 16 (Figure 5.12). 
Interestingly, medulloblastoma samples appeared to express high levels of the DENN-
SV splice form, which is associated with cell survival. Fetal cerebellar samples shared a 
similar splicing profile (Figure 5.12A). In addition, several medulloblastoma samples 
showed preferential expression of both the DENN-SV and MADD anti-apoptotic splice 
forms. I also analysed splicing patterns of the MADD gene in the three human 
medulloblastoma cell lines Daoy, UW228-2 and D425 Med, and found that they 
exclusively expressed the DENN-SV and MADD isoforms (Figure 5.12B), following a 
pattern previously reported for other human cancer cell lines [253, 261]. 
  Finally, I investigated the splicing pattern of mouse Madd exons 13L-16 in GCP 
cultures and during post-natal cerebellar development (Figure 5.12C). Previous analysis 
had shown that differential splicing of the MADD gene was not associated with the 
SHH tumour subgroup but rather with the medulloblastoma tumour set in general, and 
that the mouse equivalent of human MADD exon 34 was expressed independently of 
Shh treatment in GCP cultures (Figure 5.10). Here I confirmed that the different Madd 
gene transcript isoforms were not differentially expressed upon Shh treatment in mouse 
GCP cultures. I did however find modest but significant changes in the relative  
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expression levels of Madd gene transcript variants during mouse post-natal cerebellar 
development (P1-7 versus P14-21), with the early post-natal cerebellum expressing 
more of the MADD isoform compared to its mature counterpart. 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. MADD/IG20 splice forms.  
Schematic representation of the human MADD/IG20 gene and its transcript variants generated by 
alternative mRNA splicing. Exons 13L, 16, 21, 26 and 34, spliced in different combinations, generate 
seven different splice forms. Red and yellow arrows indicate the location of primer sets for the 
amplification of MADD exons 13L-16 and 34, respectively. Splice forms are defined as follows: blue, 
splice forms that have been shown to increase susceptibility to pro-apoptotic stimuli; red, splice forms 
associated with apoptosis resistance and cancer cell survival.  
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Figure 5.12. Analysis of MADD/IG20 mRNA splicing in human medulloblastomas and during 
mouse cerebellar development.  
Two primer sets were used to study the splicing patterns of exons 13L-16 and 34. Transcript variants 
corresponding to each PCR band are listed to the left of each gel. Pink arrows indicate heteroduplexes. A 
quantitation of individual PCR bands is represented at the bottom of the gels. The relative abundance of 
each transcript variant was measured as the fraction of the intensity of its PCR band against the total 
intensity for all of the bands amplified within the same sample. Splice variant fraction values were 
compared between sample subgroups using the Student’s t-test. The resulting p-values are shown. NS, 
non significant.   
 
A-B) RT-PCR analysis of MADD/IG20 splice forms in normal cerebellum, primary human 
medulloblastomas (A) and human medulloblastoma cell lines (B). 
  
C) RT-PCR analysis of Madd splice forms in mouse GCP cultures maintained in the presence or in the 
absence of Shh for 48 hours (left panel) and in total mouse cerebellum during early post-natal 
development (right panel).   
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5.7. An example of alternative transcript termination sites: analysis of QKI 
differential splicing 
  QKI (quaking) belongs to a family of RNA binding proteins that contain a 
nuclear ribonucleo-protein K homology (KH) domain and which are implicated in the 
regulation of mRNA splicing and stability, and protein translation. The mouse Qk gene 
was isolated as a candidate gene for the mouse neurological condition known as 
quaking, which affects the maturation of myelinating oligodendrocytes in the central 
nervous system [262]. As well as in oligodendrocytes, the QKI protein is also expressed 
in the heart, testis, lung and in other glial cell types throughout the brain [263, 264]. 
QKI expression in neuronal cell types has not been reported. The mammalian QKI gene 
undergoes alternative splicing generating at least three major transcript forms of 5, 6 
and 7 kb: QKI5,  QKI6 and QKI7 [264], whose expression is modulated during 
development.  QKI5 is the prevalent form during embryogenesis and its expression 
decreases after birth. Conversely, QKI6 and QKI7 are expressed during late 
embryogenesis, peak at mouse post-natal days 14-16, the time of myelination, and 
remain high into adulthood. The three forms differ in their C-terminal domain, which 
affects their subcellular localisation. The QKI5 C-terminus contains a non-canonical 
nuclear import signal which allows its translocation to the nucleus. The other two 
protein forms are predominantly localised in the cytoplasm [263, 264]. In silico analysis 
of QKI binding sites in the mouse genome identified several putative QKI target 
mRNAs implicated in development and morphogenesis, cell-cell adhesion, cell growth 
and differentiation, therefore suggesting a critical role for QKI proteins in regulating 
cell fate and proliferation [265]. Interestingly, a conserved QKI binding sequence was 
described downstream of MAGI1  exon 24 [266], which I found to be differentially 
spliced between normal cerebellum and medulloblastoma (Figure 5.9).   
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  In my exon array analysis, QKI appeared to be differentially spliced between 
normal cerebellum and medulloblastoma. Its probe set expression plot was indicative of 
alternative transcript termination, and in particular it suggested that normal cerebellar 
samples expressed relatively higher levels of QKI7 compared to tumour samples, as 
shown schematically in Figure 5.13. This resulted in an increase in the QKI5/QKI7 ratio 
in medulloblastomas (Figure 5.14A).  
  Of note, a recent paper by Lauriat et al. showed a positive correlation between 
QKI6 and QKI7 expression and the inclusion rate of MAGI1 exon 24 in the human 
prefrontal cortex [267]. Because of the interesting biological implications of QKI 
protein isoforms and of their role in modulating alternative splicing, I decided to 
validate differential splicing of the QKI gene in medulloblastoma. I performed Real 
Time PCR analysis to measure the fold change in expression between the QKI5 and 
QKI7 splice forms. Initially, I validated QKI5/QKI7 expression ratios in a subset of the 
samples analysed by exon array and showed that the Real Time PCR results replicated 
the exon array data (Figure 5.14B). I then analysed a larger set of independent samples 
and found a significant increase in the ratio between QKI5 and QKI7 splice forms in 
medulloblastomas compared to normal adult cerebella (p-value = 0.009, Figure 5.15).  
  Since there was no evidence that QKI was expressed in neuronal cell types, I 
wanted to verify whether neuronal expression could actually occur and confirm that the 
QKI expression signal detected in the human sample series I analysed was not produced 
by the cerebellar glial component. I therefore analysed the expression of the mouse Qk 
gene in GCP cultures, as they are almost exclusively neurons. I found strong Qk 
expression in both Shh-treated and control cultures. In addition, a significant 50% 
increase in the ratio between QKI5 and QKI7 expression levels occurred when Shh was 
added to the culture (Figure 5.16A). Accordingly, the QKI5/QKI7 ratio decreased in the  
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mouse cerebellum between post-natal days 7 and 14 (Figure 5.16B), in agreement with 
the literature [264].  
 
 
 
 
 
 
 
 
Figure 5.13. QKI probe set expression profile. 
The heatmap summarises QKI probe set expression profiles across the sample set as described in figure 
legend 5.4. Probe sets are sorted by genomic location, with red asterisks underlying putative differentially 
spliced probe sets as identified by statistical analysis. Exon structures for the two alternative splice forms 
of interest (QKI-5 and QKI-7) are shown at the top, with red and grey boxes corresponding to protein 
coding exons and untranslated regions, respectively. Transcript IDs refer to EnsEMBL release 56.   
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Figure 5.14. QKI5/QKI7 expression ratio assessed by exon arrays and Real Time PCR.  
 
A) Exon array data. QKI5/QKI7 expression ratio was calculated as the ratio between the intensity of QKI 
probe set 2935591 mapping to the 3' end of QKI5 transcript variant and the average signal value of all of 
QKI probe sets exclusively mapping to the 3' end of QKI7 transcript variant.  
 
B) Real Time PCR. QKI5/QKI7 expression ratio was calculated using the 2
-ΔΔCt relative quantitation 
method. Real Time PCR replicated exon array expression ratios between the two alternative QKI 
isoforms (correlation coefficient = 0.77). The experiment was performed in triplicate. Bars correspond to 
averages +/- standard errors.   
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Figure 5.15. Validation of QKI differential splicing in an independent set of samples. 
Real Time PCR validation of QKI differential splicing between normal cerebellum and primary 
medulloblastoma.  QKI5/QKI7 expression ratio was calculated using the 2
-ΔΔCt relative quantitation 
method in an independent set of ten normal cerebellar samples (in blue) and 20 primary 
medulloblastomas (SHH tumours in red and MB2 tumours in green).  
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Figure 5.16. QKI5 and QKI7  splice variants are differentially expressed during normal mouse 
cerebellar development. 
 
A) Mouse GCP primary cultures. Real Time PCR analysis of mouse Qk splice variants showed a 
significant 50% increase in the ratio between splice variants QKI5 and QKI7 when GCPs were cultured in 
the presence of ShhN (p-value < 0.0001). Histograms illustrate averages and standard errors of four 
independent experiments.  
 
B) Mouse post-natal cerebellum. A significant decrease in the ratio between mouse splice forms QKI5 
and  QKI7 was observed between post-natal days 7 and 14 (p-value < 0.0001). Histograms illustrate 
averages and standard errors of three independent experiments.  
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5.9. Discussion 
  Alternative pre-mRNA splicing makes a major contribution to the generation of 
protein variety in a tissue- and development-specific manner. Alterations in the normal 
pathways of AS have been associated with the growth and maintenance of several 
tumour types, and have been indicated as candidate bio-markers of tumour progression, 
metastasis and patient survival [117, 118, 120]. I applied genome-wide exon array 
technology to identify splicing variations that distinguish between medulloblastoma and 
normal cerebellum. I identified 1,262 unique genes containing at least one candidate 
exon whose inclusion rate differed between sample subgroups. As opposed to the 
analysis of differential gene expression, the statistical analysis of alternative splicing 
appeared to be particularly prone to the generation of false positives. This has been 
reported in the literature [148, 149] and required a manual inspection of each individual 
candidate event by using probe set expression plots and taking advantage of annotation 
databases. As a result, I discarded a large part of the selected events aiming at the 
selection of only the most promising candidates. Thanks to the rapid development of 
novel statistical tools specifically designed for the investigation of splicing changes, it 
will be possible in the near future to apply optimised algorithms which not only 
compare exon expression levels between sample subgroups, but also take into account 
the relative location of each individual probe set in reference to the corresponding 
transcript cluster, therefore generating more accurate prediction of differential splicing. 
  Following the analysis of candidate event expression plots and gene structure 
annotation, I selected 14 cassette exons for experimental validation by RT-PCR and 
successfully confirmed differential splicing in 11 cases. All of the validated cassette 
exons encoded an in-frame polypeptide which would be included in the final protein 
product and did not contain stop codons.   
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  Although in most cases the functional significance of AS has not yet been 
clarified, many of the validated genes have been previously implicated in key biological 
processes, such as neuronal differentiation and cancer progression. Several of the 
splicing events that I experimentally validated occurred in genes involved in 
cytoskeleton remodelling, cell morphology regulation and cell-cell interaction. 
DAAM1, EHBP1 and NAV2 all contain actin binding domains and have been 
suggested to mediate extensive reorganisation of actin structures likely affecting basic 
cellular functions, such as neurite growth and endocytic trafficking [268-270]. MAGI1 
and TJP1 (also known as ZO-1) have been described as tight junction proteins co-
localising in the apical region of polarised epithelial cells [271]. However, they are both 
expressed in non-epithelial cells, particularly in neuronal cell types, where they may be 
involved in different cell processes, such as regulation of gene expression [271, 272]. 
Interestingly, the two cassette exons of the MAGI1 gene that I studied are almost 
exclusively expressed in the brain, and it has been suggested that they might be 
important for neuronal specification [271].  
  TRRAP is a highly conserved, large nuclear adaptor protein commonly found in 
histone acetyltransferase multi-protein complexes. It is thought to be necessary for the 
regulation of key chromatin processes, including DNA replication and repair, and MYC 
and E2F-mediated transcription [273]. TRRAP has recently been reported to be 
necessary for the maintenance of a stem cell phenotype in embryonic and hematopoietic 
stem cells [274, 275] as well as for the tumorigenic potential of brain cancer initiating 
cells [276]. I observed a specific pattern of splicing for the TRRAP gene, with Shh-
driven medulloblastomas and medulloblastoma cell lines preferentially excluding the 
candidate cassette exon 22 (Figure 5.9). Also, more skipping of the equivalent mouse 
exon was seen in Shh-treated GCPs compared to controls and in the early stages of  
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mouse post-natal cerebellar development as opposed to the more mature cerebellum 
(Figure 5.10). It will be interesting to further investigate how insertion/exclusion of this 
exon alters the functioning of the TRRAP protein and whether it might affect the 
proliferation of granule cell precursors. 
  MADD encodes a death domain-containing adaptor protein which contributes to 
the propagation of apoptotic signals by modulating death receptor signalling. Five 
different exons in the MADD gene are alternatively spliced to generate seven transcript 
forms, which have been shown to elicit opposite cell responses, with at least two major 
splice forms promoting cancer cell survival and proliferation and another one associated 
with apoptosis (Figure 5.11) [253, 255, 261]. In my study I observed that, compared to 
normal adult cerebellum, primary medulloblastomas as well as the three 
medulloblastoma cell lines tested generally expressed higher levels of the two MADD 
splice forms associated with increased cell survival, namely the MADD and DENN-SV 
forms (Figure 5.12). To test whether these two forms contribute to the survival of 
medulloblastoma cells, it would be interesting to knockdown both of them or the 
MADD splice form exclusively (by targeting exon 13L) in medulloblastoma cell lines 
using shRNA silencing technology. It would also be interesting to express the 
exogenous IG20-pa splice variant and see if this sensitises medulloblastoma cells to 
spontaneous and drug-induced apoptosis.  
 The QKI gene encodes an RNA binding protein involved in RNA nuclear 
translocation, stability and processing and which affects both gene expression and 
splicing [265]. QKI is itself alternatively spliced to generate three major protein 
isoforms which differ in their C-terminal domain. Although little is known about the 
potential differences in the biological activity of the three QKI proteins, evidence has 
shown that both timing and subcellular compartmentalisation might regulate the access  
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of the different QKI proteins to their mRNA targets [263]. Exon array analysis showed 
that the relative expression ratio between the QKI5 and QKI7 splice forms was 
significantly higher in primary medulloblastomas as compared to normal cerebellum 
(Figure 5.15). QKI5 is known to be expressed during early embryogenesis, as opposed 
to QKI7, whose expression levels peak soon after birth and remain high throughout 
adulthood, following an expression pattern which I validated in mouse cerebellum. 
Possibly, QKI5 specific target genes could be implicated in the maintenance of an 
undifferentiated phenotype. Interestingly, among QKI target genes, as predicted from in 
silico analysis of QKI binding sites, there are genes which I found to be overexpressed 
in primary tumours compared to control samples, such as EYA1, NHLH1 and EZH2 
[265]. Future experiments should investigate the possible role of the QKI5 splice form 
in regulating gene expression in GCPs and medulloblastomas.  
 
  In conclusion, by profiling exon expression in normal and malignant cerebellum, 
I identified splice variants generally enriched in medulloblastomas or specifically 
associated with the Shh-driven medulloblastoma molecular subgroup. I experimentally 
validated a selection of candidate events by RT-PCR or Real Time PCR in an 
independent set of normal and tumour samples, confirming that the initial sample set 
could be used to predict splicing profiles of a larger cohort of samples. For each 
validated event both alternative splice forms were detectable in the normal cerebellar 
samples, clearly suggesting that rather than novel splice forms, medulloblastomas 
expressed a significantly unbalanced ratio between transcript variants normally 
generated through AS in the cerebellum. Interestingly, I observed that the expression of 
transcript variants characteristic of human primary medulloblastomas, and in particular 
of the SHH tumour subgroup, often depended upon Shh in in vitro cultures of mouse  
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GCPs and during mouse normal cerebellar development. It is therefore plausible that the 
splicing pattern of at least some of the candidate genes identified through the exon array 
analysis was associated with a failure of cerebellar precursor cells to undergo neuronal 
differentiation, as a consequence of the aberrant activation of oncogenic pathways, such 
as the Shh signalling pathway.   
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Chapter 6 
General discussion and future directions 
 
 
 
  Medulloblastoma is an embryonal tumour of the cerebellum and the most 
common malignant brain cancer in childhood [2]. Current treatments, which involve 
surgical resection, chemotherapy and radiotherapy, successfully cure only ~ 70% of 
patients, and are often associated with severe neurological deficits in long-term 
survivors [3]. There is, therefore, a great need for better therapies which are likely to 
derive from improvements in our understanding of the molecular pathways that drive 
medulloblastoma tumorigenesis [7].  
  During the past decade, integrative approaches for the study of the molecular 
abnormalities associated with malignant cerebellar phenotypes have revealed that 
medulloblastoma is a heterogeneous disease and that the characterisation of distinctive 
tumour molecular fingerprints has the potential to have an impact on the clinical 
management of medulloblastoma patients [7-9]. In particular, at least four 
medulloblastoma molecular subgroups have been described based on transcriptional and 
genomic data, including the WNT and SHH groups which display abnormalities 
indicative of inappropriate activation of the Wnt and Shh signalling pathways, 
respectively [20, 92]. Whereas increasing evidence indicates that SHH 
medulloblastomas originate from granule cell precursors (GCPs) in the developing 
cerebellum, the lineage of origin for the remaining medulloblastomas has not yet been 
elucidated [97].  
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  In our group, we were interested in profiling gene expression patterns in a cohort 
of medulloblastoma patients treated at GOSH, and to generate a novel expression data 
set that would provide an additional level of analysis of the molecular complexity of 
human medulloblastoma. I therefore used the Affymetrix exon array platform to 
compare profiles of gene and exon expression within a series of medulloblastoma and 
normal cerebellar samples. In contrast to traditional array platforms, the exon array 
probe design allows two levels of analysis: at the gene level, it provides robust 
estimates of global gene expression; at the exon level, it allows the measurement of 
differential exon usage, for the investigation of tumour-associated splicing patterns 
[143].  
  Following array hybridisation and an initial assessment of experiment 
performance, I looked for the presence within my data set of samples expressing one of 
the well characterised medulloblastoma gene signatures. In agreement with previous 
reports, 21% of the tumours displayed a gene expression pattern indicative of Shh 
signalling pathway activation (SHH tumours) [20, 92, 107]. However, no tumours 
matching any of the other medulloblastoma molecular signatures described in the 
literature were found in my cohort. It will be useful to integrate gene expression data 
with candidate gene mutation and cytogenetic analyses to enhance the strength of 
molecular classification. Still, it was interesting to perform statistical analysis of 
changes in gene/exon expression levels to identify putative tumour-related genes whose 
transcriptional profiles specifically changed in SHH tumours compared to the other 
samples, as they might be implicated in the regulation of Shh-dependent cerebellar 
development and tumorigenesis. 
  Gene-level analysis of differential expression confirmed that Shh-driven 
medulloblastomas expressed higher levels of transcripts known to be directly or  
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indirectly regulated by Shh. Similarly, genes which are typically expressed in mature 
granule neurons were down-regulated in tumours compared to the normal cerebellum. 
In addition, I identified several novel genes whose expression was associated with SHH 
tumours, or with medulloblastomas in general (Figure 4.5). Interestingly, many of them 
appeared to be implicated in the regulation of mitotic spindle organisation and 
chromosome segregation during mitosis (e.g. UBE2C, KIF4A, DLG7 and PTTG1). In 
normal cells, when even a single chromosome is not properly attached to the mitotic 
spindle, a mitotic checkpoint signalling cascade is initiated which results in cell cycle 
arrest [188]. Significant changes in the relative abundance of mitotic checkpoint 
proteins can lead to aneuploidy, a major molecular feature of tumour cells [188]. 
Whereas it is reasonable to consider the overexpression of genes regulating cell division 
as an index of the increased mitotic rate which typically characterises tumour tissues as 
opposed to the normal mature brain, these genes do represent appealing targets for a 
developing field of anti-cancer therapies designed to interfere with the mitotic 
checkpoint [277].  
  To test whether the level of expression of a selection of the candidate genes 
significantly up-regulated in SHH tumours was genuinely induced in response to Shh 
stimulation, I measured gene expression in in vitro cultures of mouse GCPs maintained 
in the presence or absence of Shh. When Shh was added to the cell culture, all of the 
candidate genes examined showed a significant increase in their transcript levels, 
suggesting that the Shh pathway regulates their activity to promote GCP progression 
through the cell cycle (Figure 4.9). It will be interesting in the future to investigate 
possible mechanisms by which Shh signalling may sustain candidate gene expression 
and whether any of the selected genes would be able to at least partially substitute for 
Shh in inducing cell proliferation both in normal and pathological conditions. Indeed,  
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transgenic mice overexpressing the Ube2c gene develop a variety of spontaneous 
tumours, following the disruption of the mitotic checkpoint and the accumulation of 
chromosomal abnormalities [199]. Similarly, overexpression of the Pttg1 gene induces 
cell transformation in vitro and tumour formation in immuno-compromised mice, 
possibly by causing chromosomal instability and aneuploidy [190]. 
  To determine whether the identified candidate genes regulated tumour cell 
proliferation, I wanted to investigate the effect of their down-regulation in human 
medulloblastoma cell lines. For this purpose, I set up an experimental system for the 
log-term silencing of target genes in the Daoy, UW228-2 and D425 Med cell lines 
through the delivery of gene-specific shRNAs by lentiviral transduction. In preliminary 
experiments, the targeting of a small selection of the candidate genes failed to induce 
any relevant changes in cell proliferation rate or cell cycle distribution, as described in 
section 4.8. Given more time, I would like to optimise the transduction protocol and 
improve target gene knockdown efficiency, introduce more specific biological read-outs 
as well as explore alternative ways of inhibiting the target genes, such as the use of 
dominant negative mutant proteins. I would also like to better investigate the level of 
activity of the Shh pathway in the three medulloblastoma cell lines, to assess whether 
they represent an appropriate model to study Shh-driven medulloblastomas. 
Alternatively, I could explore the potential role of Shh-related genes in promoting cell 
proliferation during normal cerebellar development using primary cultures of mouse 
GCPs, in which I would overexpress candidate genes or their dominant negative mutant 
forms.  
  The second part of my project involved an analysis of differential expression at 
the individual exon–level, which enabled me to identify splice variants significantly 
enriched in specific sample subgroups. Since the technology to perform comprehensive  
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analyses of alternative splicing patterns has been available only recently, the 
contribution of inappropriate splicing to tumour formation and growth is still not well 
understood [117-119]. However, multiple studies have shown that aberrant mRNA 
processing occurs frequently in human cancers and can directly contribute to the 
development of the disease (reviewed in [114, 115]). By comparing the normalised 
expression of individual exons between normal cerebellum and the subgroup of Shh-
driven tumours or the entire set of medulloblastomas, I identified a large number of 
genes undergoing differential splicing. I then selected a small subset of these events to 
be validated by RT-PCR. Interestingly, I was able to confirm changes in exon inclusion 
rates for most of the cases examined (11 out of 14 cases), both in a subset of the profiled 
samples, and, more importantly, in a completely independent set of normal cerebellar 
and medulloblastoma tissues (Figure 5.8). In most cases the biological significance of 
the amino acid variation between the alternative splice forms has not yet been clarified, 
however many of the differently spliced exons are known to be predominantly 
expressed in the mature brain. Furthermore, for all of the events that I verified, the two 
alternative transcripts were detectable in the normal cerebellum, which indicates that 
rather than novel splice forms, medulloblastomas expressed unbalanced ratios between 
transcript variants normally generated through alternative splicing (AS) in the 
cerebellum. I observed that the expression of transcript variants characteristic of human 
primary medulloblastomas, and in particular of the SHH tumour subgroup, often 
depended upon Shh in in vitro cultures of mouse GCPs and during the normal 
development of the mouse cerebellum (Figure 5.10).  
  These findings clearly support the well established connection between 
cerebellar development and tumorigenesis, and provide an additional perspective to the 
analysis of the molecular similarities between GCPs and Shh-dependent  
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medulloblastomas. It is not surprising that programmes of alternative splicing are shared 
between Shh-dependent tumours and normal precursor cells, however, the more general 
splicing similarities between GCPs and all of the medulloblastomas under study are less 
clear. It is intriguing to hypothesise that these splicing patterns are characteristic of an 
even more immature progenitor cell in the cerebellum that then gives rise to the granule 
neuron lineage and SHH tumours as well as to alternative lineages, which in turn may 
follow divergent pathogenesis processes. It will also be interesting to investigate 
whether subgroup-specific patterns of differential splicing occur in the medulloblastoma 
subgroup with activation of the WNT signalling pathway, or any of the other discrete 
molecular subgroups. 
  The analysis of alternative splicing in medulloblastoma and normal cerebellum 
suggested that disruption of the correct balance between alternative transcript forms can 
be associated with a malignant phenotype. It will be important to explore the possible 
role of Shh and of other key signalling pathways that function in the developing brain in 
regulating programmes of alternative splicing. Lee et al. recently applied a genome-
wide approach for the identification of genes directly regulated by Gli1 in GCPs and 
primary medulloblastomas derived from Ptch
+/- mice [278]. Interestingly, they found 
that several of the Gli1 target genes encode proteins implicated in mRNA processing 
and stability [278], suggesting that the Shh signalling pathway regulates splicing 
mechanisms in the developing cerebellum and in tumorigenesis. Consistent with these 
findings, when analysing changes in the level of expression of more than 300 genes 
encoding trans-acting splicing factors, I found a significant number of genes to be 
differentially expressed between normal adult cerebellum and medulloblastomas 
(Figure 6.1). Importantly, these include a few major regulators of splicing in the CNS, 
such as NOVA1, PTBP1 and A2BP1 [279-281].  
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Figure 6.1. Gene-level expression analysis for genes encoding splicing factors. 
The moderated t-statistic of the LIMMA package was used to compare the levels of expression of genes 
encoding splicing factors between medulloblastomas and normal cerebellar samples. The data set 
consisted of 27 total samples analysed by exon arrays, including the 19 samples analysed in my exon 
array experiment, three normal adult cerebellar samples from the Affymetrix human tissue public dataset 
(available from http://www.affymetrix.com) and five additional normal fetal cerebellar samples from 
Johnson et al. [282] (GEO dataset accession number GSE133344). Only genes with a fold change in 
expression higher or lower than 2 in medulloblastomas relative to normal adult cerebella are shown in the 
heatmap (FDR adjusted p-value < 0.05). Samples are colour-coded as follows: light blue, normal adult 
cerebellum; blue, normal fetal cerebellum, black, medulloblastoma.   
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Recent evidence has shown that one of the neuron-specific mechanisms for the 
inclusion of brain-enriched exons in transcripts involves the expression of microRNA 
miR-124 [280]. MiR-124 was able to trigger neuronal differentiation in neuroblastoma 
cell lines by directly targeting the mRNA of the PTBP1 gene, one of the best 
characterised negative regulators of neuron-specific AS. In the developing brain, 
PTBP1 activity is gradually lost, partly through negative regulation at the post-
transcriptional level by miR-124 whose expression increases in the adult brain [280, 
283]. This involves a major switch in the splice forms that are expressed in the adult 
brain as compared to the developing brain, with many neuron-specific exons (e.g. 
DAAM1 exon 16) being incorporated into the mature mRNAs, and eventually resulting  
in the neuronal differentiation of progenitor cells into post-mitotic neurons [280] [284]. 
Remarkably, miR-124 was reported to be significantly down-regulated in human 
medulloblastomas compared to normal adult cerebellum [107, 285, 286], whereas the 
level of expression of the PTBP1 gene was more than 2-fold higher in tumours 
compared to controls in my array data set (Figures 6.1 and 6.2). Moreover, Ptbp1 was 
identified as one the Gli1 target genes in the study by Lee et al. [278]. Future 
experiments will investigate whether the characteristic patterns of differential cassette 
exon exclusion that I recognised in human medulloblastomas may be related to a failure 
in the neuron-specific AS programmes regulated by miR-124 via the down-regulation of 
PTBP1, or other key signalling pathways, such as the Shh pathway, which may control 
the overall activity of the splicing machinery in the developing cerebellum. 
 
  In conclusion, I performed a genome-wide analysis of gene expression in normal 
and malignant cerebellum and identified a subset of tumour samples expressing the 
molecular signature of Shh-dependent medulloblastomas. Statistical analysis of  
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Figure 6.2. PTBP1 is over-expressed in medulloblastomas compared to normal adult cerebella.  
Box plots showing PTBP1 gene expression in a set of 27 samples profiled by exon arrays. Box plots 
efficiently describe differences in gene signal distribution between sample subgroups within a data set. 
The bottom and top edges of the box correspond to the 25th percentile and 75th percentile, respectively. 
The median value is shown as a line across the box. Whiskers extend to 1.5 times the inter-quartile range 
(defined as the difference between the 75th and 25th percentiles), and outliers are marked with circles. 
The PTBP1 gene is expressed at a significantly higher level in medulloblastomas compared to normal 
adult cerebellar samples (FDR adjusted p-value <0.001).  
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differential expression at the gene-level identified an interesting set of tumour-
associated genes implicated in the regulation of the mitotic checkpoint, neuronal 
transcriptional programmes and DNA replication and repair. These genes were also 
overexpressed in GCPs cultured in vitro in the presence of Shh and in human 
medulloblastoma cell lines. Their role in sustaining the growth of precursor and tumour 
cells will be investigated in future experiments.  
  Changes in expression at the exon-level, which are indicative of differential 
splicing, were frequently found in association with medulloblastoma. Interestingly 
human primary tumours, particularly Shh-driven medulloblastomas, shared patterns of 
splicing with mouse GCPs, further supporting the idea that they have a common origin. 
The observation that CNS-specific exons were down-regulated and several trans-acting 
splicing factors differentially expressed in tumour tissues in comparison to the normal 
cerebellum, suggests that the disruption of AS programmes in the developing 
cerebellum might be associated with a failure of precursor cells to undergo neuronal 
differentiation as a consequence of the aberrant activation of oncogenic pathways, such 
as the Shh signalling pathway. The possible casual relationship between inappropriate 
splicing and medulloblastoma pathogenesis will be the subject of future investigation.    
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Appendix 1. Primer sets for PCR analysis of gene expression and alternative splicing. 
 
Organism  Gene symbol/variant  Forward 5' ‐ 3'  Reverse 5' ‐ 3'  Assay 
Mm  B2m  CTGACCGGCCTGTATGCTAT  CAGTCTCAGTGGGGGTGAAT  RT‐PCR  
Mm  Baz1a   TGCTGATGGAGAGACGATTG  TAGGTGGGTCATCAGGGAAG  RT‐PCR  
Mm  Casc5   ATTTTGAAACCCCCAAGGAG  CTGAATTGGAGCACAAAGCA  RT‐PCR  
Mm  Chek1   CCAGAAAACCTCCTCTTGGA  AATTCTCCAGCCAACATTGC  RT‐PCR  
Mm  Dlg7   GGGAAGCTGGACCTGGACAT  TTGACCAACCGTTGTACGGATA  RT‐PCR  
Mm  Exo1   CAGGCTGTCATCACAGAGGA  CACGATATCGGGGTTATTGG  RT‐PCR  
Mm  Ezh2   TTCGTGCCCTTGTGTGATAGC  TGCACCGACATCCAGGAAA  RT‐PCR  
Mm  Foxm1   ACCTGGAGCAGAATCGGGTTA  ACAGAGTCCTGCCAAGATGTTGA  RT‐PCR  
Mm  Gli1  CTTTCTGGTCTGCCCTTTTG  ATTACGGTTTGCAGGTCGAG  RT‐PCR  
Mm  Kif4   CCAGATGCTGGAGAGGATCATT  GCATGCCGCCTGAGTTCT  RT‐PCR  
Mm  Math1  GGTGCAGCTGGACGCTTT  TCTGTGCCATCATCGCTGTT  RT‐PCR  
Mm  Melk   ATCCCTGGGTCATGCAAGATTA  AGGTGAGTCAAAGGAGTCTTGCTT  RT‐PCR  
Mm  Nusap1  GCTCACTGACCAAGACACCA  GCTTGTAGTTGAGGGGACGA   RT‐PCR  
Mm  Plk1   GGGTGCATCATGTATACCTTGCT  CTTGATCCGGAGGTAGGTCTCTT  RT‐PCR  
Mm  Pou3f2   CAGCTGAGCTTCAAGAACATGTG  GAGGATGAGTCTGCCTCTTCCA  RT‐PCR  
Mm  Pttg1  CCGACCTTGACTGGGAAAAA  CATCAGGAGCAGGAACAGAACTT  RT‐PCR  
Mm  Tead2   TGCCTTCTTCCTCGTCAAGT  CAAAGGAGCAGACCTTGGAG  RT‐PCR  
Mm  Troap   TAGCTCTGGGGGATCAAATG  GGATTCTGGGAGCCAGGTAT  RT‐PCR  
Mm  Ube2c   ATCCTCATGACATCTGGTGACAAA  CCCACTTGAACAGGTTGTCTGA  RT‐PCR  
Mm  Wdr7  TTGGCGATCACATGAAGAAG   GTCCTGCCATCTTCGAGCTA  RT‐PCR  
Mm  Trrap   GCCTCTTCCCAAATTCCTTC  GCTGGGATCAGATGGAAAAG  RT‐PCR  
Mm  Daam1  GCCCTGAAATCCTTCAACTG  TCATCAATGGCATCTGCTTC   RT‐PCR  
Mm  Ehbp1  GATGACGAGAACCGTGTGAA  GCCAAGTCCTTTTGTGCTTC  RT‐PCR  
Mm  Magi1   GACGGCTCAGTCCCAGAATA  TGGGTAACTGGACTCCAAGG  RT‐PCR  
Mm  Madd / exons 13L16   TGCCAGTGAAGTGGAGATTG  TCCTTCAGGAACTGCTGGTT   RT‐PCR  
Mm  Madd / exon 34  GAGTTCCCTGTGCAGGACAT  GCCATTGGCGTCTTGTACTT   RT‐PCR  
Mm  Qk5   GCGGTGGCTACTAAAGTTCG  GCATGGTCAGGTCATCATTG   Real Time PCR 
Mm  Qk7   CTCACCCAACTGCTGCAATA  GCAAGTCAATGGGCTGAAAT  Real Time PCR 
Hs  B2M  GGCATTCCTGAAGCTGACA  CGGCAGGCATACTCATCTTT  RT‐PCR  
Hs  BAZ1A   GAAGTCCTCCCTCCATCACA  GGTGGATCATCAGGGAAGAA  RT‐PCR  
Hs  BMI1  CAGCAATGACTGTGATGCACT  GCCTTGTCACTCCCAGAGTC  RT‐PCR  
Hs  POU3F2  CACAAAATGCAGCTTCCTGA  GGCTTCAACTCTCTCCGATG  RT‐PCR  
Hs  CASC5   TTCAAAAATGGATGGGGTGT  TCAAAGCATTGGATTCCTGA  RT‐PCR  
Hs  CHEK1  CAGGGGTGGTTTATCTGCAT  TCCACAGGACCAAACATCAA  RT‐PCR  
Hs  DLG7   ATGTTAAGCCAAGGGCAATG  TTGCTCGAACATCACTCTCG  RT‐PCR  
Hs  EXO1   GCTCCCTATGAAGCTGATGC  ACATTCCTAGCCGAGCTTGA  RT‐PCR  
Hs  FOXM1   CAACTCAGCCTCCAGGACTC  TCGAAGGCTCCTCAACCTTA   RT‐PCR  
Hs  KIF4A   CTGTTTTGGTTGCCTTGGAT  CACAAAGCCACCCTTTTTGT  RT‐PCR  
Hs  MYC   GCTGCTTAGACGCTGGATTT  CTGCTGCTGCTGGTAGAAGTT  RT‐PCR  
Hs  NUSAP1   AGCAACCAGGAAGAAGCTGA  CTGAGATCCTGGCTTTCCTG  RT‐PCR  
Hs  PLK1   GCCCCTCACAGTCCTCAATA  TACCCAAGGCCGTACTTGTC  RT‐PCR  
Hs  PTTG1   GGACCCCTCAAACAAAAACA  GAGAGGCACTCCACTCAAGG  RT‐PCR  
Hs  TEAD2   AGTTCTCAGCCTTCGTGGAA  TTGCCAAAAGAGCAGACCTT  RT‐PCR  
Hs  TROAP   CTCGGTAAGCCATCATGACC  TCCCCACCAATCTTTGTGAT  RT‐PCR  
Hs  UBE2C   TGGCGATAAAGGGATTTCTG  AGGGCAGACCACTTTTCCTT  RT‐PCR  
Hs  ATP2B1   GTGGCCAAATCTTGTGGTTT  CCGGTTTTTCTAACCCTTCA  RT‐PCR  
Hs  DAAM1   CACAAATGCCCTGAAATCCT  TCATCAATGGCATCTGCTTC  RT‐PCR   
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Hs  EHBP1   ATGAAGCAGGCTGACATTGG  GCAGCATCAGGATCATCAAA  RT‐PCR  
Hs  MADD / exon 34  TGTGCAGGACCTGAAGACTG  TAGCCCCTCTCCATCAGCTA  RT‐PCR  
Hs  MADD / exons 13L16  CCTCTGACACATGCAGCACT  CACTAACGCCCTCCTGTTTC  RT‐PCR  
Hs  MADD / exon 21  CCAAAGGCTATGGCACAACT  CGCTGATCTGGGACTTTTTC  RT‐PCR  
Hs  MADD / exon 26  AGAGACCCTTGGAGCTGACA  GGTCCATACCCATCCCTTCT  RT‐PCR  
Hs  MAGI1 / exon 15  CCCAGTCCAGGAGCATGTAT  CACCCAGTGGTACGATGTGA  RT‐PCR  
Hs  MAGI1 / exon 24  GGAGACGGCTCAGTACCAGA  TGAAGATCGGGTGGGTAACT  RT‐PCR  
Hs  NAV2  CAGCAGTCAAAAGCACAAGC  TGCGTCGGTTGTTAGCAGTA  RT‐PCR  
Hs  QKI‐5   GCGGTGGCTACTAAAGTTCG  GCATGGTCAGGTCATCATTG   Real Time PCR 
Hs  QKI‐7   ACACATTGGCACCAGCTACA  AAAACAAAGGGGTTGCACAG  Real Time PCR 
Hs  R3HDM1   GGAAGCAGCAAAAGCATAGG  GTCCAGGCACTTGGGATCTA  RT‐PCR  
Hs  TJP1  GTCTGCCATTACACGGTCCT  GACTAACGGCTGGCTGTTTC  RT‐PCR  
Hs  TRRAP  GGCTCTTCCCAAATTCCTTC  AGCAAAGGCTTCACCAGTGT  RT‐PCR  
Hs  WDR7   CGTATCGTTTGGCCTCTTGT  GGCAGCATAACACAGTGCAT  RT‐PCR  
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Appendix 2. List of genes significantly up-regulated in Shh-driven medulloblastomas. 
 
Transcript ID  Gene Symbol  SHH‐Ad CB SHH‐ CB  SHH‐MB2  Transcript ID  Gene Symbol  SHH‐Ad CB  SHH‐ CB  SHH‐MB2 
    FC  DEG  FC  DEG FC  DEG     FC  DEG  FC  DEG FC  DEG
2946215  HIST1H3B   6.7  DEG  4.9  ‐‐  0.5  ‐‐  3463112  E2F7   2.6  DEG  1.9  ‐‐  0.9  ‐‐ 
2899102  HIST1H3C   6.5  DEG  4.9  ‐‐  1.1  ‐‐  3490655  CKAP2   2.6  ‐‐  2.4  DEG 0.6  ‐‐ 
2947081  HIST1H4L   6.0  DEG  5.0  ‐‐  1.8  ‐‐  3673684  CDT1   2.5  ‐‐  2.3  DEG 0.9  ‐‐ 
3440598  FOXM1   5.7  ‐‐  4.8  DEG 1.9  ‐‐  2450345  KIF14   2.5  ‐‐  2.2  DEG 0.5  ‐‐ 
2470838  MYCN   5.7  DEG  4.5  DEG 3.8  DEG 3235789  MCM10   2.5  DEG  2.2  DEG ‐0.3  ‐‐ 
3756193  TOP2A   5.2  DEG  4.1  DEG ‐0.4  ‐‐  2859667  ADAMTS6   2.5  DEG  2.0  ‐‐  0.5  ‐‐ 
3590388  NUSAP1   5.2  DEG  4.1  DEG 1.0  ‐‐  3225855  ANGPTL2   0.6  ‐‐  0.5  ‐‐  2.5  DEG
2946369  HIST1H3G   5.1  DEG  4.3  ‐‐  0.9  ‐‐  3727449  TOM1L1   1.7  ‐‐  2.0  ‐‐  2.5  DEG
2900059  HIST1H2BM   4.9  DEG  3.4  ‐‐  1.0  ‐‐  3458783  CDK4   2.5  ‐‐  2.3  DEG 1.0  ‐‐ 
2469252  RRM2   4.7  DEG  3.6  ‐‐  ‐0.4  ‐‐  2980241  FBXO5   2.5  ‐‐  2.2  DEG 0.6  ‐‐ 
3587457  ARHGAP11A   4.7  DEG  3.9  DEG 1.4  ‐‐  3639031  PRC1   2.5  ‐‐  2.3  DEG 0.1  ‐‐ 
3629103  KIAA0101   4.7  ‐‐  3.8  DEG ‐0.4  ‐‐  3903146  E2F1   2.5  DEG  2.0  DEG 0.0  ‐‐ 
3445741  MGP   4.7  DEG  3.7  ‐‐  2.7  ‐‐  4006280  NDP   ‐0.3  ‐‐  ‐0.5  ‐‐  2.5  DEG
2333136  CDC20   4.7  ‐‐  4.0  DEG 1.4  ‐‐  3288518  C10orf72   1.4  ‐‐  1.4  ‐‐  2.4  DEG
4035833  CD24   4.6  DEG  3.5  ‐‐  0.6  ‐‐  3861786  FBXO17   0.4  ‐‐  0.7  ‐‐  2.4  DEG
2745899  HHIP   2.3  ‐‐  2.1  ‐‐  4.6  DEG 2703902  BCHE   1.5  ‐‐  1.1  ‐‐  2.4  DEG
3887049  UBE2C   4.6  DEG  3.7  DEG 1.1  ‐‐  3676300  RPS2   2.4  DEG  2.4  ‐‐  1.4  ‐‐ 
3595979  CCNB2   4.5  DEG  3.9  DEG 1.2  ‐‐  2427619  KCNA3   0.7  ‐‐  0.8  ‐‐  2.4  DEG
3788560  DCC   4.5  DEG  3.8  ‐‐  1.3  ‐‐  2965739  C6orf167   2.4  ‐‐  1.9  DEG 1.0  ‐‐ 
3312490  MKI67   4.5  DEG  3.4  DEG 1.1  ‐‐  3750785  SPAG5   2.4  ‐‐  2.1  DEG ‐0.1  ‐‐ 
3881443  TPX2   4.5  DEG  3.6  DEG 0.9  ‐‐  3703112  GINS2   2.4  ‐‐  2.2  DEG ‐0.3  ‐‐ 
2838201  PTTG1   4.5  DEG  3.7  DEG 1.5  ‐‐  2894573  GCNT2   1.1  ‐‐  0.8  ‐‐  2.3  DEG
4018218  DCX   4.4  DEG  2.5  ‐‐  0.0  ‐‐  3720896  WIPF2   2.3  ‐‐  2.0  DEG ‐0.5  ‐‐ 
3428268  GAS2L3   4.4  DEG  3.1  ‐‐  1.2  ‐‐  3890109  C20orf108   2.1  ‐‐  2.3  DEG 1.2  ‐‐ 
2654454  SOX2   1.4  ‐‐  0.8  ‐‐  4.4  DEG 2714955  TACC3   2.3  ‐‐  2.0  DEG 0.5  ‐‐ 
2720251  NCAPG   4.3  DEG  3.4  DEG 0.9  ‐‐  2780172  CENPE   2.3  ‐‐  2.1  DEG 0.6  ‐‐ 
2796951  PDLIM3   2.0  ‐‐  1.2  ‐‐  4.3  DEG 2569908  SEP10  2.3  ‐‐  1.7  ‐‐  2.3  DEG
2899756  HIST1H2AG   4.2  DEG  3.4  DEG 0.4  ‐‐  3454223  RACGAP1   2.3  ‐‐  2.0  DEG ‐0.5  ‐‐ 
2736224  ATOH1   3.3  ‐‐  2.5  ‐‐  4.2  DEG 4021508  SUHW3   2.3  ‐‐  2.1  DEG 1.0  ‐‐ 
2900051  HIST1H3H   4.2  DEG  3.6  DEG 0.9  ‐‐  2540157  ODC1   2.3  ‐‐  1.9  DEG ‐0.5  ‐‐ 
3440568  NRIP2   1.2  ‐‐  1.9  ‐‐  4.2  DEG 2373564  CRB1   ‐0.1  ‐‐  ‐0.2  ‐‐  2.3  DEG
2363128  NHLH1  4.2  DEG  2.6  ‐‐  2.3  ‐‐  3169331  ALDH1B1   2.3  ‐‐  2.1  DEG 0.5  ‐‐ 
2816459  F2R   4.2  DEG  2.9  ‐‐  1.2  ‐‐  2620256  KIF15   2.3  ‐‐  2.0  DEG 0.2  ‐‐ 
2946219  HIST1H2AB   4.1  DEG  3.4  DEG 0.9  ‐‐  3865568  SNRPD2   2.3  ‐‐  2.0  DEG 0.8  ‐‐ 
2798915  TRIP13   4.1  ‐‐  3.7  DEG 1.5  ‐‐  2783596  PDE5A   1.8  ‐‐  1.5  ‐‐  2.3  DEG
3565663  DLG7   4.1  DEG  3.6  DEG 0.9  ‐‐  2783715  MAD2L1   2.2  ‐‐  2.1  DEG 0.8  ‐‐ 
3449700  FAM60A   4.1  ‐‐  3.6  DEG 2.1  ‐‐  3197955  GLDC   1.1  ‐‐  0.7  ‐‐  2.2  DEG
2946225  HIST1H2BB   4.1  DEG  3.2  ‐‐  0.9  ‐‐  3130244  TEX15   2.2  ‐‐  1.8  DEG 2.1  DEG
3140037  EYA1   3.8  DEG  3.5  DEG 4.0  DEG 3983537  PABPC5   1.6  ‐‐  1.3  ‐‐  2.2  DEG
3927392  CYYR1   4.0  DEG  3.0  ‐‐  3.6  DEG 3527493  APEX1   2.2  ‐‐  1.9  DEG 0.8  ‐‐ 
2830638  KIF20A   4.0  ‐‐  3.4  DEG 1.3  ‐‐  3670772  CMIP   2.2  ‐‐  1.9  DEG 1.7  DEG
3611625  ALDH1A3   2.6  ‐‐  2.9  ‐‐  4.0  DEG 3563395  POLE2   2.2  DEG  1.8  DEG 0.2  ‐‐ 
3168508  MELK   4.0  DEG  3.3  DEG 0.7  ‐‐  3168938  POLR1E   2.2  ‐‐  2.0  DEG 1.2  ‐‐ 
2379863  CENPF   4.0  DEG  3.2  DEG 0.4  ‐‐  3342426  FLJ25416   2.2  ‐‐  2.0  DEG 0.4  ‐‐ 
2467855  SOX11   4.0  DEG  2.7  ‐‐  0.3  ‐‐  2970532  HDAC2   2.2  ‐‐  2.0  DEG 0.3  ‐‐ 
3258168  KIF11   4.0  DEG  3.3  DEG 0.8  ‐‐  3924573  PCNT   2.2  ‐‐  2.0  DEG 2.0  DEG
2650199  SMC4   3.8  ‐‐  3.3  DEG 0.9  ‐‐  3845365  TCF3   2.1  ‐‐  1.7  DEG 0.9  ‐‐ 
2752725  NEIL3   3.8  ‐‐  3.2  DEG 1.0  ‐‐  2633691  TMEM45A   2.1  ‐‐  1.8  ‐‐  1.6  DEG
3061319  CDK6   3.8  DEG  2.8  ‐‐  0.5  ‐‐  3427352  NEDD1   2.1  ‐‐  2.0  DEG 0.7  ‐‐ 
2636319  BOC   2.9  ‐‐  2.1  ‐‐  3.8  DEG 2522212  SGOL2   2.1  ‐‐  2.0  DEG 0.6  ‐‐  
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2604254  DKFZp762E1312   3.8  DEG  3.0  DEG 1.0  ‐‐  2617276  CTDSPL   0.5  ‐‐  0.4  ‐‐  2.1  DEG
3401804  DYRK4   3.7  ‐‐  3.5  DEG 1.5  ‐‐  3928070  CCT8   1.7  ‐‐  2.1  DEG 0.8  ‐‐ 
3653072  PLK1   3.7  ‐‐  3.2  DEG 1.0  ‐‐  2797393  FAT   ‐1.0  ‐‐  ‐0.8  ‐‐  2.1  DEG
3354799  CHEK1   3.6  DEG  2.9  DEG 0.4  ‐‐  2781138  LEF1   1.9  ‐‐  1.4  ‐‐  2.1  DEG
3855856  EDG4   3.6  DEG  2.3  ‐‐  0.6  ‐‐  2838656  HMMR   2.1  ‐‐  2.0  DEG 0.9  ‐‐ 
2378937  DTL   3.6  DEG  2.8  DEG ‐0.2  ‐‐  2339786  PGM1   0.6  ‐‐  0.8  ‐‐  2.1  DEG
3736290  BIRC5   3.6  DEG  3.0  DEG 0.3  ‐‐  3680583  RSL1D1   2.0  ‐‐  2.1  DEG 1.1  ‐‐ 
2388219  EXO1   3.6  DEG  2.9  DEG 0.5  ‐‐  3619945  OIP5   2.1  ‐‐  1.9  DEG 0.2  ‐‐ 
3504617  C13orf3   3.6  ‐‐  3.0  DEG 0.6  ‐‐  2823551  MAN2A1   0.9  ‐‐  0.8  ‐‐  2.1  DEG
3728964  PRR11   3.6  ‐‐  3.0  DEG 0.7  ‐‐  2407191  GNL2   2.0  ‐‐  2.0  DEG 1.1  ‐‐ 
2740896  NDST3   1.1  ‐‐  1.0  ‐‐  3.6  DEG 2431112  NOTCH2   0.1  ‐‐  ‐0.2  ‐‐  2.0  DEG
3744263  AURKB   3.5  DEG  2.8  ‐‐  0.9  ‐‐  2589255  FKBP7   2.0  ‐‐  1.8  DEG 0.9  ‐‐ 
3599811  KIF23   3.5  DEG  2.9  DEG 0.6  ‐‐  2416218  ITGB3BP   2.0  ‐‐  1.9  DEG 0.7  ‐‐ 
2334098  KIF2C   3.5  DEG  3.0  DEG 0.9  ‐‐  2694817  PLXND1   2.0  ‐‐  1.9  DEG 1.9  DEG
3129149  PBK   3.5  DEG  2.9  ‐‐  0.7  ‐‐  4052881  FAM72A   2.0  ‐‐  2.0  DEG 0.8  ‐‐ 
2784113  CCNA2   3.4  ‐‐  2.9  DEG 0.9  ‐‐  3979659  MSN   1.0  ‐‐  0.8  ‐‐  2.0  DEG
2570616  BUB1   3.4  DEG  2.8  DEG 0.6  ‐‐  2698565  TFDP2   2.0  ‐‐  1.7  ‐‐  1.9  DEG
2449559  F13B   3.4  DEG  2.8  DEG 0.6  ‐‐  3845868  LSM7   2.0  ‐‐  1.9  DEG 0.6  ‐‐ 
3178583  CKS2   3.4  DEG  3.1  DEG 0.4  ‐‐  3983228  DACH2   2.0  ‐‐  1.9  ‐‐  1.8  DEG
2516023  CDCA7   3.4  DEG  2.9  ‐‐  0.6  ‐‐  3603408  PSMA4   1.7  ‐‐  2.0  DEG 0.5  ‐‐ 
2748198  KIAA0922   3.4  ‐‐  2.4  ‐‐  2.6  DEG 2687979  KIAA1524   2.0  ‐‐  1.7  DEG 0.4  ‐‐ 
3560711  BAZ1A   3.4  DEG  2.8  DEG 1.3  ‐‐  2827185  LMNB1   1.9  ‐‐  1.8  DEG ‐0.2  ‐‐ 
2364438  NUF2   3.3  DEG  2.8  DEG 0.3  ‐‐  3200611  SCARNA8   1.8  ‐‐  1.9  DEG 1.1  DEG
2947100  HIST1H2AM   3.3  DEG  2.6  DEG 0.4  ‐‐  3561532  SLC25A21   1.9  ‐‐  1.9  DEG 1.9  DEG
3980560  KIF4A   3.3  DEG  2.8  DEG 0.7  ‐‐  2695941  TOPBP1   1.9  ‐‐  1.7  DEG 0.7  ‐‐ 
2914777  TTK   3.3  DEG  2.9  DEG 0.6  ‐‐  3164914  MTAP   1.9  ‐‐  1.8  DEG 1.5  ‐‐ 
3949055  GTSE1   3.3  DEG  2.6  DEG 0.5  ‐‐  3529908  NFATC4   1.5  ‐‐  1.4  ‐‐  1.9  DEG
2594089  SATB2   2.8  ‐‐  2.1  ‐‐  3.3  DEG 3523881  KDELC1   1.9  ‐‐  1.8  DEG 1.3  DEG
3850660  SPC24   3.2  DEG  2.6  ‐‐  0.2  ‐‐  3493391  C13orf34   1.8  ‐‐  1.9  DEG 0.8  ‐‐ 
2899772  HIST1H2AH   3.2  DEG  2.8  ‐‐  1.5  ‐‐  3721452  FKBP10   1.5  ‐‐  1.1  ‐‐  1.9  DEG
2494484  NCAPH   3.2  DEG  2.8  DEG 0.5  ‐‐  3974098  MID1IP1   1.2  ‐‐  1.4  ‐‐  1.9  DEG
3765580  BRIP1   3.2  DEG  2.5  DEG ‐0.2  ‐‐  3821908  RNASEH2A   1.9  ‐‐  1.8  DEG 0.0  ‐‐ 
2947063  HIST1H2AK   3.2  DEG  2.5  ‐‐  0.8  ‐‐  3484641  BRCA2   1.8  ‐‐  1.5  DEG 0.0  ‐‐ 
3677969  SRL   3.2  ‐‐  3.0  DEG 3.2  DEG 3204534  FANCG   1.6  ‐‐  1.8  DEG 0.8  ‐‐ 
3867796  TEAD2   3.2  DEG  2.4  ‐‐  1.5  ‐‐  2911413  PRIM2A   1.8  ‐‐  1.7  DEG 0.3  ‐‐ 
2454444  NEK2   3.2  ‐‐  2.8  DEG 0.4  ‐‐  4001369  SCML2   1.8  ‐‐  1.5  DEG 0.9  ‐‐ 
2897899  SOX4   3.2  DEG  1.9  ‐‐  ‐1.0  ‐‐  4012299  PHKA1   0.8  ‐‐  0.8  ‐‐  1.8  DEG
2813414  CCNB1   3.2  ‐‐  3.0  DEG 1.0  ‐‐  2532699  INPP5D   1.3  ‐‐  1.2  ‐‐  1.8  DEG
3780334  MC5R   3.1  ‐‐  2.9  ‐‐  2.9  DEG 2727116  RASL11B   0.4  ‐‐  0.9  ‐‐  1.8  DEG
3590014  CASC5   3.1  DEG  2.5  DEG 0.4  ‐‐  3040897  CDCA7L   1.8  ‐‐  1.8  ‐‐  1.5  DEG
3883941  TGIF2   3.1  DEG  2.3  ‐‐  2.4  ‐‐  3879467  XRN2   1.8  ‐‐  1.8  DEG 0.7  ‐‐ 
3391653  DRD2   3.1  DEG  2.9  ‐‐  2.3  ‐‐  3565571  WDHD1   1.8  ‐‐  1.7  DEG 0.1  ‐‐ 
2858592  DEPDC1B   3.1  DEG  2.6  DEG 0.2  ‐‐  3996667  DKC1   1.7  ‐‐  1.8  DEG 0.3  ‐‐ 
3291435  PLEKHK1   3.1  DEG  2.5  DEG 0.3  ‐‐  2412799  ORC1L   1.7  ‐‐  1.5  DEG 0.3  ‐‐ 
3248289  CDC2   3.1  DEG  2.6  DEG 0.4  ‐‐  4007216  UXT   1.7  ‐‐  1.7  DEG 0.9  ‐‐ 
2520429  MYO1B   3.1  DEG  2.4  ‐‐  1.2  ‐‐  3367036  CCDC34   1.7  ‐‐  1.7  DEG 0.4  ‐‐ 
2652675  ECT2   3.1  DEG  3.0  DEG 1.0  ‐‐  3944147  MCM5   1.7  ‐‐  1.6  DEG 0.4  ‐‐ 
3776139  NDC80   3.1  DEG  2.6  DEG 0.6  ‐‐  3428845  C12orf48   1.7  ‐‐  1.5  DEG 0.5  ‐‐ 
2791419  C4orf18   1.5  ‐‐  1.6  ‐‐  3.0  DEG 3911814  SLMO2   1.4  ‐‐  1.7  DEG 0.3  ‐‐ 
2665572  SGOL1   3.0  ‐‐  2.6  DEG 0.7  ‐‐  3250055  DDX21   1.5  ‐‐  1.7  DEG 0.1  ‐‐ 
3607510  FANCI   3.0  ‐‐  2.7  DEG 0.9  ‐‐  2603987  NGEF   1.6  ‐‐  1.5  ‐‐  1.6  DEG
3413875  TROAP   3.0  ‐‐  2.6  DEG 0.8  ‐‐  3831260  ZNF146   1.6  ‐‐  1.6  DEG 0.5  ‐‐ 
3607698  C15orf42   3.0  DEG  2.2  ‐‐  1.0  ‐‐  3488942  NUDT15   1.6  ‐‐  1.6  DEG 0.3  ‐‐  
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2470805  MYCN   3.0  ‐‐  2.8  DEG 2.3  DEG 2409847  PTCH2   1.3  ‐‐  1.2  ‐‐  1.6  DEG
3302533  SFRP5   2.4  ‐‐  2.5  ‐‐  3.0  DEG 2332711  PPIH   1.6  ‐‐  1.5  DEG 0.8  ‐‐ 
2640855  MCM2   3.0  DEG  2.8  DEG 0.9  ‐‐  3463522  PAWR   1.5  ‐‐  1.3  ‐‐  1.6  DEG
2330773  CDCA8   3.0  ‐‐  2.6  DEG 1.1  ‐‐  2691798  IQCB1   1.4  ‐‐  1.6  DEG 0.8  ‐‐ 
3968303  SHROOM2   3.0  ‐‐  2.9  DEG 2.7  DEG 3421177  NUP107   1.4  ‐‐  1.6  DEG 0.5  ‐‐ 
2710599  CLDN1   2.9  ‐‐  2.8  ‐‐  2.8  DEG 3929038  C21orf45   1.6  ‐‐  1.5  DEG 0.8  ‐‐ 
2571457  IL1A   2.9  DEG  2.5  DEG 0.3  ‐‐  3852034  TRMT1   1.6  ‐‐  1.5  DEG 0.7  ‐‐ 
3910785  AURKA   2.9  ‐‐  2.7  DEG 1.0  ‐‐  4012142  FLJ20105   1.6  ‐‐  1.4  DEG 0.5  ‐‐ 
2918388  POU3F2   2.2  ‐‐  1.4  ‐‐  2.9  DEG 3485863  EXOSC8   1.6  ‐‐  1.5  DEG 0.5  ‐‐ 
3078348  EZH2   2.9  DEG  2.0  ‐‐  ‐0.5  ‐‐  2616166  CRTAP   1.1  ‐‐  1.2  ‐‐  1.6  DEG
2915571  C6orf117   1.2  ‐‐  1.6  ‐‐  2.9  DEG 2543066  C2orf43   1.6  ‐‐  1.4  DEG ‐0.3  ‐‐ 
2451200  UBE2T   2.9  ‐‐  2.6  DEG 0.3  ‐‐  2340186  RAVER2   0.4  ‐‐  0.6  ‐‐  1.5  DEG
3333595  GNG3   ‐1.5  ‐‐  ‐1.6  ‐‐  2.8  DEG 3160773  RCL1   1.5  ‐‐  1.4  DEG 1.2  DEG
3587495  SCG5   ‐0.2  ‐‐  0.3  ‐‐  2.8  DEG 3877776  SNRPB2   1.5  ‐‐  1.5  DEG 0.4  ‐‐ 
2417528  DEPDC1   2.8  ‐‐  2.4  DEG 0.5  ‐‐  3838809  PRMT1   1.5  ‐‐  1.5  DEG 0.2  ‐‐ 
3367338  KIF18A   2.8  DEG  2.5  DEG 0.9  ‐‐  2593352  GTF3C3   1.4  ‐‐  1.5  DEG 0.5  ‐‐ 
3862167  DYRK1B   2.8  DEG  2.5  DEG 1.4  ‐‐  2741768  EXOSC9   1.3  ‐‐  1.5  DEG 0.7  ‐‐ 
2541523  MYCNOS   2.7  ‐‐  2.4  ‐‐  2.1  DEG 3875195  MCM8   1.3  ‐‐  1.5  DEG 0.5  ‐‐ 
3555300  CCNB1IP1   2.7  ‐‐  2.3  DEG 1.8  DEG 3167383  NUDT2   1.4  ‐‐  1.4  DEG 0.9  ‐‐ 
3884892  FAM83D   2.7  DEG  2.2  ‐‐  0.5  ‐‐  3246888  PRKG1   0.4  ‐‐  0.5  ‐‐  1.4  DEG
3576441  CCDC88C   2.7  DEG  1.8  ‐‐  0.5  ‐‐  3627363  NARG2   1.4  ‐‐  1.4  DEG 0.5  ‐‐ 
2451958  RPL21   1.0  ‐‐  1.0  ‐‐  2.7  DEG 3852691  DDX39   1.4  ‐‐  1.4  DEG 0.2  ‐‐ 
3400190  CCDC77   2.7  ‐‐  2.5  DEG 1.4  ‐‐  2805786  TARS   1.2  ‐‐  1.4  DEG 0.5  ‐‐ 
3420442  IRAK3   2.4  ‐‐  1.9  ‐‐  2.7  DEG 3257338  MPHOSPH1   1.4  ‐‐  1.4  DEG 0.3  ‐‐ 
2593796  RFTN2   ‐0.2  ‐‐  ‐0.3  ‐‐  2.7  DEG 2944068  DEK   1.2  ‐‐  1.4  DEG 0.3  ‐‐ 
3515965  DIAPH3   2.7  DEG  2.0  ‐‐  0.7  ‐‐  2645764  ATP1B3   0.9  ‐‐  1.0  ‐‐  1.3  DEG
3377423  CDCA5   2.7  ‐‐  2.3  DEG 0.6  ‐‐  3318009  RRM1   1.2  ‐‐  1.3  DEG 0.0  ‐‐ 
2654023  ACTL6A   2.6  ‐‐  2.7  DEG 0.9  ‐‐  3556924  PRMT5   1.3  ‐‐  1.3  DEG 0.4  ‐‐ 
2742985  PLK4   2.7  DEG  2.1  DEG 0.4  ‐‐  3373724  SSRP1   1.3  ‐‐  1.3  DEG 0.2  ‐‐ 
2584134  IFIH1   2.6  ‐‐  2.3  DEG 2.5  DEG 2893721  RIOK1   1.1  ‐‐  1.3  DEG 0.0  ‐‐ 
3402571  NCAPD2   2.6  ‐‐  2.3  DEG 0.8  ‐‐  3468261  NUP37   1.2  ‐‐  1.2  DEG 0.1  ‐‐ 
3063685  MCM7   2.6  DEG  2.0  ‐‐  0.3  ‐‐  2809885  SKIV2L2   1.1  ‐‐  1.2  DEG 0.4  ‐‐ 
2380590  TGFB2   0.8  ‐‐  0.6  ‐‐  2.6  DEG 2425118  SASS6   1.2  ‐‐  1.2  DEG 0.3  ‐‐ 
3635737  RKHD3   2.6  DEG  1.8  ‐‐  ‐0.2  ‐‐  3252170  ADK   1.1  ‐‐  1.2  ‐‐  1.1  DEG
3536336  CDKN3   2.6  ‐‐  2.5  DEG 0.1  ‐‐  3200689  RPS6   1.1  ‐‐  1.1  DEG 0.6  ‐‐ 
3258444  CEP55   2.6  ‐‐  2.3  DEG 0.9  ‐‐  3259503  DNTT   1.1  ‐‐  1.0  ‐‐  1.0  DEG
 
Ad CB, adult cerebellum; CB, cerebellum (including adult and fetal samples); FC, fold change in gene 
expression; DEG, differentially expressed gene.  
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Appendix 3. List of genes significantly down-regulated in Shh-driven 
medulloblastomas. 
 
Transcript 
ID 
Gene 
Symbol 
SHH‐Ad CB  SHH‐ CB  SHH‐MB2 
Transcript 
ID 
Gene 
Symbol 
SHH‐Ad CB  SHH‐ CB  SHH‐MB2 
      FC  DEG  FC  DEG  FC  DEG        FC  DEG  FC  DEG  FC  DEG 
2838399  GABRA6   ‐7.4  DEG ‐ 5.2  ‐‐  ‐1.2  ‐‐  2679406  CADPS   ‐2.0  ‐‐  ‐1.8  ‐‐  ‐3.2  DEG 
3558270  CBLN3   ‐6.9  DEG ‐ 4.2  ‐‐  ‐0.1  ‐‐  4054481  GABRD   ‐3.2  DEG ‐ 1.9  ‐‐  ‐0.3  ‐‐ 
2882026  FAT2   ‐6.6  DEG ‐ 5.8  DEG ‐ 0.3  ‐‐  2833286  ARHGAP26   ‐3.2  ‐‐  ‐2.8  DEG  0.4  ‐‐ 
3985717  PLP1   ‐6.2  DEG ‐ 6.3  ‐‐  ‐1.3  ‐‐  2842194  CPLX2   ‐3.1  ‐‐  ‐2.8  DEG ‐ 0.4  ‐‐ 
3830320  MAG   ‐5.6  DEG ‐ 6.2  DEG ‐ 0.3  ‐‐  3779950  C18orf1   ‐3.1  DEG ‐ 3.0  ‐‐  ‐2.4  ‐‐ 
2513471  SCN2A   ‐5.7  DEG ‐ 4.4  DEG ‐ 1.9  ‐‐  3841102  PRKCG   ‐3.1  ‐‐  ‐2.5  DEG  0.1  ‐‐ 
3887241  SLC12A5   ‐5.6  DEG ‐ 4.4  ‐‐  ‐1.6  ‐‐  2587790  GPR155   ‐3.1  DEG ‐ 2.8  ‐‐  ‐1.3  ‐‐ 
3762753  CA10   ‐5.6  DEG ‐ 4.8  DEG ‐ 2.9  ‐‐  2339139  INADL   ‐3.1  DEG ‐ 2.1  ‐‐  ‐1.3  ‐‐ 
2678448  FAM107A   ‐5.5  DEG ‐ 5.2  DEG ‐ 2.5  ‐‐  3946944  CSDC2   ‐3.1  DEG ‐ 2.8  DEG ‐ 0.9  ‐‐ 
3662093  MT3   ‐5.4  ‐‐  ‐5.2  DEG ‐ 2.0  ‐‐  2764004  LGI2   ‐3.1  DEG ‐ 2.3  ‐‐  0.4  ‐‐ 
3280573  NEBL   ‐5.4  DEG ‐ 4.7  DEG ‐ 1.2  ‐‐  3260985  SFXN3   ‐3.1  ‐‐  ‐3.0  DEG ‐ 2.9  DEG 
3144033  CALB1   ‐5.4  DEG ‐ 4.7  ‐‐  0.0  ‐‐  3528013  RPGRIP1   0.4  ‐‐  0.3  ‐‐  ‐3.1  DEG 
3177111  NTRK2   ‐5.4  DEG ‐ 5.3  DEG ‐ 2.8  ‐‐  2975867  MAP3K5   ‐3.1  ‐‐  ‐2.9  DEG ‐ 0.5  ‐‐ 
3396249  HEPACAM   ‐5.4  DEG ‐ 5.3  ‐‐  ‐0.8  ‐‐  2715016  FGFR3   ‐3.1  ‐‐  ‐2.4  DEG ‐ 0.4  ‐‐ 
3867842  SLC17A7   ‐5.4  ‐‐  ‐4.6  DEG ‐ 3.3  DEG  2362469  CADM3   ‐3.1  ‐‐  ‐2.8  DEG ‐ 2.1  DEG 
2408041  HPCAL4   ‐5.3  DEG ‐ 4.3  DEG ‐ 0.7  ‐‐  2321466  KIAA1026   ‐3.1  ‐‐  ‐2.8  DEG ‐ 0.2  ‐‐ 
2838416  GABRA1   ‐5.3  DEG ‐ 3.9  ‐‐  ‐2.5  ‐‐  2829905  FBXL21   ‐0.3  ‐‐  ‐0.3  ‐‐  ‐3.0  DEG 
2512752  TBR1   0.0  ‐‐  0.0  ‐‐  ‐5.2  DEG  3155901  KCNK9   ‐3.0  ‐‐  ‐2.6  DEG  1.1  ‐‐ 
3214227  DIRAS2   ‐5.2  DEG ‐ 3.9  ‐‐  ‐2.1  ‐‐  3884793  SLC32A1   ‐3.0  DEG ‐ 2.4  ‐‐  0.0  ‐‐ 
3700158  ADAMTS18   ‐4.9  DEG ‐ 3.9  ‐‐  ‐0.7  ‐‐  3572929  ZDHHC22   0.0  ‐‐  ‐0.2  ‐‐  ‐3.0  DEG 
2511153  KCNJ3   ‐4.8  ‐‐  ‐4.6  DEG ‐ 0.6  ‐‐  3779207  GNAL   ‐3.0  DEG ‐ 3.0  ‐‐  ‐2.4  ‐‐ 
2900940  MOG   ‐4.5  DEG ‐ 4.8  DEG ‐ 0.5  ‐‐  3189714  GARNL3   ‐3.0  DEG ‐ 2.8  DEG ‐ 1.7  ‐‐ 
3401994  KCNA1   ‐4.8  DEG ‐ 3.6  ‐‐  ‐3.4  ‐‐  3693141  PLLP   ‐2.9  ‐‐  ‐3.0  DEG ‐ 0.2  ‐‐ 
3744965  GAS7   ‐4.8  DEG ‐ 4.1  DEG ‐ 0.9  ‐‐  3901191  NAPB   ‐3.0  DEG ‐ 2.1  ‐‐  ‐2.1  ‐‐ 
3190242  DNM1   ‐4.8  DEG ‐ 4.1  DEG ‐ 2.8  DEG  3384718  DLG2   ‐3.0  ‐‐  ‐2.9  DEG ‐ 0.5  ‐‐ 
3965536  MLC1   ‐4.8  DEG ‐ 4.7  DEG ‐ 1.3  ‐‐  2398820  PADI2   ‐3.0  ‐‐  ‐2.7  DEG ‐ 0.7  ‐‐ 
3751237  SEZ6   ‐3.1  ‐‐  ‐3.0  ‐‐  ‐4.8  DEG  3788097  MAPK4   ‐3.0  DEG ‐ 2.5  ‐‐  ‐1.0  ‐‐ 
2950970  GRM4   ‐4.8  ‐‐  ‐3.9  DEG  0.0  ‐‐  3900545  NKX2‐2   ‐3.0  ‐‐  ‐3.0  DEG ‐ 0.1  ‐‐ 
3750767  SPAG5   ‐4.8  DEG ‐ 4.2  ‐‐  ‐0.3  ‐‐  2906333  DAAM2   ‐3.0  ‐‐  ‐2.8  DEG ‐ 0.7  ‐‐ 
3684007  ZP2   ‐4.7  DEG ‐ 2.7  ‐‐  0.2  ‐‐  3267382  INPP5F   ‐3.0  DEG ‐ 2.6  ‐‐  ‐2.2  ‐‐ 
3708938  ATP1B2   ‐4.7  DEG ‐ 4.4  DEG ‐ 2.8  ‐‐  3590498  TCEB1   ‐2.9  ‐‐  ‐2.5  DEG ‐ 0.4  ‐‐ 
2994835  CHN2   ‐4.7  ‐‐  ‐3.5  ‐‐  ‐4.0  DEG  2999334  HECW1   ‐2.9  ‐‐  ‐2.9  DEG ‐ 0.3  ‐‐ 
2438169  C1orf61   ‐4.6  ‐‐  ‐4.7  DEG ‐ 2.0  ‐‐  3063035  TMEM130   ‐2.9  ‐‐  ‐2.8  DEG ‐ 2.1  ‐‐ 
2602770  DNER   ‐4.6  DEG ‐ 4.4  ‐‐  ‐1.7  ‐‐  2841699  CPEB4   ‐2.9  DEG ‐ 2.8  ‐‐  ‐1.9  ‐‐ 
3210497  KIAA0367   ‐4.6  DEG ‐ 3.5  ‐‐  ‐0.7  ‐‐  2997907  EPDR1   ‐2.9  DEG ‐ 2.1  ‐‐  0.2  ‐‐ 
2643217  TF   ‐4.6  DEG ‐ 4.6  ‐‐  ‐1.1  ‐‐  2475911  EHD3   ‐2.9  DEG ‐ 2.2  ‐‐  0.2  ‐‐ 
2959039  KHDRBS2   ‐0.7  ‐‐  ‐1.1  ‐‐  ‐4.6  DEG  2578790  LRP1B   ‐2.9  ‐‐  ‐2.9  DEG  0.0  ‐‐ 
3841439  TTYH1   ‐4.5  ‐‐  ‐4.6  DEG ‐ 1.1  ‐‐  3301782  TMEM10   ‐2.8  ‐‐  ‐2.7  DEG  0.5  ‐‐ 
3720322  PPP1R1B   ‐4.5  ‐‐  ‐4.1  DEG ‐ 1.5  ‐‐  3957938  PISD   ‐2.8  DEG ‐ 2.0  ‐‐  ‐1.1  ‐‐ 
3137120  CA8   ‐4.5  DEG ‐ 3.8  DEG ‐ 0.1  ‐‐  2324820  EPHA8   0.1  ‐‐  ‐0.3  ‐‐  ‐2.8  DEG 
2767932  GABRG1   ‐4.5  ‐‐  ‐4.5  DEG ‐ 0.8  ‐‐  3364878  ABCC8   ‐1.9  ‐‐  ‐2.0  ‐‐  ‐2.8  DEG 
2608469  ITPR1   ‐4.5  DEG ‐ 3.8  DEG  0.2  ‐‐  2980449  PIP3‐E   ‐2.8  DEG ‐ 1.9  ‐‐  ‐1.2  ‐‐ 
3127385  PHYHIP   ‐4.5  DEG ‐ 3.4  ‐‐  ‐0.7  ‐‐  3457891  GLS2   ‐2.8  DEG ‐ 1.8  ‐‐  ‐0.2  ‐‐ 
3209726  ALDH1A1   ‐4.5  DEG ‐ 3.5  ‐‐  ‐0.4  ‐‐  2553262  PSME4   ‐2.8  ‐‐  ‐2.6  DEG ‐ 0.3  ‐‐ 
2929571  GRM1   ‐4.5  DEG ‐ 4.0  ‐‐  ‐1.9  ‐‐  3097701  SNTG1   ‐2.8  DEG ‐ 2.4  DEG ‐ 0.6  ‐‐ 
3209060  TRPM3   ‐4.5  DEG ‐ 3.9  ‐‐  ‐3.1  ‐‐  3183604  ZNF462   ‐1.1  ‐‐  ‐1.3  ‐‐  ‐2.8  DEG 
2387126  RYR2   ‐4.5  ‐‐  ‐4.0  DEG ‐ 0.3  ‐‐  2693409  ALDH1L1   ‐2.3  ‐‐  ‐2.8  DEG ‐ 0.2  ‐‐ 
2855963  HCN1   ‐4.4  DEG ‐ 4.1  DEG ‐ 1.9  ‐‐  3307851  AFAP1L2   ‐2.8  ‐‐  ‐2.4  DEG ‐ 0.2  ‐‐  
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3764527  39329 ‐ 4.4  DEG ‐ 3.8  DEG ‐ 0.9  ‐‐  3961023  CBX7   ‐2.8  DEG ‐ 2.0  ‐‐  ‐0.8  ‐‐ 
2514969  GAD1   ‐4.4  ‐‐  ‐3.9  DEG  0.4  ‐‐  2374926  TMEM58   ‐2.7  ‐‐  ‐2.7  DEG ‐ 0.3  ‐‐ 
2707045  PEX5L   ‐2.4  ‐‐  ‐2.2  ‐‐  ‐4.4  DEG  2656146  MAP3K13   ‐1.7  ‐‐  ‐2.1  ‐‐  ‐2.7  DEG 
3127352  LGI3   ‐4.3  DEG ‐ 4.0  DEG ‐ 0.2  ‐‐  2996563  BMPER   ‐2.7  DEG ‐ 2.1  ‐‐  0.0  ‐‐ 
2622970  DOCK3   ‐4.3  ‐‐  ‐4.2  DEG ‐ 3.1  DEG  3872380  ZNF154   ‐2.4  ‐‐  ‐2.5  DEG ‐ 2.7  DEG 
3239667  GAD2   ‐4.3  DEG ‐ 3.3  DEG  0.2  ‐‐  3423301  NAV3   ‐2.6  ‐‐  ‐2.7  DEG ‐ 0.5  ‐‐ 
3362159  NRIP3   ‐4.3  DEG ‐ 3.4  ‐‐  ‐0.7  ‐‐  2893562  RREB1   0.5  ‐‐  0.1  ‐‐  ‐2.7  DEG 
2444899  TNR   ‐4.3  ‐‐  ‐4.1  DEG ‐ 0.8  ‐‐  2600089  PTPRN   ‐2.7  ‐‐  ‐2.2  ‐‐  ‐2.2  DEG 
3173673  PIP5K1B   ‐4.3  DEG ‐ 3.5  DEG ‐ 0.5  ‐‐  2704143  WDR49   ‐2.7  ‐‐  ‐2.5  DEG ‐ 0.4  ‐‐ 
2736060  GRID2   ‐4.3  DEG ‐ 4.2  DEG  0.1  ‐‐  3758692  MPP2   ‐2.7  ‐‐  ‐2.5  DEG ‐ 2.5  DEG 
2836242  GRIA1   ‐4.3  DEG ‐ 4.3  DEG ‐ 1.9  ‐‐  3706659  ASPA   ‐2.7  DEG ‐ 2.5  DEG ‐ 0.3  ‐‐ 
2361635  BCAN   ‐3.8  ‐‐  ‐4.3  DEG ‐ 1.2  ‐‐  3190420  CEECAM1   ‐2.7  ‐‐  ‐2.5  DEG ‐ 1.6  ‐‐ 
2888399  SNCB   ‐4.3  ‐‐  ‐3.9  DEG ‐ 0.4  ‐‐  3901296  CST3   ‐2.5  ‐‐  ‐2.6  DEG ‐ 0.9  ‐‐ 
2460296  AGT   ‐4.3  DEG ‐ 3.7  ‐‐  ‐1.1  ‐‐  3043895  SCRN1   ‐2.6  DEG ‐ 2.2  ‐‐  ‐0.5  ‐‐ 
2451261  SYT2   ‐4.3  ‐‐  ‐3.6  DEG  0.1  ‐‐  3337042  KIAA1394   ‐2.4  DEG ‐ 2.6  DEG  0.0  ‐‐ 
3793827  CNDP1   ‐4.2  DEG ‐ 3.1  ‐‐  ‐0.5  ‐‐  3219030  ‐‐‐  0.0  ‐‐  ‐0.5  ‐‐  ‐2.6  DEG 
3710505  LOC284033   ‐4.2  DEG ‐ 4.2  ‐‐  ‐1.4  ‐‐  2933175  ZDHHC14   ‐2.6  ‐‐  ‐2.3  DEG ‐ 0.4  ‐‐ 
3353640  GRAMD1B   ‐4.2  DEG ‐ 3.5  ‐‐  ‐3.2  ‐‐  2511045  GALNT13   ‐2.6  DEG ‐ 1.8  ‐‐  1.0  ‐‐ 
2512790  SLC4A10   ‐4.2  DEG ‐ 3.7  DEG ‐ 2.3  DEG  3467351  ANKS1B   ‐2.6  DEG ‐ 2.5  ‐‐  ‐2.1  ‐‐ 
2323172  IGSF21   ‐3.1  ‐‐  ‐2.7  ‐‐  ‐4.2  DEG  3307939  ABLIM1   ‐2.6  DEG ‐ 2.0  ‐‐  0.3  ‐‐ 
3529467  CPNE6   ‐4.2  DEG ‐ 3.1  ‐‐  ‐2.1  ‐‐  3286211  RASGEF1A   ‐2.6  DEG ‐ 2.0  ‐‐  ‐0.8  ‐‐ 
3566176  OTX2   1.4  ‐‐  0.8  ‐‐  ‐4.2  DEG  2715749  GRK4   ‐2.6  DEG ‐ 2.3  DEG ‐ 1.9  DEG 
3411721  CNTN1   ‐4.2  DEG ‐ 3.9  ‐‐  ‐3.2  ‐‐  2364016  NOS1AP   ‐2.6  ‐‐  ‐2.4  DEG ‐ 1.8  DEG 
2439960  KCNJ10   ‐4.1  ‐‐  ‐3.6  DEG ‐ 0.8  ‐‐  2740067  ANK2   ‐2.6  DEG ‐ 2.2  ‐‐  0.0  ‐‐ 
3507199  FLT3   ‐4.1  DEG ‐ 2.6  ‐‐  0.0  ‐‐  3907934  ZNF334   ‐1.6  ‐‐  ‐1.9  ‐‐  ‐2.6  DEG 
2385873  KCNK1   ‐4.1  DEG ‐ 3.4  ‐‐  ‐1.0  ‐‐  3831975  ZNF540   ‐2.6  ‐‐  ‐2.3  ‐‐  ‐2.0  DEG 
2955691  DSCR1L1   ‐4.1  DEG ‐ 3.2  ‐‐  ‐2.0  ‐‐  3155489  FAM135B   ‐2.6  DEG ‐ 2.2  ‐‐  ‐1.6  ‐‐ 
3353417  CRTAM   ‐4.1  DEG ‐ 2.5  ‐‐  0.0  ‐‐  3417249  ERBB3   ‐2.4  ‐‐  ‐2.5  DEG  0.0  ‐‐ 
3672059  KIAA0513   ‐4.0  DEG ‐ 3.2  ‐‐  ‐1.5  ‐‐  3124333  C8orf5   ‐2.4  ‐‐  ‐2.5  DEG ‐ 2.3  DEG 
3184925  ‐‐‐  ‐4.0  DEG ‐ 3.2  ‐‐  ‐1.1  ‐‐  2623426  ABHD14A   ‐2.1  ‐‐  ‐1.6  ‐‐  ‐2.5  DEG 
3222534  ASTN2   ‐3.3  ‐‐  ‐3.1  ‐‐  ‐4.0  DEG  2705266  TNIK   ‐2.0  ‐‐  ‐2.3  ‐‐  ‐2.5  DEG 
3184896  ZNF483   ‐4.0  DEG ‐ 2.9  ‐‐  ‐1.0  ‐‐  3456212  MAP3K12   ‐2.5  ‐‐  ‐2.2  DEG ‐ 0.1  ‐‐ 
2949772  PRRT1   ‐4.0  DEG ‐ 3.2  ‐‐  ‐1.1  ‐‐  3190558  SPTAN1   ‐2.5  DEG ‐ 2.3  ‐‐  ‐2.1  DEG 
2438016  PAQR6   ‐3.9  DEG ‐ 4.0  DEG ‐ 0.5  ‐‐  3665049  FLJ37464   ‐2.5  ‐‐  ‐2.3  DEG ‐ 1.6  ‐‐ 
2375038  GPR37L1   ‐4.0  DEG ‐ 3.2  ‐‐  ‐0.5  ‐‐  2321607  FLJ43806   ‐2.4  ‐‐  ‐2.4  DEG ‐ 0.4  ‐‐ 
2842255  CPLX2   ‐4.0  ‐‐  ‐3.7  DEG ‐ 0.7  ‐‐  3200762  SLC24A2   ‐2.4  DEG ‐ 2.1  ‐‐  ‐0.4  ‐‐ 
3347431  ELMOD1   ‐4.0  DEG ‐ 3.3  DEG ‐ 1.1  ‐‐  3074912  DGKI   ‐2.4  DEG ‐ 2.4  ‐‐  0.2  ‐‐ 
2975741  MAP7   ‐4.0  DEG ‐ 3.4  ‐‐  ‐0.8  ‐‐  3945781  SYNGR1   ‐2.4  ‐‐  ‐2.0  DEG ‐ 1.1  ‐‐ 
3217242  GABBR2   ‐4.0  DEG ‐ 3.6  ‐‐  ‐2.7  ‐‐  2711225  ATP13A4   ‐2.4  ‐‐  ‐2.4  DEG ‐ 0.4  ‐‐ 
2607568  CHL1   ‐3.8  DEG ‐ 4.0  ‐‐  ‐3.5  ‐‐  2765590  CENTD1   ‐2.3  ‐‐  ‐2.4  DEG ‐ 0.2  ‐‐ 
3555736  NDRG2   ‐4.0  ‐‐  ‐3.8  DEG ‐ 1.4  ‐‐  3726569  SPATA20   ‐2.4  ‐‐  ‐2.0  ‐‐  ‐2.3  DEG 
3448088  BHLHB3   ‐4.0  DEG ‐ 3.2  ‐‐  ‐1.2  ‐‐  3764399  RNF43   ‐2.3  ‐‐  ‐2.2  DEG  0.4  ‐‐ 
2703836  SLITRK3   ‐4.0  DEG ‐ 3.8  ‐‐  ‐2.1  ‐‐  3721956  TUBG2   ‐2.3  ‐‐  ‐2.0  DEG ‐ 0.6  ‐‐ 
3684039  CRYM   ‐3.9  DEG ‐ 2.5  ‐‐  ‐0.1  ‐‐  2458513  TMEM63A   ‐2.2  ‐‐  ‐2.3  DEG  0.2  ‐‐ 
2616596  ARPP‐21   ‐3.9  ‐‐  ‐3.6  DEG ‐ 1.3  ‐‐  3036565  MMD2   ‐2.1  ‐‐  ‐2.3  ‐‐  ‐2.2  DEG 
2874920  ACSL6   ‐3.9  DEG ‐ 3.4  DEG ‐ 1.9  ‐‐  3071459  LRRC4   ‐2.3  ‐‐  ‐1.9  ‐‐  ‐2.3  DEG 
3249369  LRRTM3   ‐3.8  ‐‐  ‐3.9  DEG ‐ 0.8  ‐‐  3906062  ZHX3   ‐2.3  ‐‐  ‐2.1  DEG ‐ 1.2  ‐‐ 
2452478  LEMD1   ‐0.8  ‐‐  ‐0.7  ‐‐  ‐3.9  DEG  3758615  DUSP3   ‐2.3  ‐‐  ‐2.1  ‐‐  ‐1.8  DEG 
2610972  SYN2   ‐3.9  ‐‐  ‐3.3  DEG ‐ 2.4  DEG  3901696  ACSS1   ‐2.3  ‐‐  ‐2.3  DEG ‐ 0.1  ‐‐ 
3910360  BCAS1   ‐3.6  ‐‐  ‐3.9  DEG ‐ 0.4  ‐‐  3868557  SYT3   ‐2.3  ‐‐  ‐2.0  DEG ‐ 0.3  ‐‐ 
3936224  SLC25A18   ‐3.6  ‐‐  ‐3.9  DEG ‐ 0.7  ‐‐  3230610  ABCA2   ‐2.3  ‐‐  ‐2.0  DEG ‐ 0.5  ‐‐ 
3258713  LGI1   ‐3.9  DEG ‐ 3.0  ‐‐  ‐2.4  ‐‐  3846076  TLE2   ‐2.0  ‐‐  ‐1.9  ‐‐  ‐2.3  DEG  
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3733238  KCNJ16   ‐3.8  DEG ‐ 2.9  ‐‐  ‐0.6  ‐‐  3715368  NLK   ‐0.4  ‐‐  ‐0.4  ‐‐  ‐2.3  DEG 
2750753  TLL1   ‐3.8  DEG ‐ 3.5  ‐‐  ‐2.3  ‐‐  3678369  ROGDI   ‐2.2  ‐‐  ‐2.1  ‐‐  ‐2.2  DEG 
2733360  FGF5   ‐3.6  ‐‐  ‐3.8  DEG  1.2  ‐‐  3101629  ADHFE1   ‐2.1  ‐‐  ‐2.2  DEG  0.0  ‐‐ 
3604287  IL16   ‐3.8  ‐‐  ‐2.9  DEG ‐ 0.1  ‐‐  2777333  PPM1K   ‐2.2  ‐‐  ‐1.9  DEG ‐ 0.1  ‐‐ 
2662698  ATP2B2   ‐3.8  ‐‐  ‐3.2  DEG ‐ 0.9  ‐‐  3230932  C9orf75   ‐2.1  ‐‐  ‐2.1  DEG ‐ 1.0  DEG 
3633699  NRG4   ‐3.7  DEG ‐ 2.4  ‐‐  ‐0.8  ‐‐  2875454  39333 ‐ 2.1  ‐‐  ‐1.8  DEG ‐ 1.1  ‐‐ 
3322521  KCNC1   ‐3.7  ‐‐  ‐3.1  DEG ‐ 1.4  ‐‐  2884727  ATP10B   ‐2.0  ‐‐  ‐2.1  DEG ‐ 0.4  ‐‐ 
2868265  LIX1   ‐3.5  ‐‐  ‐3.7  DEG ‐ 0.7  ‐‐  2786567  OSAP   ‐2.1  DEG ‐ 1.3  ‐‐  0.2  ‐‐ 
3148871  FLJ20366   ‐3.7  ‐‐  ‐2.9  DEG  0.6  ‐‐  2567447  TBC1D8   ‐1.3  ‐‐  ‐1.0  ‐‐  ‐2.1  DEG 
3726618  CACNA1G   ‐3.7  DEG ‐ 3.5  ‐‐  ‐3.2  DEG  3980643  DLG3   ‐0.9  ‐‐  ‐1.0  ‐‐  ‐2.1  DEG 
3369366  SLC1A2   ‐3.7  ‐‐  ‐3.6  DEG ‐ 1.6  ‐‐  3830961  APLP1   ‐2.0  ‐‐  ‐2.1  ‐‐  ‐1.8  DEG 
3750723  UNC119   ‐1.1  ‐‐  ‐1.1  ‐‐  ‐3.7  DEG  3632492  NPTN   ‐2.1  DEG ‐ 1.6  ‐‐  ‐0.8  ‐‐ 
2397600  C1orf126   ‐3.6  ‐‐  ‐3.0  DEG  0.0  ‐‐  3226138  AK1   ‐2.0  ‐‐  ‐1.7  ‐‐  ‐2.1  DEG 
2636483  SIDT1   ‐3.6  ‐‐  ‐2.9  DEG ‐ 0.2  ‐‐  3094778  TACC1   ‐2.1  ‐‐  ‐2.1  DEG ‐ 0.9  ‐‐ 
3223157  DBC1   ‐3.6  DEG ‐ 3.6  DEG ‐ 2.7  DEG  2493858  MAL   ‐1.9  ‐‐  ‐2.1  DEG  0.1  ‐‐ 
2708203  MAP6D1   ‐3.6  DEG ‐ 3.1  DEG ‐ 0.5  ‐‐  4012178  CITED1   ‐0.2  ‐‐  0.0  ‐‐  ‐2.1  DEG 
2734270  CDS1   ‐3.6  DEG ‐ 2.8  ‐‐  ‐0.9  ‐‐  3777470  PTPRM   ‐2.1  ‐‐  ‐2.0  DEG  0.0  ‐‐ 
2945129  PRL   1.7  ‐‐  1.5  ‐‐  ‐3.6  DEG  3709244  CHD3   ‐0.2  ‐‐  ‐0.8  ‐‐  ‐2.0  DEG 
3758640  MPP3   ‐3.0  ‐‐  ‐2.7  ‐‐  ‐3.6  DEG  2376457  PCTK3   ‐1.6  ‐‐  ‐2.0  DEG ‐ 0.5  ‐‐ 
3868768  KLK6   ‐3.5  ‐‐  ‐3.5  DEG ‐ 0.5  ‐‐  2431877  ‐‐‐  ‐2.0  ‐‐  ‐1.9  DEG ‐ 0.2  ‐‐ 
2450865  CSRP1   ‐3.5  ‐‐  ‐3.3  DEG ‐ 0.8  ‐‐  2675801  PCBP4   0.2  ‐‐  0.1  ‐‐  ‐2.0  DEG 
2607757  CNTN6   ‐3.5  DEG ‐ 3.1  ‐‐  ‐1.3  ‐‐  3893973  MYT1   ‐1.4  ‐‐  ‐1.4  ‐‐  ‐1.9  DEG 
3064361  ACHE   ‐3.5  ‐‐  ‐3.1  ‐‐  ‐3.1  DEG  3185498  SLC31A2   ‐1.9  ‐‐  ‐1.7  DEG ‐ 0.4  ‐‐ 
3011180  GRM3   ‐3.5  ‐‐  ‐3.2  DEG ‐ 0.1  ‐‐  2351121  FAM40A   ‐1.9  ‐‐  ‐1.8  DEG ‐ 0.3  ‐‐ 
3876245  SNAP25   ‐3.5  DEG ‐ 2.5  ‐‐  ‐0.9  ‐‐  2682436  RYBP   0.0  ‐‐  ‐0.3  ‐‐  ‐1.9  DEG 
2463567  PLD5   ‐3.5  DEG ‐ 3.5  DEG ‐ 0.9  ‐‐  3567243  C14orf39   0.0  ‐‐  0.0  ‐‐  ‐1.8  DEG 
3690747  CBLN1   ‐3.5  DEG ‐ 3.1  ‐‐  ‐0.6  ‐‐  2327817  PTPRU   ‐1.8  ‐‐  ‐1.6  ‐‐  ‐1.7  DEG 
3032647  DPP6   ‐3.5  DEG ‐ 3.4  ‐‐  ‐2.6  ‐‐  3740367  SLC43A2   ‐1.8  ‐‐  ‐1.7  DEG ‐ 1.4  DEG 
3601931  CPLX3   ‐0.9  ‐‐  ‐0.3  ‐‐  ‐3.5  DEG  3947258  WBP2NL   ‐1.8  ‐‐  ‐1.8  DEG ‐ 1.3  DEG 
3886867  DBNDD2   ‐3.5  ‐‐  ‐3.0  DEG ‐ 0.3  ‐‐  2711205  ATP13A4   ‐1.7  ‐‐  ‐1.8  DEG ‐ 0.4  ‐‐ 
2880051  PPP2R2B   ‐3.5  ‐‐  ‐3.4  ‐‐  ‐3.1  DEG  3720695  THRA   ‐1.8  ‐‐  ‐1.8  ‐‐  ‐1.7  DEG 
3124227  XKR6   ‐3.5  ‐‐  ‐3.3  DEG ‐ 2.0  ‐‐  3872398  ZNF671   ‐1.6  ‐‐  ‐1.6  ‐‐  ‐1.7  DEG 
2648991  KCNAB1   ‐3.4  DEG ‐ 2.8  ‐‐  ‐1.1  ‐‐  3751323  TIAF1   ‐1.7  ‐‐  ‐1.5  ‐‐  ‐1.5  DEG 
2941632  MAK   ‐0.2  ‐‐  ‐0.3  ‐‐  ‐3.4  DEG  3972657  IL1RAPL1   ‐1.4  ‐‐  ‐1.6  DEG  0.3  ‐‐ 
3884830  PPP1R16B   ‐3.3  DEG ‐ 3.0  DEG  0.1  ‐‐  3221395  ALAD   ‐1.6  ‐‐  ‐1.4  ‐‐  ‐1.4  DEG 
3545634  NRXN3   ‐3.2  DEG ‐ 3.3  ‐‐  ‐1.3  ‐‐  3719210  MRM1   ‐1.1  ‐‐  ‐0.9  ‐‐  ‐1.6  DEG 
2827299  MEGF10   ‐3.2  ‐‐  ‐3.3  DEG ‐ 0.5  ‐‐  3553337  TRAF3   ‐0.9  ‐‐  ‐0.9  ‐‐  ‐1.5  DEG 
3755790  NEUROD2   ‐2.6  ‐‐  ‐2.5  ‐‐  ‐3.3  DEG  2787459  INPP4B   ‐1.4  ‐‐  ‐1.5  DEG  0.2  ‐‐ 
3549605  KIAA1622   ‐3.3  DEG ‐ 2.5  ‐‐  ‐0.3  ‐‐  2331213  MACF1   ‐1.4  ‐‐  ‐1.5  ‐‐  ‐1.4  DEG 
3059258  PCLO   ‐3.3  ‐‐  ‐2.9  DEG ‐ 1.8  ‐‐  3677612  ZNF597   ‐1.1  ‐‐  ‐0.9  ‐‐  ‐1.4  DEG 
3029900  CNTNAP2   ‐2.8  DEG ‐ 3.3  ‐‐  ‐1.4  ‐‐  2708720  EIF2S2   ‐0.9  ‐‐  ‐0.8  ‐‐  ‐1.4  DEG 
3504213  GJB6   ‐3.3  ‐‐  ‐3.2  DEG ‐ 0.2  ‐‐  3350775  SIDT2   ‐1.4  ‐‐  ‐1.4  DEG ‐ 0.3  ‐‐ 
3300242  CPEB3   ‐3.3  DEG ‐ 2.8  ‐‐  ‐1.9  ‐‐  3720402  ERBB2   ‐1.2  ‐‐  ‐1.4  ‐‐  ‐1.3  DEG 
3173974  C9orf61   ‐3.0  ‐‐  ‐3.2  DEG ‐ 0.6  ‐‐  3872370  ‐‐‐  ‐1.0  ‐‐  ‐1.1  ‐‐  ‐1.4  DEG 
2725977  GABRB1   ‐3.2  DEG ‐ 3.1  ‐‐  ‐1.1  ‐‐  2340819  TCTEX1D1   ‐1.1  ‐‐  ‐1.3  DEG ‐ 0.1  ‐‐ 
2975014  SGK   ‐1.7  ‐‐  ‐2.0  ‐‐  ‐3.2  DEG  3189864  LRSAM1   ‐1.2  ‐‐  ‐1.1  ‐‐  ‐1.0  DEG 
2672821  CSPG5   ‐2.1  ‐‐  ‐2.0  ‐‐  ‐3.2  DEG  3432798  SDSL   ‐0.1  ‐‐  ‐0.2  ‐‐  ‐1.2  DEG 
3033127  HTR5A   ‐3.2  DEG ‐ 2.3  ‐‐  ‐1.6  ‐‐  3770699  MIF4GD   ‐0.6  ‐‐  ‐0.7  ‐‐  ‐1.2  DEG 
2865390  EDIL3   ‐2.6  ‐‐  ‐2.6  ‐‐  ‐3.2  DEG  3751121  FLOT2   ‐0.6  ‐‐  ‐0.5  ‐‐  ‐1.1  DEG 
3989448  GRIA3   ‐3.2  DEG ‐ 3.2  DEG ‐ 0.3  ‐‐  3228621  SURF6   ‐0.4  ‐‐  ‐0.3  ‐‐  ‐1.1  DEG 
Ad CB, adult cerebellum; CB, cerebellum (including adult and fetal samples); FC, fold change in gene 
expression; DEG, differentially expressed gene. 